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Abstract 
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Abstract 
 
For almost a century, antibiotics have been used as treatment agents in the combat of 
infections caused by pathogenic microbes. For a short while, antibiotics were heralded as 
miracle drugs; their discovery and introduction into the clinic has no doubt saved countless 
animal and human lives. The use of antibiotics in surgical procedures has ushered in the 
modern medical era where surgeons are afforded a whole host of cutting edge treatment and 
ground-breaking surgical techniques thanks to the benefits and treatment options antibiotics 
offer. The dark times of the pre-antibiotic era where many lives were lost through trivial 
illnesses have long been forgotten. However, what was once a trickle of reports of antibiotic 
resistance has since turned into a flood of pandemic proportions; the once lethal actions of 
antibiotics are threatened by the seemingly unstoppable march of resistance. Pathogenic 
microbes, once susceptible to the killing mechanisms of antibiotics, are now equipped with 
several mechanisms capable of shrugging off the previously deadly antibiotics. The main 
weapon in our antibiotic armamentarium is β-lactam antibiotics, owing to their cheapness, 
efficacy, and limited side effects. It is perhaps unsurprising then that the main driver of 
antibiotic resistance is by the production of β-lactamases, enzymes capable of efficiently 
catalysing the hydrolysis of the β-lactam ring present in β-lactam antibiotics, rendering them 
useless. Unfortunately, soil which was once a rich source of novel antibiotic producing 
bacteria has long been described as an over-mined resource and attempts to match the 
success of natural and semi synthetic antibiotics with truly synthetic antibiotics has largely 
been a failure. 
It is known that the majority of bacteria in situ are unculturable in laboratory conditions. 
The work in this thesis explores novel methods to increase the in vitro growth rate of bacteria 
Abstract 
ii 
 
in an attempt to revitalise traditional antimicrobial discovery methods, by use of a novel 
incubation tool known as the isolation chip or “iChip” for short. The iChip is designed in 
the hope to increase the in vitro growth rate of previously unculturable bacteria. The work 
in this thesis describes the characterisation and antimicrobial activity of a previously little 
described strain of Pseudomonas baetica, a bacterium of little interest, only noted for its 
pathogenicity towards certain species of fish.  
Given the dearth of novel antibiotics, β-lactamase inhibitors represent an alternative 
mechanism for overcoming antimicrobial resistance as compared to novel antimicrobials. 
This thesis also explores the potential of novel β-lactamase inhibitors, in the hope of 
extending the shelf life of existing “resistance vulnerable” β-lactam antibiotics. Several ring-
opened carbamate ester analogues of avibactam, a novel β-lactamase inhibitor, were 
synthesised and their effectiveness as serine-β-lactamase inhibitors were assessed. One of 
the inhibitors was found to be even more effective than avibactam itself. Also, the effect of 
pH upon inhibition of serine-β-lactamases by these inhibitors and the catalytic activity of 
these enzymes was measured showing that the catalytic machinery is the same for both 
hydrolysis and inhibition. 
Finally, several other existing compounds were tested for their inhibitory effectiveness 
against -lactamases. Ellagic acid was found to be a good inhibitor of serine-β-lactamases 
and showed an interesting inhibitory profile dependent upon pH demonstrating that both the 
mono- and di-anions are effective inhibitors. 
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The following is a list of abbreviations the reader may find useful to refer back to throughout this 
thesis. 
 
AChE Acetylcholinesterase 
ACN Acetonitrile 
AmpC Class C serine-β-lactamase 
βla                                                                                                                          β-lactamase 
BP Base Pairs 
BuChE Butyrylcholinesterase 
CTX-M-15 Class C serine-β-lactamase 
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DNA Deoxyribonucleic acid 
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GCMS Gas chromatography mass spectrometry 
HPLC High performance liquid chromatography 
IC50 50 % Inhibitory concentration 
IMP Metallo-β-lactamase imipenemase 
JS-ESI Jet-Stream electrospray ionisation 
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LC Liquid chromatography 
LCMS Liquid chromatography mass spectrometry 
MBL Metallo-β-lactamase 
MeOH Methanol 
NDM-1 New Delhi metallo-β-lactamase 1 
PBP Penicillin binding protein 
PCR Polymerase chain reaction 
P99 β-Lactamase from E. cloacae strain P99 
QqQ Triple quadrupole mass spectrometry 
QToF Quadrupole time of flight mass spectrometry 
RNA Ribonucleic acid 
SBL Serine-β-lactamase 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TEM-1 Temoniera 1 β-lactamase 
TSA Tryptone soy agar 
TSB Tryptone soy broth 
UV Ultraviolet 
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Chapter One: General Introduction 
1.1: Antimicrobial Chemotherapy 
 
Infections from microbes have long proved problematic to human health. This can be in the 
form of innocuous injuries obtained throughout an individual’s daily activities, through 
contagious diseases or infections from a nosocomial origin. Antibiotics are a type of 
antimicrobial which can be used in the treatment of microbial infections, mainly from 
bacteria but also from other types of microbes such as protozoa and fungi (Davies, 2006). 
The first antibiotic synthesised and introduced into a clinical environment in the modern era 
was arsphenamine (figure 1.1), a drug pioneered by Paul Ehrlich used to treat syphilis 
infections at the beginning of the 1910’s (Williams, 2009). However, whilst arsphenamine 
was useful in the treatment of syphilis, it was a relatively toxic compound, and was not the 
‘’magic bullet’’ that Ehrlich had hoped for. However, Ehrlich had shown that chemistry may 
be used as a weapon in the battle against pathogenic infections.  
Spurred on by the horrendous infected wounds witnessed in World War 1, the 
pharmaceutical company Friedrich Bayer began research into treating bacterial infections 
with synthetic chemicals inspired by the earlier work of Ehrlich (Bentley, 2009). After a few 
years, sulfamidochrysoidine, marketed by Bayer as prontosil, was introduced into the clinic 
in the early 1930s to treat human Streptococcal infections. Prontosil acts as an inhibitor in 
the bacterial folate pathway (Finch, 2010), which in turn prevents the bacteria from 
synthesising nucleic acids, therefore preventing bacterial growth. Humans do not synthesise 
folate as it is acquired through diet; therefore, prontosil specifically targets bacteria in 
bacterial infections. The success of prontosil inspired research into similar compounds, 
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eventually resulting in modifications to prontosil which spawned the sulfonamide (sulfa) 
class of antibiotics in the mid-1930s. 
While work on the sulfa drugs began and prospered, in 1929 a Scottish physician with an 
interest in antimicrobials, Alexander Fleming, had serendipitously discovered a fungi 
capable of inhibiting Staphylococci. He noticed on a petri dish in his laboratory on which he 
was growing Staphylococci, there was a contaminant on the dish around which he noticed 
extensive bacterial lysis (Bentley, 2009). Fleming did not know it yet, but he had discovered 
what would soon become the basis of our antibiotic armamentarium, penicillin; a β-lactam 
antibiotic. Crude preparations of the product were made to treat infections at the Sheffield 
Royal Infirmary. However, no further significant progress was made despite Fleming 
conceding that there were possible uses for penicillin as an antimicrobial agent. Fleming had 
struggled to isolate a pure sample of penicillin and had concerns regarding the compound’s 
stability. Thankfully, Fleming maintained the fungal growth in his laboratory for potential 
future work, but throughout the late 1920’s and early 1930’s, aside from one paper by 
Fleming in 1929 (Fleming, 1929), penicillin was mostly relegated to notebooks in the depths 
of Fleming’s laboratory. 
Whilst the clinical use of the sulfa drugs continued to grow throughout the mid to late 1930’s, 
it was becoming clear that antimicrobials had an important role to play in the chemotherapy 
of microbial diseases. Physiologist Howard Florey and biochemist Ernst Chain became 
interested in Fleming’s penicillin. In 1939 with the world on the cusp of World War 2, the 
two scientists developed a pilot plant for producing penicillin. The antibiotic capability of 
penicillin was demonstrated, and the two moved their operations to the relative safety of 
America, where the scale up of operations from their initial pilot plant began. Their 
operational conditions were optimised, and an efficient fermentation process to produce 
Chapter One: General Introduction 
3 
 
penicillin was established, leading to the production and isolation of penicillin G (Bentley, 
2009). 
 
 
Figure 1.1: Structures of the first marketed antibiotics. 
Following the introduction of sulfonamides in the 1930’s, there followed a rich discovery 
period from the 1940’s to the 1970’s, often termed the ‘’golden age’’ of antibiotic discovery 
(Davies, 2006a). The date of discovery of various antibiotics can be seen in figure 1.2 below. 
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Figure 1.2: Timeline of discovery of different antibiotic classes, showing a rich discovery 
era in the 1940’s-1970’s, and a discovery void from 1990 onwards. The introduction of four 
new classes from 1999 to present reflects a regeneration of interest by pharmaceutical 
companies in antibiotic development (adapted from Silver, 2011). 
The structures of the various classes of antibiotics vary greatly, from small molecules such 
as the monobactams (Bodey, 1990) to the larger polypeptide antibiotics (Hancock & 
Chapple, 1999). The molecular mechanisms of action also vary depending on the type of 
antibiotic, with examples including inhibition of cell wall synthesis and inhibition of protein 
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synthesis (Kapoor, Saigal & Elongavan, 2017). Due to the relatively wide range of antibiotic 
classes discovered and introduced into the clinic throughout the prosperous golden era of 
antibiotic discovery, some healthcare professionals had declared victory over man’s war 
with infectious disease. With the wide array of drugs available and the competitive 
conditions in this marketplace, pharmaceutical companies looked elsewhere and began 
scaling back their antibiotic discovery operations, moving resources to combat more 
lucrative non-infectious diseases such as heart problems and cancer (Cohen, 2000).  
Antibiotics are often hailed as a miracle of modern medicine; their discovery and use in the 
clinic has transformed patient care (Bartlett, Gilbert, & Spellberg, 2013) and has saved 
millions of patient and animal lives (Ventola, 2015). After the introduction of penicillin, the 
scientific community, armed with new knowledge of antibiotics and that perhaps they could 
be readily produced by a wide range of microbes, soil was deemed to be a good medium to 
screen for microbes exhibiting antimicrobial activity, as soil is an incredibly dense source 
of microbes, with 1 gram of soil containing one billion bacterial cells on average (Pham & 
Kim, 2012). However, by the late 1960’s this new platform of discovery yielded fewer and 
fewer results (Lewis, 2013) and soil has since been described as an over-mined resource, as 
around 99 % of bacteria present in soil are un-culturable in laboratory conditions (Ling et 
al., 2015), leaving only around 1 % of bacteria present in the soil environment which can be 
analysed and worked with in a laboratory. Scientists have so far been mostly unable to match 
the impressive collection of antibiotics that have been isolated from bacteria themselves 
through synthetic approaches (Berdy, 2012). Alternative approaches to traditional screening 
platforms are being explored, with the focus on trying to increase the growth rate of microbes 
in vitro. Such approaches have resulted in the discovery of new antibiotics, indicating that 
there could be potentially be a plethora of interesting discoveries to be made from previously 
un-culturable bacteria (Ling et al., 2015). 
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Antibiotics are now considered miracle drugs; common infections which used to result in 
death are now treatable within a week, and once lethal infections are considered no more 
than minor inconveniences. It’s difficult to imagine a world without antibiotics, but that 
could be very well what humanity has to face; the efficacy of antibiotics is being severely 
threatened by antibiotic resistance. Pathogenic microbial strains which were once 
susceptible to common antibiotics are now resistant to the once lethal killing mechanisms 
of our antimicrobial armamentarium. Resistant bacteria which were once susceptible to 
common antibiotics are now estimated to cause the death of over 23,000 people a year in the 
United States, and over 25,000 people a year in Europe, numbers which are only expected 
to increase as resistance spreads (World Health Organisation, 2015). Urgent action is needed 
to overcome the threat of resistance, including the development of novel antibiotics and 
novel β-lactamase inhibitors to aid in combat of β-lactamases, the main driver of antibiotic 
resistance. 
 
1.2: Antimicrobials: Examples and Mechanism of Action 
 
Bacteria can be broadly divided into two different categories based upon their structure: 
Gram-positive and Gram-negative bacteria. Gram-positive bacteria have a thick 
peptidoglycan cell wall, where-as Gram-negative bacteria have a thinner peptidoglycan cell 
wall, but are equipped with an additional outer lipopolysaccharide membrane layer. The 
additional outer membrane layer makes Gram-negative bacteria a more difficult target for 
antibiotics, presenting challenging scenarios for antibiotic development (Qin, Panunzio & 
Biondi, 2014). Different antibiotics have different mechanisms of action, for example, β-
lactams work by inhibiting cell wall synthesis (Miller, 2002), whilst polymyxins disrupt cell 
membrane integrity and are therefore useful at combatting Gram-negative bacteria, due to 
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the structural differences between Gram-positive/negative bacteria (Landman, Georgescu, 
Martin & Quale, 2008) and rifamycins work by interfering with the enzymes involved in 
bacterial growth such as RNA polymerases (Floss & Yu, 2005). The origins of most 
commercially successful antibiotics can be found as secondary metabolites produced by 
microbes such as bacteria and fungi (Davies, 2006) although many have been chemically 
altered to increase their microbe killing potential (Todar, 2012a). For example, penicillins 
can be modified by replacing the acyl group with other substituents through the intermediate 
formation of aminopenicillanic acid, to give an extended range of activity against Gram-
negative bacteria such as Escherichia coli and other Enterobacteriaceae (Deacon, n.d.).  
There was a large effort by the pharmaceutical industry to develop fully synthetic antibiotics. 
In a perfect world, a resistance-proof, high efficacy synthetic antibiotic would be created 
which exhibited highly efficient microbial killing capabilities with no side effects. However, 
given the large amount of effort and resources that went into developing a totally synthetic 
antibiotic, the mission has been a relative failure with the exception of the sulfa drugs, 
quinolones, oxazolidinones, and diarylquinolines, being the only examples of synthetic 
antibiotics to reach the clinic. Natural and semi-synthetic antibiotics outnumber synthetic 
antibiotics two to one; scientific approaches to developing synthetic antibiotics have simply 
been unable to replicate the relatively vast library of natural antibiotics. Bacterial resistance 
has been recorded against all synthetic antibiotics created, meaning science has fallen well 
short of creating the ‘’ultimate’’ synthetic antibiotic. Owing to the relative failure of 
developing synthetic antibiotics, pharmaceutical companies are largely abandoning 
development of synthetic antimicrobials, instead focusing on semi-synthetic derivatives of 
natural products (Fair & Tor, 2014). Table 1.1 below shows an overview of the different 
categories of antimicrobials available and their mechanisms of action. It also shows how 
resistance inevitably appears a short while after their introduction in the clinic. 
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Table 1.1: Examples of the different antibiotic classes and their mechanisms of action 
(Lewis, 2013). 
 
 
1.3: β-Lactam Antibiotics 
 
The β-lactam group of antibiotics consists of four sub classes: penicillins (e.g. 
benzylpenicillin), cephems (cephalosporins such as cephalothin etc.), penems 
(carbapenems) and monobactams (for example, aztreonam). Carbapenems exhibit the 
broadest spectrum of activity against Gram-positive and Gram-negative pathogens and are 
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often reserved for only the most severe multi drug resistant (MDR) infections when patients 
are gravely ill, due to drug toxicity concerns (Papp-Wallace, Endimiani, Taracila, & 
Bonomo, 2011).  β-Lactam antibiotics represent some of the most widely used antibiotics in 
the clinic, owing to their efficacy, low cost and minimal side effects (Wilke, Lovering, & 
Strynadka, 2005). It is estimated β-lactam antibiotics represent around 60 % of total 
worldwide usage of antibiotics (Livermore & Woodford, 2006). β-Lactam antibiotics are 
named as such due to their chemical structure; all β-lactams contain a four membered β-
lactam ring, which is the key to the molecule’s antimicrobial activity (Poole, 2004).  The 
carbapenems, cephalosporins and penicillins all have a fused bicyclic core; the β-lactam ring 
may be fused to a thiazolidine ring as is the case for penicillins. The β-lactam ring in 
cephalosporins is fused to a dihydrothiazine ring. Carbapenems contain a β-lactam ring 
fused to dihydropyrrole ring. Finally, monobactams only contain one ring system – the β-
lactam ring, which is not fused to a secondary ring (figure 1.3). 
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Figure 1.3: Overview of the structure of the different types of β-lactam antibiotics. 
 β-Lactam antibiotics work by inhibiting cell wall synthesis by binding to cell wall 
transpeptidases – enzymes that are membrane bound outside of the cell’s cytoplasmic 
membrane that facilitate the cross linking of the cell’s peptidoglycan cell wall. Therefore, 
the transpeptidase enzymes which are the target of penicillin are often termed Penicillin 
Binding Proteins (PBPs) (Wilke et al., 2005). The β-lactam ring mimics the structure of the 
substrate of the transpeptidase enzyme, the D-Ala-D-Ala peptide terminus (figure 1.5) which 
is removed from the peptidoglycan precursor by transpeptidase to catalyse the crosslinking 
of adjacent glycan chains (Tulane University School of Medicine, 2015). Whilst the 
polysaccharide peptidoglycan units are produced inside the cell, their final crosslinking is 
catalysed outside of the membrane by transpeptidase enzymes (Poole, 2004). β-Lactam 
antibiotics therefore prevent the crosslinking of the peptidoglycan cell wall layers, resulting 
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in inhibition of cell wall synthesis, which results in cell death (Fisher, Meroueh, & 
Mobashery, 2005). The key to β-lactam antibiotics’ success in inhibiting the cell wall 
transpeptidase enzymes is the fact that the β-lactam ring acts as an acylating agent, resulting 
in a covalent bond to the active site serine residues, present in the penicillin binding 
transpeptidase enzymes. As the β-lactam ring occupies the active site of the transpeptidase 
enzyme, the intended substrate of the enzyme (the D-Ala-D-Ala peptide terminus) cannot 
be acted upon by the enzyme. This interaction between the β-lactam and the transpeptidase 
can be considered an un-reversible reaction, as the bacterial cell will eventually lyse well 
before the acyl-enzyme complex is hydrolysed (Yocum, Waxman, Rasmussen & 
Strominger, 1979). Therefore, the D-Ala-D-Ala terminus on the PBP is the substrate upon 
which the penicillin acts to inhibit, and penicillin can therefore be considered an inhibitor of 
transpeptidase. The reaction schemes of the D-Ala-D-Ala terminus and transpeptidase and 
penicillin and transpeptidase can be seen in figure 1.4 below. 
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Figure 1.4: Reaction between D-Ala-D-Ala terminus and transpeptidase resulting in cross 
linkage of cell wall, and the reaction between penicillin and transpeptidase, resulting in 
inhibition of cell wall synthesis and eventual cell death. 
 
 
 
 
Figure 1.5: Structure of penicillin antibiotic superimposed onto the substrate for PBPs, 
showing how penicillin acts as a mimic for the substrate. 
Humans do not possess any enzymes or proteins which can be considered homologous to 
the PBPs present in bacterial cell walls. This is important to note, as it results in β-lactam 
antibiotics having a high specificity towards PBP and preventing side effects in humans. 
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A major hurdle in the mode of action of other antibiotics is penetrating the cell’s membrane 
or wall (Lewis, 2013). β-Lactam antibiotics therefore avoid this challenge, as their targets 
(the PBPs) are outside of the cell’s cytoplasmic membrane. An overview of the process of 
transpeptidase inhibition by β-lactam antibiotics is shown below in figure 1.6. 
 
 
Figure 1.6: Overview of the Mode of Action of β-Lactam Antibiotics. 
 
1.4: Antibiotic Resistance 
 
Although antibiotics have undeniably revolutionised modern medicine, their efficacy is 
being severely threatened by the onset of antibiotic resistance (Davies & Davies, 2010). 
Antibiotic resistance is the action of bacteria becoming resistant to the normally lethal 
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actions of antibiotics and is resulting in bacterial infections which cannot be treated by any 
available antibiotics, such as multi-drug resistant gonorrhoea, caused by Neisseria 
gonorrhoea, a Gram-negative pathogen typically treated with β-lactam antibiotics such as 
penicillin (Liu et al., 2015). 
Considering that bacteria themselves are the source of around 70 % of commercially 
available antibiotics (Kitani et al., 2011), it is unsuprising that resistance is present in 
environments where there is no clinical use of antibiotics. Microbes have been present on 
Earth for billions of years and over that time, they have had eons to evolve and perfect killing 
and defensive mechanisms against their microbial neighbours (Bennett, 2008). This is why 
the majority of antibiotics have been isolated from microbial sources – microbes use 
antibiotics to kill off surrounding competitors in their never-ending battle for resources. But 
over this time bacteria have also evolved defensive mechanisms to their neighbours’ 
antibiotics, and although we are witnessing a sharp increase in the number of antibiotic 
resistant bacteria and multi-drug resistant (MDR) infections (Fair & Tor, 2014), antibiotic 
resistant genes providing the necessary genetic information to code for  β-lactamase 
production have been isolated from 30,000 year old bacteria located in permafrost sediments 
in Canada (D/'Costa et al., 2011). This finding supports the theory that antibiotic resistance 
is a natural phenomenon, which greatly pre-dates the invention and mass use of modern 
antibiotics. Antibiotic resistance therefore seems an unfortunate inevitability, with resistant 
strains appearing for every single class of antibiotics used against them shortly after the 
antibiotic is introduced in the clinic (Woodford, 2005). When penicillin was introduced in 
the early 1940s, almost all Staphylococcus aureus strains were susceptible to it. Today, 
virtually all strains are resistant to natural penicillins (Rice, 2006). Antibiotic resistance 
continues to spread, whilst the antibiotic development pipeline is drying up (MacGowan & 
Macnaughton, 2013), presenting a concerning scenario and a desperate need for novel 
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antimicrobials. In an attempt to overcome antibiotic resistance, work was undertaken to 
create semi-synthetic derivatives of the original penicillin/cephalosporin antibiotics, 
resulting in so called third and fourth generation cephalosporins, penicillinase resistant 
penicillins and carbapenems (Yang, Ramussen & Shlaes, 1999). Exploiting semi-synthetic 
derivatives of existing antibiotics has been a well explored route by the pharmaceutical 
industry in the grim dearth of completely novel antibiotic development. At the time of their 
introduction into the clinic in the 1980s, these drugs were highly resistant to β-lactamases 
and were poorly hydrolysed (Garau, Wilson, Wood & Carlet, 1997). However, after the 
introduction of such drugs in the clinic in the 1980s, resistance inevitably arose a short time 
later. 
One of the key concerns of antibiotic resistance is the way in which it is disseminating 
rapidly and indiscriminately between species of pathogenic and non-pathogenic microbes 
alike. Antibiotic resistance encoding genes can be spread from one bacterial species to 
another in several ways. One example is vertical gene transfer; this can come around from 
selective pressure on the bacteria. Bacteria have incredibly short generation times relative 
to humans, with some strains of Escherichia coli having generation times of around 20 
minutes (Fossum, Crooke & Skarstad, 2007), meaning genetic information can be passed on 
to offspring extremely quickly (Todar, 2012b). When an antibiotic is administered to a 
patient, some bacteria may survive due to genetic mutations that confer some sort of 
resistance to the antibiotic (Woodford & Ellington, 2007). The bacterium will then grow and 
divide, passing down this genetic resistance to all their offspring (Kolář, Urbánek, & Látal, 
2001). Also, bacteria can transfer genetic information ‘’horizontally’’ by several 
mechanisms on mobile genetic elements. For example, bacteria can transfer plasmids via 
conjugation, even between different strains. The genes that code for many resistance 
mechanisms (such as β-lactamase production and efflux pumps) can be coded on plasmids 
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and transposons, so this provides an efficient way for these resistant genes to be transported 
between bacterial species (Bennett, 2008). Plasmids are circular rings of DNA found in some 
bacterial cells that are separate from the chromosomal DNA. Typically, plasmids code for 
proteins that are not essential for the normal growth of the cell. They are capable of 
independently replicating, and can be transported amongst different strains, and often 
species of bacteria (Darnell, Lodish & Baltimore, 1986). Transposons are transportable 
pieces of DNA, which may be encoded chromosomally or in plasmids (Cooper & Hausman, 
2004). Transposons can contain genetic information that codes for β-lactamase production 
(Bennett, 2008). Transduction is another mechanism of gene transfer; a virus that is able to 
infect bacteria (bacteriophages) transfers the DNA from one bacterium to another. The genes 
the bacteriophage transfers can include genes that code for antibiotic resistant traits 
(Balcazar, 2014). Another method of bacteria spreading antibiotic resistance genes is via 
transformation. Transformation is where the bacterial cell uptakes, integrates and expresses 
exogenous DNA (Domingues, Nielsen, & da Silva, 2012). This DNA can include genes that 
will code for antibiotic resistance traits. 
The best way to combat antibiotic resistance is to use antibiotics against which the bacterium 
has no mechanisms of resistance. However, as eluded to earlier, since the 1980s, 
pharmaceutical companies have all but lost interest in development of completely novel 
antimicrobials, with the exception of a few classes. The success of penicillin and altering 
the core drug scaffold leading to new antibiotics can be a lesson exploited by chemists in 
the development of novel antimicrobials. This does, however, enter scientists into a race 
against bacterial evolution, one that we are unlikely to ever win (Chakraborty, 2017). 
Although antibiotic resistance is a natural phenomenon, many scientists attribute the 
accelerated spread of resistance to reckless misuse and overuse of antibiotics (Fair & Tor, 
2014). In the United States, it is estimated that 50 % of antibiotic prescriptions are prescribed 
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incorrectly; either the incorrect antibiotic is prescribed or antibiotics are prescribed for viral 
infections, both of which can lead to increased resistance (Fair & Tor, 2014) via selective 
pressure. Antibiotics are used indiscriminately in the meat industry, to prevent infections in 
livestock when they are kept in crowded conditions, and to promote growth (Fair & Tor, 
2014). This irresponsible use of antibiotics promotes the spread of antibiotic resistance, 
again via selective pressure. One of the latest pieces of evidence showing misuse leading to 
resistance has been recently documented in China; colistin is a polymyxin antibiotic that is 
known as one of the ‘’last line’’ of drugs used, reserved for only the most severe infections 
of MDR owing to its toxicity in humans (Inamasu, Ishikawa, Oheda, Nakae, Hirose & 
Yoshida, 2016). But because it is rarely used, resistance to colistin was almost unheard of 
(Spapen, Jacobs, Van Gorp, Troubleyn, & Honoré, 2011). That was until recently, when a 
plasmid mediated gene that provides resistance to colistin (MCR-1) was identified in human 
and animal isolates from Escherichia coli in China (Liu et al., 2016). China is one of the 
world’s highest users of colistin in agriculture, which is attributed to the appearance of 
colistin resistance in that country (Liu et al., 2016). 
Antibiotic resistance is a growing concern amongst scientists and health practitioners for 
several reasons. Antibiotic resistance is spreading faster than the development of new 
antibiotics which counter resistance (Ling, et al., 2015). Antibiotic resistant infections are 
associated with increased patient care costs (Lin. et al., 2015), and increased morbidity 
amongst patients (Qin, Panunzio & Biondi, 2014). Also, an ever-increasing number of 
patients susceptible to bacterial infections are being witnessed, due to an ageing population, 
an increase in the immuno-compromised due to transplant operations and ever increasing 
advancements in chemotherapy of malignant diseases. Currently, 566 million people are 
aged 65 and over, with this number predicted to increase to 1.5 billion by 2050 globally 
(Kline & Bowdish, 2016). The relation between age and a deteriorating immune system has 
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long been established (Dorrington & Bowdish, 2013), (Kroll, Berger, Lepperdinger, 
Loebenstein, 2015). Clearly, in an ageing population, infections by bacteria of a pathogenic 
nature are only likely to increase. As a result, indiscriminate use of antibiotics is increasing, 
resulting in a dissemination of antibiotic resistant genes (Thomson & Bonomo, 2005). The 
reliance of antibiotics to treat infections present in the elderly and immunocompromised is 
therefore only going to increase, meaning there is a desperate need for novel antibiotics. 
Since the end of the golden era of discovery in the late 1960s, only 2 new classes of 
antibiotics have been introduced in the clinic: lipopeptides and oxazolidinones, which can 
be seen in figure 1.7 below (Butler & Cooper, 2011). The first lipopeptides, daptomycin, 
was introduced into the clinic in 2003 and is effective against most Gram-positive pathogens 
and is particularly effective in the treatment of complicated skin and skin structure infections 
(Lee, Fan, Kuti & Nicolau, 2006). Daptomycin was initially discovered as a secondary 
metabolite of Streptomyces roseosporus (Miao et al., 2005). Daptomycin’s mechanism of 
action is causing cell membrane instability by causing membrane depolarisation and 
potassium ion reflux, causing the arrest of DNA and RNA synthesis (Steenbergen, Alder, 
Thorne & Tally, 2005). Linezolid is an example of the oxazolidinone class of synthetic 
antibiotics, which is effective against Gram-positive pathogens, including methicillin-
resistant Staphylococcus aureus (MRSA) (Diekema & Jones, 2001). Linezolid exhibits 
antimicrobial activity by binding to the 50S sub unit of the prokaryotic ribosome, preventing 
the formation of the initial complex required for protein synthesis (Livermore, 2003). 
Linezolid was originally developed from a compound that showed activity against plant 
pathogens. It was investigated further by EI Du Pont in 1987, but was found to be toxic so 
development of oxazolidinone antibiotics was halted.  In 1996, Upjohn Laboratories carried 
out further work and developed a non-toxic derivative of the original drug and introduced it 
into the clinic (Bozdogan & Appelbaum, 2004). 
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Figure 1.7: Structures of daptomycin (upper), a lipopeptide and linezolid, an oxazolidinone. 
The structure of daptomycin contains a 13-member amino acid cyclic lipopeptide with a 
decanoyl side-chain; whilst linezolid is based on an oxazolidinone and acetamide. 
Antibiotic resistance is spreading faster than new antibiotic development, leading to a 
potentially catastrophic scenario unless more work is done in this area to introduce novel 
antibiotics, preferably with novel modes of action or antibiotics belonging to novel classes. 
Bacteria of particular concern are Gram-negative bacteria, as these are equipped with an 
additional outer membrane which makes them much less susceptible to conventional 
antibiotics. As discussed earlier, bacteria are seemingly always able to evolve resistance 
mechanisms to any antibiotic introduced against them. New antibiotics are always a 
welcome addition to our antibiotic armamentarium, but what is really needed are antibiotics 
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with novel modes of action, against which bacteria will take a longer time to develop 
resistance to. However, creating new antibiotics is expensive, and many pharmaceutical 
companies are moving away from new antibiotic development, owing to a multitude of 
reasons. For example: the high cost it takes to research, develop and manufacture a novel 
antibiotic, the fact that antibiotics are only used in short courses, so there’s never as much 
demand as for other drugs that are required to be taken daily for life long illnesses, antibiotics 
are prescribed less owing to better antibiotic stewardship and the fact that antibiotic 
resistance will arise eventually so the drug will be less effective against its initial target, are 
just a few reasons pharmaceutical companies are moving away from this area of drug 
development (Cooper & Shlaes, 2011). This results in a drastic need for novel antibiotics to 
be introduced into the clinic as soon as possible.  
The primary mechanism of antibiotic resistance is the production of β-lactamase enzymes 
by pathogenic bacteria. β-Lactamases catalyse the hydrolysis of the four membered β-lactam 
ring present in β-lactam antibiotics. It is the β-lactam ring in β-lactam  antibiotics which 
prevent the crosslinking of cell walls, therefore if this ring is hydrolysed the antibiotic loses 
its potency and is rendered useless by the β-lactamase (Badarau, Llinás, Laws, Damblon, & 
Page, 2005). Whilst β-lactamases represent the most important mechanism of antibiotic 
resistance, this will be explored in much more detail later. Other important mechanisms of 
antibiotic resistance should be mentioned, and will be described briefly here: 
Efflux systems and alteration of membrane permeability: Membrane permeability plays an 
important role in antibiotic resistance. In Gram-negative bacteria, β-lactam antibiotics must 
first navigate past the outer membrane before they can carry out inhibition of cell wall 
synthesis. Efflux pumps located on the outer membrane are a way of the bacteria removing 
the antibiotic from the periplasm (the space between the outer and inner membrane on Gram-
negative bacteria) to the extracellular environment surrounding the cell before the antibiotic 
Chapter One: General Introduction 
21 
 
has chance to carry out its intended mechanism. Specifically, they are transport proteins 
which may act upon a single substrate or a range of different compounds (including 
antibiotics of different classes, leading to multi drug resistance) (Webber & Piddock, 2003). 
Whilst efflux pumps are responsible for removing compounds from the cell, porins in the 
outer membrane allow small hydrophilic compounds (such as β-lactam antibiotics) to enter 
the cell membrane from the extracellular environment. Therefore, down-regulation of cell 
membrane porins will permit less antibiotic to pass through the outer membrane of the cell, 
therefore decreasing the cell’s susceptibility to the antibiotic (Delcour, 2009). 
Modification of Penicillin Binding Proteins:  Mutations at the PBP active site via selective 
pressure on the bacteria can result in decreased affinity for the antibiotic, whilst maintaining 
the efficiency of the transpeptidase enzyme. This results in a PBP which the β-lactam 
antibiotic cannot inhibit, resulting in resistance (Al-Obeid, Gutmann & Williamson, 1990).  
Enzymatic Hydrolysis of the Antibiotic (β-lactamases): Enzymes are biological macro 
molecules that catalyse chemical reactions. They are often highly selective, meaning that 
specific enzymes will only act upon specific substrates to produce a certain product. 
Enzymes are typically made up of proteins in a globular structure, they may or may not have 
cofactors (such as positively charged metal ions [for example Zn2+ in group B metallo-β-
lactamases]) and can be pH and temperature dependent (Royal Society of Chemistry, 2004). 
For example, the lactose hydrolysing enzymes produced by species of Lactobacillus have a 
slightly acidic optimum pH of 5.0 and an optimum temperature of 37°C, which is best suited 
to the environments they operate in, forming part of the gastrointestinal microbiota (Premi, 
Sandine & Elliker, 1972). By contrast alkaline phosphatases are enzymes that work best in 
a slightly alkaline environment with an optimum pH of around 8-9.5 (Millán, 2006). 
Enzymes have an active site which is uniquely shaped so that it will interact with the specific 
substrate, offering an alternate reaction pathway with lower activation energy, in turn 
Chapter One: General Introduction 
22 
 
catalysing the reaction (Royal Society of Chemistry, 2004.). An overview of the four main 
mechanisms of resistance is shown in figure 1.8 below. 
 
 
Figure 1.8: Key mechanisms of antibiotic resistance (adapted from Vranakis et al., 2013). 
The production of β-lactamase enzymes by pathogens is one of the most significant 
contributors to modern day antibiotic resistance (Shaikh, Fatima, Shakil, Mohd, Rizvi & 
Kamal, 2014). The genes which code for β-lactamase production can be coded on plasmid 
or chromosomal DNA, meaning that the specific gene sequence can easily be transferred 
between different microbes (Shaikh et al., 2014). Therefore, β-lactamases present an 
extremely important contributor to resistance mechanisms.  
There are four classes of β-lactamase enzymes, the classifications of which are based upon 
their amino acid sequence. Class B β-lactamase enzymes are unique in that they contain 
either one or two Zn2+ ions which are needed to carry out hydrolysis. The positive charge 
exhibited by the Zn2+ ions enhances also the attraction between the negatively charged 
Chapter One: General Introduction 
23 
 
substrate and the active site, leading to hydrolysis (Drawz & Bonomo, 2010). Table 1.1 
below shows an overview of the different classes of β-lactamases and their favoured 
antibiotic substrates. 
Table 1.1: Ambler Classification of β-lactamases showing preferred substrates with 
examples of enzymes (Adapted from Drawz & Bonomo, 2010). 
Ambler Class Preferred Substrates Representative Enzyme(s) 
A (Serine Penicillinases) 
Penicillins PC1 from S. aureus 
Penicillins, narrow-
spectrum cephalosporins 
TEM-1, TEM-2, SHV-1 
Penicillins, narrow-
spectrum and extended-
spectrum cephalosporins 
SHV-2 to SHV-6, TEM-3 to 
TEM-26, CTX-Ms 
Penicillins, carbenicillins PSE-1 
Extended-spectrum 
cephalosporins 
FEC-1 CepA 
Penicillins, cephalosporins 
and carbapenems 
KPC-2, SME-1, NMC-A 
B (Metallo-β-lactamases) Most β-lactams (except 
monobactams), including 
carbapenems 
IMP-1, VIM-1, CcrA and 
BcII (BL): CphA (B2): L1 
(B3) 
C (Cephalosporinases) Cephalosporins AmpC, CMY-2, ACT-1 
D (Oxacillinases) Penicillins, cloxacillin OXA-1, OXA-10 
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Shortly after the introduction of penicillin in the clinic, the first identification of a β-
lactamase enzyme capable of hydrolysing penicillin antibiotics was made in 1940 (Abraham 
& Chain, 1940). Abraham and Chain could not have possibly comprehended the magnitude 
of their discovery; indeed, at the time β-lactamases were first reported, they were thought of 
no more than a scientific curiosity. However, since these first early discoveries of resistance, 
β-lactamases now represent a global health crisis. β-Lactamases have been well classified, 
with recent studies suggesting the number of unique β-lactamases reported as over 1,300 
(Bush, 2013), with these enzymes collectively being able to catalyse the hydrolysis of all 
classes of β-lactam antibiotics. 
 
1.5: β-Lactamases 
 
Based upon their amino acid sequence or the mechanism used to catalyse the hydrolysis of 
the β-lactam ring in β-lactam antibiotics, β-lactamases can be broadly categorised into two 
different groups: the serine-β-lactamases (SBLs), or the metallo-β-lactamases (MBLs). The 
SBLs are the most prevalent type of β-lactamases present in antibiotic resistant bacteria and 
can be further separated into three subclasses dependent upon their amino acid sequence: 
class A, C and D. All these proteins contain a similar Ser-Xaa-Xaa-Lys motif, where the 
serine is the active site residue (Wouters & Bauvois, 2012). The SBLs share a similar 
reaction mechanism to hydrolyse their β-lactam targets, as seen in figure 1.9 below. Much 
like PBPs, they employ a nucleophilic serine residue at their active site to catalyse the 
hydrolysis of β-lactam rings present in β-lactam antibiotics. On the other hand, MBLs 
require one or two zinc metal ions at their active site to be able to carry out hydrolysis of the 
β-lactam ring (Brem et al., 2016) (Matagne, Dubus, Galleni & Frére, 1999). 
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Figure 1.9: General hydrolysis mechanism of SBL. 
Although the hydrolysis mechanism is different for each class of SBL on account of the base 
utilised to deprotonate the active site serine, the general mechanism is similar for the SBLs. 
The reaction commences by non-covalent formation of a Michaelis complex, followed by 
nucleophilic attack on the carbonyl carbon of the β-lactam ring by the active site serine 
residue concerted with proton abstraction by a basic group. Protonation of the β-lactam 
nitrogen leads to the cleavage of the C-N bond to form a covalent acyl enzyme intermediate. 
Attack by a catalytic water leads to a high energy deacylation intermediate, with subsequent 
hydrolysis of the bond between the β-lactam carbonyl and the oxygen of Ser70. This results 
in the release of the hydrolysed antibiotic and regeneration of free β-lactamase enzyme. 
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As mentioned, the SBLs can be further categorised into three categories based on their amino 
acid sequences and substrate preferences; they can be categorised into Ambler classes A, C 
and D (Ambler, 1980). Problematic Gram-negative pathogens such as strains of Escherichia 
coli, Pseudomonas aeruginosa and Klebsiella pneumoniae are typical producers of β-
lactamases (Zeng & Lin, 2013). 
β-Lactamases can be inducible or constitutive enzymes. The production of inducible β-
lactamases is normally repressed by some mechanism under normal conditions, but can be 
induced in the presence of a suitable molecular inducer such as a β-lactam antibiotic. This 
means that when the antibiotic is detected by the bacterial cell, genes coding for the 
production of β-lactamases are activated and the enzyme is expressed, resulting in hydrolysis 
of the antibiotic (Bedenic & Zagar, 1995). β-Lactamases may also be constitutive, meaning 
that the bacterium constantly produces a level of β-lactamase, whether or not a molecular 
inducer is present. Inducible β-lactamases are most commonly associated with Gram-
positive organisms, whilst constitutive β-lactamases are normally found in Gram-negative 
bacteria (Livermore, 1995).  
β-Lactamases can be extracellular or intracellular, meaning they can be excreted to the 
extracellular environment, or remain in the intracellular environment of the periplasmic 
space in Gram-negative bacteria. It is normally the case for Gram-positive pathogens to 
excrete the enzyme to the extracellular space, as they do not have an additional outer 
membrane as Gram-negative bacteria do. Gram-negative are more likely to produce 
intracellular enzymes within their periplasmic space between their outer membrane and 
inner cell membrane, where the β-lactam antibiotics are trying to reach to interact with the 
PBP of the bacteria’s cell wall. Although Gram-negative bacteria can also excrete β-
lactamases to the extracellular environment more often than not this is due to cell wall 
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damage resulting in poor cell membrane stability caused by β-lactam antibiotics 
(Matsumura, Minami, Araki, Hori, Ogake, Watanabe, 2000). 
 
1.5.1: Class A SBLs 
 
Group A SBLs consist of the penicillinases, such as Temoneira β-lactamase (e.g. TEM-1), 
first isolated from a strain of E. coli in 1965 (Shaikh et al., 2015) and the plasmid encoded 
sulfhydryl reagent variable β-lactamase enzymes (SHV) (Philippon, Slama, Deny & Labia, 
2016). SHV β-lactamases are most commonly associated with Klebsiella spp of bacteria. 
The gene coding for the precursor of SHV enzymes, SHV-1, is universally found in 
Klebsiella pneumoniae (Shaikh et al., 2015). Class A SBLs are the most widely studied of 
the SBL classes and are the most commonly encountered class of β-lactamases with more 
than 550 enzymes being classified (Philippon et al., 2016). Class A SBLs all share a common 
mechanism of action, which involves a nucleophilic attack at the carbonyl position on the 
β-lactam ring by the active site serine (Ser70), which is deprotonated by the general base 
Glu at position 166 (Glu166). This is followed by the formation of an acyl-enzyme 
intermediate, followed by hydrolysis of this intermediate by a general base activated water 
module, resulting in a cleaved β-lactam ring and the regeneration of free enzyme (Sougakoff, 
2012). Class A SBLs are widely recognised to have initially evolved to hydrolyse penicillin 
(Christensen, Martin, & Waley, 1990). This claim has been given a firm backing by the work 
of Hardy and Kirsch (1984), that showed the class A SBL β-lactamase I from Bacillus cereus 
operates at the diffusion controlled limit, meaning that the hydrolysis reaction the enzyme 
catalyses is carried out so efficiently, that the rate limiting step is the diffusion of the 
substrate into the enzyme’s active site (Bulychev & Mobashery, 1999). 
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Although some class A SBLs are considered extended spectrum β-lactamases (ESBLs), 
capable of hydrolysing later generation penicillins and cephalosporins such as ceftriaxone 
(Rawat & Nair, 2010), they typically can be inhibited by some of the clinically available β-
lactamase inhibitors (BLIs), such as clavulanic acid (Bush & Jacoby, 2010) and avibactam 
(Ehmann et al., 2013). Resistance of class A SBLs to the aforementioned inhibitors is 
difficult to analyse, so specifics of resistance to inhibitors remains unknown. The usual 
mechanism of resistance for this class of enzymes is to simply mass produce the β-lactamase 
in high concentrations in the periplasmic space of the bacterial cell, which overwhelms the 
BLI (Blazquez, Baquero, Canton, Alos & Baquero, 1993), (Martinez, Delgado-Iribarren, 
Perez-Diaz & Baquero, 1989), (Yang, Ramussen & Shlaes, 1999). 
 
1.5.2: Class B Metallo-β-lactamases 
 
The class B β-lactamases are known as the metallo-β-lactamases (MBLs). MBLs are a 
critical concern for physicians as, currently, there are no known clinically significant 
inhibitors of MBLs (Faridoon & Islam, 2013). Carbapenem β-lactam antibiotics are highly 
effective antibiotics and are more resistant than other antibiotics to hydrolysis by β-
lactamases than other β-lactam antibiotics (Meletis, 2016). Carbapenems are often referred 
to as the ‘’last resort’’ antibiotics, owing to their relative toxicity in humans, and as such, 
use of carbapenems is only recommended after treatment with other β-lactams have had little 
impact on the infection (Shah & Isaacs, 2003). It is recommended in clinical practice to 
withhold from the use of carbapenems in the clinic until all other options have been 
exhausted (Baughman, 2009). Because of the relative scarcity of their use compared to other 
β-lactam antibiotics, resistance of bacteria towards carbapenems had been practically 
unheard of until the emergence of MBLs (Codjoe & Donkor, 2018); indeed, carbapenems 
Chapter One: General Introduction 
29 
 
themselves have been reported as inhibitors of SBLs by reacting with the serine active site 
and forming a long-lasting acyl-enzyme intermediate (Palzkill, 2013). MBLs have emerged 
relatively recently in the last two decades and have become a significant threat in the clinic, 
owing to the lack of inhibitors and the fact they are capable of hydrolysing carbapenems 
(Cornaglia, Giamarellou & Rossolini, 2011). The family of MBLs have evolved from 
seemingly insignificant beginnings to become capable of hydrolysing every class of β-
lactam antibiotics except the monobactams (Palzkill, 2013). The first MBL was reported in 
1966 by Sabath and Abraham (1966), from a strain of Bacillus cereus. Interestingly, 
although β-lactamases are more typically associated as problematic in Gram-negative 
pathogens, Bacillus cereus is a widespread Gram-positive pathogen, more often typically 
associated in food poisoning cases (Bottone, 2010). Much like the first reported cases of 
SBLs, MBLs were considered no more than a scientific curiosity, as they were mainly 
encountered in non-pathogenic bacteria (Bebrone, 2007) (Walsh et al., 1994). However, 
curiosity gave way to concern when the unrelenting spread of genes encoding for MBLs 
transferred from non-pathogenic bacteria to particularly concerning nosocomial strains such 
as Pseudomonas aeruginosa and Chryseobacterium meningosepticum (Watanabe, Iyobe, 
Inoue & Mitsuhashi, 1991), (Rossolini et al., 1998). 
Whilst metal ions are required as cofactors for a wide array of enzymes in nature, a unique 
feature of the MBLs amongst β-lactamases is that they are dependent upon the presence of 
one or two zinc metal ions at their active site for their catalytic activity (Jiang et al., 2018). 
The genes that code for MBLs can be found on plasmids, allowing these genes to be 
transported easily between species of bacteria. As such, a key concern is that non-pathogenic 
bacteria such as commensal micro flora can act as a source, or a reservoir of genes coding 
for MBL production, increasing the amount of antibiotic resistance. As the gene can spread 
from non-pathogenic bacteria to harmful pathogens on mobile genetic elements, resistance 
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is conferred from one bacterium to another (Machado, Coque, Cantón, Sousa & Peixe, 
2013). 
MBLs are typically classified into one of four subclasses depending upon their sequences, 
substrate profiles and structures: B1, B2, B3 and B4, with subclass B4 being a recent 
addition following the discovery of a novel MBL isolated from Serratia proteamaculans 
(Vella et al., 2013). Although all classes require zinc ions to carry out their catalytic activity 
(normally Zn2+), the classes differ upon the number of Zn ions required. Subgroups B1, B3 
and B4 require two Zn ions at their active sites, subgroup B2 needs only one, and are 
inhibited in the presence of two Zn ions. The notable exception to these general rules is BcII, 
which is interesting owing to the fact it exhibits catalytic activity in the presence of one or 
two Zn ions (Jiang et al., 2018). 
The most commonly encountered MBLs in the clinic are the carbapenems hydrolysing New 
Delhi Metallo-β-lactamase (NDM-1) and Verona Imipenemase (VIM), both belonging to 
the B1 subclass of MBL. Almost all clinically significant MBLs are members of the B1 
subclass (Logan & Bonomo, 2016). 
As mentioned, there are no clinically significant inhibitors of the MBLs available to 
clinicians (McGeary, Tan & Schenk, 2017). However, work towards a clinical inhibitor has 
been steadily increasing as the threat posed by the emergence of the MBLs, particularly 
NDM-1, VIM and IMP variants has become apparent. Two general techniques for MBL 
inhibition have been identified – Zn dependent and independent inhibition mechanisms 
(Rotondo & Wright, 2017). Typically, most work into novel MBL inhibitors has been the 
former, exploiting the Zn ions that are essential for catalysis. Specifically, already approved 
drugs that are known metal chelators have been screened for inhibitory activity against 
MBLs. Chelating agents have been shown to be effective inhibitors of certain MBLs by 
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forming ligands with Zn ions to interfere with their catalytic mechanism, as identified in a 
study by Klingler and colleagues (2015). This study looked at already approved drugs which 
are known chelating agents and screened them for inhibition against MBLs. The most 
effective inhibitor in this study was dimercaprol, a chelating agent used in the treatment of 
heavy metal poisoning (Rotondo & Wright, 2017). Similarly, another study by Brem and 
colleagues (2015) found that captopril, a well-established drug that is known to modulate 
blood pressure by binding to the Zn2+ ion in the human angiotensin converting enzyme 
causing inhibition (Jenkins, Dreslinski, Tadros, Groel, Fand & Herczeg, 1985) was an 
effective inhibitor of clinically relevant MBLs in the B1 class (IMP, VIM and BCII); with 
IC50 values in the sub 10 µM range. 
The consensus regarding the MBL mechanism of catalysis is that a nucleophilic attack takes 
place on the carbonyl carbon in the β-lactam ring of β-lactam antibiotics. This is followed 
by the C-N bond breaking and the protonation of the amide nitrogen before the hydrolysed 
β-lactam antibiotic is released (Page & Badarau, 2008). An example of the catalytic 
mechanisms of BCII can be seen in figure 1.10 below. 
 
Figure 1.10: Overview of catalytic mechanism of MBLs (Page & Badarau, 2008). 
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1.5.3: Class C SBLs 
 
Class C SBLs are also termed AmpC β-lactamases and are commonly encountered in Gram-
negative pathogens such as Escherichia coli, Pseudomonas aeruginosa and Serratia 
marcescens (Philippon, Arlet & Jacoby, 2002). Class C SBLs represent the second most 
common class of SBL after class A SBLs (Bush & Mobashery, 1998). Crystallographic 
structures of class C enzymes have been resolved and help to elucidate the mechanism of 
hydrolysis employed by this class of enzyme (Powers & Shoichet, 2002). Ser-64 is the active 
serine and performs the nucleophilic attack onto the β-lactam carbonyl facilitated by Tyr150 
acting as the general base to active the serine residue (Wouters & Bauvois, 2012). Class C 
SBLs are predominantly chromosomally mediated, although plasmid mediated enzymes do 
exist, and were first discovered from a Klebsiella pneumoniae isolate by Papanicolaou, 
Medeiros and Jacoby (1990). The preferred substrate of the class C SBLs is cephalosporin 
β-lactams, but they are also able to catalyse the hydrolysis of penicillins. Similarly to some 
class A SBLs, it has been shown that class C SBLs can operate at the diffusion limit for their 
preferred cephalosporin substrates. Specifically, Bulychev and Mobashery have shown that 
the P99 class C SBL from Enterobacter cloacae, reaches the diffusion limit for its preferred 
cephalosporin substrates. Class C SBLs are typically not inhibited by the two historical β-
lactamase inhibitors clavulanic acid and sulbactam, but they are inhibited by the novel non-
β-lactam β-lactamase diazabicyclooctane inhibitors such as avibactam, relebactam and 
nacubactam (Lahiri, Johnstone, Ross, McLaughlin, Olivier & Alm, 2014), (Zhanel et al., 
2018), (Docquier & Mangani, 2018). AmpCs typically hydrolyse older cephalosporins, such 
as the first generation cephalothin cephadroxil drugs. Later generations of cephalosporins 
such as the zwitterionic fourth generation cefpirome, cefepime and carbapenems are not 
normally hydrolysed by AmpCs. However, the emergence of extended spectrum AmpCs has 
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been reported, which are able to hydrolyse later generations of cephalosporins and 
carbapenems, broadening the substrate profile of typical AmpCs (Rodríguez-Martínez et al., 
2011). 
 
1.5.4: Class D SBLs 
 
Class D SBLs are also known as oxacillinase enzymes (OXA type) and consist of over 400 
genetically diverse enzymes that are largely disseminated from Gram-negative bacteria, with 
this number steadily increasing (Antunes, Lamoureaux, Toth, Stewart, Frase & Vakulenko, 
2014). Like class A and C SBLs, class D SBLs also have a serine active site, but differ from 
class A and C enough in their structure to require their own class. Class D enzymes have 
mostly higher rates of hydrolysis for antibiotics such as cloxacillin and oxacillin than for 
benzylpenicillins (hence the name OXA), but not all class D enzymes have this ability to 
hydrolyse oxacillins (Poirel, Naas & Nordmann, 2010). Class D enzymes were amongst the 
first type of β-lactamases discovered, were originally very rare and were only found on 
plasmid DNA (Evans &Amyes, 2014). OXA enzymes were originally found to be very 
similar to class A SBLs, having a common substrate profile of being able to hydrolyse 
penicillins. However, OXA enzymes can be distinguished from class A SBLs by their ability 
to hydrolyse oxacillin (Evans & Amyes, 2014). The class D SBLs have experienced the 
largest increase in growth compared to any other class of SBL due to discovery of new 
enzyme variants (Antunes & Fisher, 2014). Class D SBLs are resistant to inhibition by the 
classic SBL inhibitors such as clavulanic acid or sulbactam, but are prone to inhibition by 
halide ions such as I- and Cl- (Héritier, Poirel, Aubert & Nordmann, 2003), (Stojanoski et 
al., 2015). The OXA class can be typically classified into narrow and extended spectrum β-
lactamases depending upon their substrate profile. OXA-2 and OXA-10 are considered 
Chapter One: General Introduction 
34 
 
examples of narrow-spectrum enzymes capable of hydrolysing penicillins and early 
generation cephalosporins. However, some class D enzymes are capable of hydrolysing 
carbapenems, which represents serious clinical concern due to the nature of carbapenems as 
mentioned previously. Such examples of class D carbapenemases include OXA-23, OXA-
24 and OXA-51, and are predominantly found in Gram-negative pathogens such as 
Acinetobacter baumannii (Antunes at al., 2014). 
For class D β-lactamases an active site lysine (Lys70), serves as the general acid/base to 
facilitate hydrolysis of β-lactams. Lys70 may be carboxylated as a result of a reaction 
between ε-NH2 of the lysine and carbon dioxide: 
 
The carboxylation of the lysine is pH dependent, and is a compromise between the 
concentration of CO2 (favoured by lower pH levels) and deprotonation of CO2H (favoured 
by higher pH levels). 
 
1.5.5: SBLs Mechanism of Action 
 
As one might imagine, the catalytic mechanism of the SBL classes of enzymes is very 
similar to the mechanism of PBPs from which they have evolved; due to similarities in 
sequence analyses, PBPs and β-lactamases are thought to have emerged from a common 
ancestor (Kong, Schneper & Mathee, 2010). 
The chemistry and sterics of the β-lactam ring makes the antibiotic susceptible to hydrolysis. 
The carbonyl carbon has a bond angle of 90 °, which is far from the ideal bond angle of 
109.5 °, meaning the lactam is susceptible to ring strain. The easiest way for the molecule 
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to alleviate this strain is to break the ring by hydrolysing the amide in the β-lactam ring. The 
cleavage of the amide bond allows the β-lactam ring to open, meaning the bond angle is 
closer to 109.5 °. 
Furthermore, resonance has a role to play in facilitating the opening of the β-lactam ring. 
Linear amides typically have strong resonance, meaning electrons from the nitrogen lone 
pair are delocalised towards the carbon as they are drawn by the electronegativity of the 
oxygen atom. This increases the electron density around the carbon, making it less 
electrophilic and therefore less reactive/susceptible to a nucleophilic attack (considering that 
the β-lactamase carries out a nucleophilic attack at the carbonyl carbon). Additionally, the 
nitrogen in the lactam ring cannot be planar due to the sterics of the molecule.  
With the chemistry of the lactam ring considered, one might assume it does not take much 
for a molecule to be able to hydrolyse the ring. However, research has shown that β-lactams 
are not particularly reactive, showing similar reactivity to normal amides (Page, Laws, Slater 
& Stone, 1995) (Page, 1999). It is therefore perhaps testament to the evolutionary finesse of 
SBLs that they are so able to efficiently catalyse the hydrolysis of β-lactam rings. SBLs 
perform a nucleophilic attack on the carbonyl carbon in order to break open the ring. 
Typically, a hydroxyl group on a serine residue performs a nucleophilic attack on the 
carbonyl of the β-lactam ring. The protonation of the β-lactam nitrogen leads to cleavage of 
the C-N bond and the formation of the covalent acyl enzyme intermediate. This complex is 
then hydrolysed by water, leading to deacylation of the enzyme from the β-lactam ring, 
regenerating free enzyme and resulting in a hydrolysed antibiotic. The ability of the SBL 
enzyme to hydrolyse the acyl-enzyme complex resulting in liberated enzyme and hydrolysed 
β-lactam antibiotic is what sets them apart from the PBP; the PBPs are unable to efficiently 
hydrolyse the acyl-enzyme intermediate formed when a β-lactam antibiotic inhibits the PBP, 
resulting in the β-lactam antibiotic being able to exhibit its antibiotic activity (Hata et al., 
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2006). In the case of SBLs, the efficient hydrolysis of this acyl-enzyme intermediate is what 
allows the SBL to break down the β-lactam ring before it can reach its intended target of the 
PBP. The fact that Gram-negative pathogens tend to constitutively produce β-lactamases in 
the periplasmic space of the bacterial cell wall, means that in many cases the β-lactam cannot 
even reach its intended target of the inner membrane bound PBP before being hydrolysed in 
the periplasmic space by β-lactamases, representing an extremely challenging scenario for 
overcoming antimicrobial resistance of this type (Georgopapadakou & Lio, 1980). 
The reactions of the SBLs with β-lactam antibiotics, and indeed PBPs and β-lactam 
antibiotics follow a similar kinetic pathway as detailed below: 
 
Where E is the enzyme, S the substrate, ES is the Michaelis complex, EA* is the covalent 
acyl enzyme, and P is the product (Oliva, Dideberg & Field, 2003). As mentioned, the main 
difference between β‐lactamases and PBPs is that the former undergo fast deacylation after 
ring‐opening (k3 ∼ 103 s−1) whereas the latter are inhibited by the antibiotic (k3 ∼ 10−5 s−1) 
(Oliva, Dideberg & Field, 2003). 
Whilst all of the SBLs utilise an active site serine to carry out the nucleophilic attack on the 
carbonyl carbon, depending upon the class of SBL, different acid/base catalytic residues are 
used to facilitate hydrolysis of the antibiotic (Hata et al., 2006). Whilst all of the SBLs utilise 
Ser70 as the active site serine to carry out the nucleophilic attack on the carbonyl carbon, In 
the case of class A SBLs, a glutamate residue at position 166 (Glu166) is employed as a 
general base to assist in the deprotonation of the active site serine Ser70, for formation of 
the acyl enzyme intermediate and also for the hydrolysis of it (Hermann, Ridder, Mulholland 
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& Holtje, 2003). The mechanism of the first step used by class A SBLs is shown in figure 
1.11 below. 
 
 
Figure 1.11: Catalytic Mechanism of Class A SBLs showing formation of the tetrahedral 
intermediate (Hermann et al., 2003). 
In the case of class C SBLs, there is no single key amino acid to serve as the general 
acid/base, but rather an active site hydrogen bonding network that serves as the key to 
catalysis, unlike class A SBLs where Glu166 is utilised to assist in the deprotonation of the 
Ser70 residue (Madgwick &Waley, 1987). Asn152, Lys67 and Tyr150 form a hydrogen 
bonding network between them which is key for the hydrolysis mechanism of class C 
enzymes (Goldberg, Iannuccilli, Nguyen, Ju & Cornish, 2003). These residues are 
accompanied with Gln120 and Lys315 and these residues are also considered necessary for 
catalysis, but are less important than the other residues mentioned previously. The identity 
of the residue that serves as the general base for the catalysis mechanism is unknown, but 
can be narrowed down to either Lys67 or Tyr150 (Goldberg et al., 2003). 
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The class D SBLs rely on a post-translationally modified carboxylated lysine at Lys70 to 
serve as the general base residue for the enzyme acylation and deacylation steps in their 
hydrolysis of β-lactams (Golemi, Maveyraud, Vakulenko, Samama & Mobashery, 2001). 
Lysine reacts with CO2 to produce the lysine carbamylate residue that is needed to serve as 
the general acid/base in the hydrolytic mechanism of class D SBLs (Golemi et al., 2001). 
The carboxylated lysine is stabilised by an interaction between itself and the indole group 
of Trp154. Catalytic activity is greatly reduced when Trp154 is replaced with a different 
amino acid such as Gly, Ala or Phe (Baurin et al., 2009). It is thought that the Lys is 
carboxylated by reaction of the amino group with CO2, as in the following reaction:  
ε-NH2 + CO2 + H2O ⇌ ε-NH-COO- + H3O+ 
(Maveyraud et al., 2000). 
The carbamylated lysine serves as the general base to deprotonate the nucleophilic serine in 
the first step of the β-lactam hydrolysis and serves as a base once again to abstract a proton 
of water during the turnover of the acyl-enzyme intermediate (Golemi et al., 2001). 
 
1.6: SBL Inhibitors 
 
Due to the rich history of novel antibiotic development in the ‘’golden era’’ of antibiotic 
discovery, resistance to antibiotics was seen as more of a minor inconvenience rather than 
the pandemic health crisis it is today. If resistance arose, it was simply overcome by the 
development of novel analogues and newer generations of existing cephalosporins and 
penicillins (Gaude & Hattiholli, 2013). 
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As mentioned, the predominant method of antibiotic resistance amongst microbes is via the 
production of β-lactamase enzymes.  Owing to the dearth of development of novel 
antibiotics, pharmaceutical companies have explored the avenue of β-lactamase inhibition, 
with the aim of restoring the efficacy of β-lactam antibiotics (Drawz & Bonomo, 2010). 
Inhibitors themselves do not usually possess any antibiotic activity; therefore, they are 
usually paired with a β-lactam antibiotic, with the aim of preserving the β-lactam core of the 
antibiotic by inhibiting β-lactamase enzymes produced by the pathogen (King, Sobhanifar 
& Strynadka, 2016).  There are generally 4 widely used examples of β-lactam/β-lactamase 
inhibitor combinations (BLICs): amoxicillin/clavulanate, ticarcillin/clavulanate, 
ampicillin/sulbactam, and piperacillin/tazobactam (Toussaint & Gallagher, 2015). BLIC 
combinations aid in restoring activity to previously susceptible antibiotics. These 
combinations work well against class A β-lactamases, but are less effective against class C 
and D enzymes (Toussaint & Gallagher, 2015).  
The first SBL introduced into the clinic was clavulanic acid, named after the strain of 
Streptomyces clavuligerus it was isolated from towards the end of the 1970s (Reading & 
Cole, 1977). Clavulanic acid’s structure is similar to that of penicillin, in that it contains a 
β-lactam ring fused to a 5-membered heterocycle, but contains an oxygen atom compared 
to penicillin’s sulfur (Fulston, Davison, Elson, Nicholson, Tyler & Woroniecki, 2001). 
Clavulanic acid is approved for use with two β-lactam antibiotics, co-administered with the 
semi synthetic penicillin antibiotic ticarcillin as timentin (Labia, Morand & Péduzzi, 1986), 
and with amoxicillin as augmentin (Ball, Mehtar & Watson, 1982) and has restored the 
efficacious nature of penicillins against infections caused by problematic SBL producing 
bacteria such as Acinetobacter baumannii (Brauers, Frank, Kresken, Rodloff & Seifert, 
2005), Escherichia coli (Harris et al., 2015) and Pseudomonas aeruginosa (Strateva & 
Yordanov, 2009). 
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Following the introduction of clavulanic acid in the early 1980s, two synthetic SBL 
inhibitors were introduced; the penicillinate sulfone sulbactam (Wright & Wise, 1983) and 
tazobactam (Gutmann, Kitzis, Yamabe & Acar, 1986). Tazobactam is approved for use with 
the β-lactam antibiotic piperacillin and has been shown to inhibit SBLs caused by infections 
from Staphylococci, Streptococci, Escherichia and Klebsiella families of bacteria (Daniel & 
Krop, 1996), whilst sulbactam is approved for use with the β-lactam antibiotic ampicillin 
and is useful in the treatment of intra-abdominal infections associated with SBL producing 
Gram-negative bacteria such as Escherichia coli and Klebsiella (Benson & Nahata, 1988). 
Whilst these β-lactamase inhibitors have little antibacterial activity themselves, the 
mechanism of their inhibition of SBLs is very similar to the mechanism of inhibition of 
PBPs by β-lactam antibiotics. The inhibitors react with the active site serine nucleophile 
forming an acyl-enzyme complex that is subject to low turnover rates, resulting in inhibition 
of the enzyme (Brown, Aplin & Schofield, 1996), (Thierren & Levesque, 2006). 
BLICs have undoubtedly restored efficacy to previously susceptible β-lactam antibiotics 
leading to improved outcomes in patients suffering infections from SBL producing bacteria, 
but the previously mentioned inhibitors have no antibiotic capability by themselves, and are 
only effective against class A SBLs and are typically poor inhibitors of class C and D SBLs. 
Renewed interest in antibacterials and novel inhibitors of SBL has led to the recent 
introduction and development of a novel class of β-lactamase inhibitors, the non-β-lactam 
inhibitors such as avibactam (Ehmann et al., 2012), relebactam (Blizzard et al., 2014), 
nacubactam (Monogue, Giovagnoli, Bissantz, Zampaloni & Nicolau, 2018), zidebactam 
(Moya et al., 2017) and the cyclic boronic vaborbactam (Lomovskaya et al., 2017). 
Avibactam is approved for use with the cephalosporin antibiotic ceftazidime, targeting 
complicated intra-abdominal infections caused by Gram-negative pathogens (Temkin et al., 
2017). Relebactam is in clinical trials for use alongside imipenem/cilastin for infections 
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caused by Gram-negative bacteria (Lob et al., 2017). Nacubactam is in clinical trials in 
conjunction with meropenem to help combat urinary tract infections caused by SBL 
producing Gram-negative pathogens (Livermore, 2018). Zidebactam is currently in clinical 
trials to be used in conjunction with the cephalosporin antibiotic cefepime, targeting 
infections caused by Gram-negative bacteria (Sader, Castanheira, Huband, Jones & Flamm, 
2017). Finally, vaborbactam is approved for use alongside meropenem, marketed as 
vabormere and is useful to combat infections caused by carbapenemase producing Klebsiella 
pneumoniae (Patel, Pogue, Millis & Kaye, 2018). Figure 1.12 shows an overview of the 
clinically relevant SBL inhibitors. 
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Figure 1.12: Clinically Useful SBL inhibitors. Note how avibactam, relebactam and 
zidebactam are diazabicyclooctanes whilst vaborbactam is a cyclic boronic compound, 
representing the novel non-β-lactam β-lactamase inhibitors. 
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Typically, β-lactamase inhibitors can be generally classified in two different ways: the 
mechanism of their inhibition, or by their structure. Inhibition can be ‘’suicide’’ inhibition, 
or reversible inhibition as in the case of avibactam. Suicide inhibition involves inhibitors 
which permanently inactivate the β-lactamase enzyme via chemical reactions in the 
enzyme’s active site, resulting in a permanent change in the structure of the active site, 
resulting in enzyme inhibition (Drawz & Bonomo, 2010). Tazobactam, sulbactam and 
clavulanic acid are examples of suicide inhibitors.  In terms of structure, β-lactamase 
inhibitors can be classified as being β-lactam, non-β-lactam, or diazabicyclooctane. An 
example of the mechanism of clavulanic acid inhibiting an SBL can be seen in figure 1.13 
below. 
 
Figure 1.13: Mechanism of inhibition of clavulanic acid and an SBL. 
 
1.6.1: Avibactam 
 
Avibactam is a non β-lactam β-lactamase inhibitor developed by Actavis and AstraZeneca 
(Wang, Abboud, Markoulides, Brem, & Schofield, 2016). It is a good inhibitor of class A 
β-lactamase enzymes, with less inhibition exhibited against class C and D β-lactamases. 
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Avibactam is the first non-β-lactam β-lactamase inhibitor developed for clinical use (Wang 
et al., 2016). In terms of its chemical nature, avibactam is a diazabicyclooctane, which is 
capable of reversibly inhibiting target β-lactamases via covalent bonding. Although not a β-
lactam, the structure of avibactam strongly resembles that of a β-lactam. 
 
Figure 1.14: Chemical structure of avibactam (Zhanel et al., 2013). 
The carbonyl at position 7 in figure 1.14 above mimics those found in β-lactam antibiotics 
such as penicillins and cephalosporins and the anionic sulfamate on the nitrogen at position 
6 mimics the carboxylate anion found in other β-lactams (Zhanel et al., 2013). This allows 
avibactam, to have 2 anchor points to inhibit β-lactamase enzymes. Hydrogen bonding 
occurs to the O on the carbonyl at position 7 between avibactam and the amino acids round 
the active site of the enzyme, where-as the negatively charged sulfamate group is attracted 
to the positive charge of lysine amino acids. An example of the reversible inhibition of a 
SBL by avibactam can be seen in figure 1.15 below. 
Chapter One: General Introduction 
45 
 
 
Figure 1.15: Reversible inhibition of SBL by avibactam 
The introduction of avibactam in the clinic has led to the development of similar non-β-
lactam β-lactamase inhibitors, including relebactam (Merck)  and nacubactam (Fedora 
Pharmaceuticals/Roche). Both are structurally similar analogues to avibactam, with different 
groups being added to the amide at position 2 in figure 1.15 above. The structures of 
relebactam and nacubactam are shown below in figure 1.16. 
 
Figure 1.16: Chemical structures of nacubactam and relebactam 
Nacubactam is currently nearing the end of phase 1 clinical trials (Roche, 2016), with the 
intention of it being partnered with β-lactam antibiotics (much like avibactam) to assist in 
restoring efficacy to β-lactam antibiotics. Relebactam has entered phase 3 clinical trials, with 
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the intention of it being partnered with imipenem to treat patients with complicated urinary 
tract infections (Merck, 2016). Initial studies against gram-negative pathogens show 
promise, with activity against troublesome pathogens including multidrug resistant 
Pseudomonas aeruginosa (Lapuebla et al., 2015). 
 
1.7: Search for Novel Antibiotics 
 
The majority of antibiotics first introduced in the clinic over 40 years ago had microbial 
origins. These drugs were found and developed by screening samples for antimicrobial 
activity against common pathogens, in what is known as the Waksman Platform of discovery 
(Lewis, 2013). Soil provided a rich source of antimicrobial compounds, with more than 70 
% of commercially important antibiotics being derived from the secondary metabolites of 
the Streptomyces genus of bacteria (Kitani et al., 2011), which are ubiquitous in soil (Seipke, 
Kaltenpoth, & Hutchings, 2012). However, as described earlier, this once rich source of 
novel compounds yielded diminishing results, and this approach has now been largely 
abandoned. The problem of antibiotic resistance is compounded by the fact there is a 
desperate lack of novel antibiotics in clinical development. Almost all antibiotics in clinical 
use were first developed in the golden era of antibiotic discovery, during the 1940s to 1960s 
(Lewis, 2013), with resistance more often than not appearing shortly after their introduction 
in the clinic (Ventola, 2015). There is a steady, but slow continued stream of antibiotic 
compounds in development, and many are derivatives of old compounds that were initially 
thought to be unsuccessful but have gained renewed interest largely due to the desperate 
need for novel antibiotics (Lewis, 2013). Some ‘’new’’ antibiotics in development are 
simply old derivatives combined with novel β-lactamase inhibitors, such as ceftolozane, a 
combination of a cephalosporin and tazobactam (Draenert, Seybold, Grützner, & Bogner, 
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2015) and Ceftazidime-avibactam, a combination of a cephalosporin and avibactam, a novel 
β-lactamase inhibitor with inhibitory action against class D β-lactamases (Theuretzbacher, 
2015). As discussed, synthetic approaches to antibiotics have largely been unsuccessful, 
despite the massive effort pharmaceutical companies invested into discovering novel 
synthetic compounds (Lewis, 2013). One of the main problems with synthetic antibiotics is 
ensuring their uptake into the cell, a process that is made more difficult in Gram-negative 
bacteria. This approach has now largely been abandoned due to the minimal return in 
investment. The most successful discovery platform to date for novel antibiotics has clearly 
been the screening of natural products. One pitfall of this discovery platform is that around 
99 % of bacteria present in the environment do not grow in vitro. This means there’s 
potentially a huge source of interesting, novel antimicrobial compounds waiting to be 
discovered in this un-explored resource (Ling, Schneider, Peoples, Spoering, Engels, 
Conlon, Mueller, Schaberle, et al., 2015). One of the greatest conundrums that is pondered 
by modern microbiologists is the sheer lack of colonies that are able to be cultivated in vitro 
compared with the amount of organisms observed directly from environmental samples. 
Whether observing through a light microscope, or metagenomic analysis direct from 
samples, it is clear that the amount and diversity of microbes that are present in the sample 
but do not grow in vitro is staggering.  
As mentioned, around 99 % of bacteria present in the environment are not grown under 
standard laboratory conditions, including the classic incubation technique of growing 
microbes on agar plates. Agar plates consist of a medium, containing salts and nutritional 
substituents that give microbes everything that they are needed to grow. These can be strain 
specific, such as MacConkey agar for Gram-negative organisms (Mossel, Mengerink & 
Scholts, 1962) or malt extract agar for selective fungi growth (Skaar & Stenwig, 1996). It is 
ironic in a way, that scientists seemingly give microbes everything they need to grow, from 
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nutrients, pH adjustments, temperature and atmospheric conditions tailored to specific 
microbes, but still microbes are simply unable to be grown in laboratory conditions. We are 
seemingly unable to replicate the infinitely intricate and sensitive environments in which 
these microbes prosper. 
One recent study used a novel method of growing previously uncultivable bacteria by use 
of an ‘’iChip’’ (Ling et al., 2015), a multi welled plastic device which allows the growth of 
bacteria in situ. After incubation in the environment, the iChip and its contents are 
transported to the laboratory and disassembled for further analyses. The use of the iChip 
raised the in vitro growth rate of microbes in soil from 1 % up to 50 %. This novel method 
of growing previously un-grown microbes could lead to the discovery of a wealth of novel 
metabolites, and potentially novel antibiotics. Ling’s team has discovered one such 
antibiotic, teixobactin, which is currently in clinical trials. Teixobactin belongs to a new 
class of antibiotics, presenting a novel method of inhibiting microbial growth, by binding to 
lipid pre-cursor molecules needed in cell wall formation (Ling et al., 2015). It is likely that 
there is potentially a plethora of novel and useful antibiotic producing organisms present in 
the environment which scientists are unable to cultivate in the laboratory. Novel approaches 
to growing previously un-cultivatable bacteria appear to be a pathway to revitalising the 
Waksman platform approach to discovering novel antimicrobials. The iChip essentially aims 
not to replicate the environment in which the microbes grow, but utilise the actual 
environment itself to allow microbes to grow in their unadultered natural environment 
(Kaeberlein, Lewis & Epstein, 2002). From this work, the group were able to grow 
previously uncultivated bacteria in vitro. 
In a similar vein of research, the work of Rappé, Connon, Vergin & Giovannoni (2002), 
involved collecting samples of sea water and taking them back to the laboratory, from which 
the bacteria were isolated, rather than attempting to replicate the environment in the media 
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used in a petri dish. From this work, they were able to cultivate and characterise the 
previously uncultivated SAR11 carbon-oxidising bacteria. SAR11 bacteria represent some 
of the most ubiquitous bacteria present in sea-water, but had long avoided in vitro 
cultivation. 
Aside from novel incubation techniques taking place in-situ, metagenomics has been 
identified as a potential solution to probing the unknowns of unculturable bacteria. 
Metagenomics is described as the culture-independent analysis of microbial genomes 
(Scholes & Handelsman, 2005). Metagenomics unravels the secrets of unculturable 
microbes by extracting the DNA straight from the environmental sample, rather than relying 
on incubation first. Whilst the metagenomic approach can provide clues to the yet to be 
cultivated microbes lurking in the environment, even the largest metagenomic studies are 
only capable of identifying fractions of genes; discovering novel antimicrobials from 
sequence data is essentially impossible. It is much more feasible to identify novel methods 
to cultivate previously unculturable microbes. As discussed, novel cultivation methods have 
resulted in identification of novel bacteria and so far, have represented the most feasible way 
of cultivating previously un-culturable bacteria in vitro. 
 
1.8: Summary 
 
Antibiotics are rightly held in high esteem, and their discovery and introduction to the clinic 
is regarded as one of human kind’s finest accomplishments in modern medical sciences 
(Aminov, 2010). However, the action of pathogenic bacteria becoming resistant to the once 
lethal actions of antibiotics by the mechanisms previously discussed and the spread of said 
mechanisms of antibacterial resistance is a pandemic health crisis and is recognised by the 
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World Health Organisation (WHO) as being one of the greatest clinical threats to human 
health (World Health Organisation, 2018). By a considerable margin, the key driver of 
antibiotic resistance is the evolution and spread of β-lactamase enzymes, which confer 
resistance to bacteria by producing enzymes which are capable of hydrolysing the β-lactam 
ring present in β-lactam antibiotics. Despite their age and the rise of resistant bacteria, β-
lactam antibiotics are still the most prescribed class of antibiotics, representing around 70 % 
of all prescribed antibiotics worldwide annually (Versporten, Bielicki, Drapier, Sharland & 
Goossens, 2016). Whilst science cannot possibly hope to have an ever-lasting victory over 
bacteria in battle of antibiotic resistance, it has clearly been shown that development of novel 
β-lactamase inhibitors can provide renewed action to once susceptible antibiotics, including 
action against carbapenemase producing Enterobacteriaceae. Therefore, the development 
of novel β-lactamase inhibitors, particularly compounds capable of inhibiting class C and D 
SBLs are of great clinical interest and significance. 
Antibiotics are expensive to develop, time consuming to research and introduce into the 
clinic, and do not offer a huge return of investment for pharmaceutical companies. They are 
inexpensive to patients, clinicians are being encouraged to reduce the number of 
prescriptions for antibiotics, and resistance will inevitably rise to the drug leading to their 
inefficacy and eventual decline. Therefore, large pharmaceutical companies have been 
pulling out of the field of antibiotic development altogether (Lewis, 2013). This presents a 
bleak scenario in the battle against antibiotic resistance; development of new compounds is 
essential in order to turn the tide in our favour. Clearly, novel antibiotics are needed 
desperately.  
Antibiotics from natural sources vastly outnumber completely synthetic antibiotics in the 
clinic. Natural sources have provided us with the vast majority of the antibiotics used in the 
clinic, and science has simply been unable to replicate the success of these products via 
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synthetic drugs. Therefore, antibiotics from natural sources represent our best discovery 
platform for antibiotics. Microbes have had eons to evolve and develop lethal killing 
mechanisms aimed towards their microbial neighbours in the never ending competition for 
resources. However, more than 98 % of microbes present in the environment cannot be 
cultured in the laboratory. Metabolites from bacteria or their derivatives account for a 
staggering 50 % of all commercially available pharmaceuticals (Demain & Sanchez, 2009). 
Novel incubation methods are needed to attempt to increase the in vitro growth rate. Even 
managing to increase the percentage of culturable organisms from 2 % to 10 % would 
represent a huge achievement, and a massive potential for the discovery of novel 
metabolites, potentially including bacteria. These unculturable bacteria could potentially 
represent a vast treasure trove of interesting discoveries, potentially giving humanity   an 
untapped supply of novel antibiotics, able to combat antimicrobial resistance. 
 
1.9: Project and Research Aims 
 
The project will begin by attempting to isolate an antibiotic from a soil environment. Once 
an antibiotic producing microbe has been isolated, a method will be developed to identify 
the bacteria’s metabolites. Samples will be analysed via liquid chromatography mass 
spectrometry (LC-MS), specifically, by use of a quadrupole time of flight (Q-TOF) 
instrument. A Q-TOF is favourable over other instruments owing to being more suited to 
screen for a wide variety of substances when attempting to locate an unknown sample, and 
also because it can report results to its accurate mass. Use of an iChip will also be 
investigated in an attempt to discover and isolate a novel antibiotic. Furthermore, analogues 
of avibactam, a novel non-β-lactam β-lactamase inhibitor will be synthesised and tested for 
their inhibitory effects against SBL enzymes from classes A, C and D. The pH dependence 
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of these enzymes will also be investigated, as this will provide useful information regarding 
their kinetic properties. Finally, potential novel β-lactamase inhibitors will be investigated 
and screened for inhibitory effects. 
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2.1: Introduction 
 
As discussed in the general introduction, the vast majority of current antibiotics used in the 
clinic originated as being identified as secondary metabolites of bacteria. Specifically, more 
than 70 % of commercial antibiotics were isolated from strains of Streptomyces (Raja & 
Prabakarana, 2011). Examples of antibiotics isolated from Streptomyces include the 
aminoglycoside antibiotic neomycin and the macrolytic peptide antibiotic bottromycin 
(Bibb, 2013). It was the pioneering work of Ukrainian scientist Selman Waksman (Waksman 
& Woodruff, 1940) that first identified soil as being a potentially rich source of novel 
antimicrobial products with the discovery of Actinomycetes antibioticus which produced 
actinomycin, which had bacteriostatic and bactericidal properties (Kresge, Simoni & Hill, 
2004). Whilst actinomycin had potent effects against Gram-positive organisms, it had little 
effect on Gram-negative pathogens, and was also found to be extremely toxic in animal test 
cases and was therefore of little clinical value. 
Despite this initial relative failure, Waksman had clearly shown soil to be a potential source 
of novel antimicrobials in the emerging era of antibiotics. He developed a platform for the 
screening of novel antimicrobial products from bacteria isolated from soil. Briefly, this 
comprised of suspending a sample of soil in sterile liquid, carrying out serial dilutions and 
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then streaking a sample of this soil solution onto an agar plate. Even with serial dilutions, 
the concentration of microbes in soil is estimated to be in the region of 1 billion cells per 
gram of soil. Therefore, the plates will still contain thousands of microbes in close proximity 
with each other. This close proximity will increase competition for resources from the agar 
plate during incubation. Therefore, this will initiate microbes capable of producing 
antibiotics to do so, resulting in inhibitory effects on their immediate microbial neighbours. 
The plates were then incubated and antimicrobial producing organisms were identified by 
observing for inhibition zones around the microbe in question. Figure 2.1 below is taken 
from Waksman’s paper (1940) showing the examples of inhibition zones around 
antimicrobial producing microbes. 
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Figure 2.1: Examples of microbes producing antimicrobial products resulting in inhibition 
of growth of their neighbouring organisms (Waksman & Woodruff, 1940). 
Once inhibition zone inducing microbes had been identified, they were then isolated so 
further analyses could be commenced. Waksman, along with the help of others in his 
laboratory (namely Woodruff and a post graduate student, Schatz) pioneered a cross-
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streaking technique for fast, qualitative analysis of a microbe’s antimicrobial potential. 
Briefly, the now isolated antimicrobial producing organism in question would be streaked 
vertically down the centre of an agar plate. Pathogenic organisms would be streaked in 
perpendicular to the antimicrobial producing isolate. If the organism produced inhibition 
zones where they came into close contact with each other, then the antimicrobial producing 
organism showed potential with producing a useful, potent antibiotic (Woodruff, 2014). A 
visual example of this technique is shown in figure 2.2 below. 
 
Figure 2.2: Example of the cross-streak method pioneered by Waksman and colleagues 
(American Chemical Society, 2005). 
Waksman continued with this discovery platform and soon after his initial discovery of 
Actinomycetes antibioticus, he and his team discovered streptomycin in 1944, isolated from 
Actinomycetes griseus (Schatz, Bugle & Waksman, 1944). Streptomycin, an aminoglycoside 
protein synthesis inhibitor (Demirci et al., 2013) was a breakthrough for Waksman and his 
team, as it was not only effective against Gram-positive and negative bacteria, but most 
importantly was not toxic, like the other antibiotics he had isolated previously. His work laid 
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the foundation for future work isolating antibiotic producing bacteria from soil, which for 
many years throughout the golden era of antibiotic discovery provided a rich source of novel 
antibiotics (Lyddiard, Jones & Greatrex, 2016). However, as discussed in the general 
introduction, this platform of discovery yielded fewer and fewer novel prospects up to the 
point that most ‘’new’’ antibiotics introduced into the clinic were simply novel analogues 
of existing antibiotics, with no novel mode of action. 
The fact that more than 98 % of bacteria are unculturable in laboratory conditions has 
spurred research into novel methods of culturing bacteria, with the aim of increasing the in 
vitro growth rate (Wade, 2002). Scientists know that the vast majority of bacteria are 
unculturable through various ways. Chiefly, one simply has to look down a microscope to 
see that in an environmental sample, the number of microbes that can be seen visually far 
outweigh the number that has grown from the same sample on a petri dish. Furthermore, 
PCR analysis of environmental samples shows there is simply a huge array of bacteria 
present in the sample that have not grown on the dish (Stewart, 2012). It is not fully 
understood why microbes fail to grow in vitro, but the chief suspicion amongst scientists is 
that we are simply unable to exactly replicate the incredibly unique conditions of the 
environment from which samples are taken. It goes much more beyond simple pH and 
temperature adjustments. Nevertheless, it is not for lack of effort or cleverness that science 
has been unable to answer this quandary, but there are many intricate factors which must be 
replicated which in most cases are simply not feasible to attempt. Therefore, the attitude 
towards growing unculturable bacteria has moved from simply trying different compositions 
of media in the microbiology laboratory to completely novel growth techniques that try to 
simulate the in situ growth environment as much as possible. One such novel technique is 
that of the isolation chip or ‘’iChip’’.  
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As discussed in the general introduction, the iChip aims to increase the in vitro growth rate 
of microbes by first growing the microbes in situ in the iChip device, and then transferring 
the iChip to the laboratory to continue the culturing of the microbes. This is thought to 
increase the in vitro growth rate from 2 % to above 15 %, which is in the region of a tenfold 
increase of in situ growth rate (Nichols et al., 2010). Clearly, this is an extremely promising 
avenue of research; as human kind has simply been unable to recreate the successfulness of 
antibiotics in a synthetic sense, novel techniques for growing previously un-culturable 
bacteria that could potentially yield many novel classes of antimicrobials is an area of 
research that has been growing intensely in recent years (Vartoukian, Palmer & Wade, 
2010).  
 
2.2: Chapter Aims 
 
The aims of this chapter were to investigate novel microbes which may show inhibitory 
effects on pathogenic bacteria. First, an extract of kombucha tea was analysed to detect for 
the presence of an inhibitory effect on pathogenic microbes. Then, the Waksman platform 
of discovery was first utilised to attempt to find antibiotic producing microbes from a soil 
environment. This work was expanded by use of an iChip to attempt to grow previously 
unculturable bacteria, and then investigate whether any novel antimicrobial producing 
microbes could be isolated. LCMS analysis then took place to attempt to identify any 
metabolites responsible for any detected inhibition. 
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2.3: Methods 
 
2.3.1: Potential Antimicrobials Within a Kombucha Tea Extract 
 
The search for novel antibiotics began by investigating a kombucha tea, also known as a 
symbiotic culture of bacteria and yeast (SCOBY).  Kombucha tea is a generic term for any 
fermented tea product that is drank for supposed health benefits. A kombucha tea sample 
was obtained from the Department of Human and Health Sciences at the University of 
Huddersfield. The kombucha tea contained a cellulose layer created by the microbes present 
in the culture. This cellulose layer was collected with a sterile hook and samples were taken 
using an autoclaved 10 mm cork borer. Plates of pathogenic bacteria were prepared by 
suspending a loop full of culture in 9 ml of maximum recovery diluent (MRD) solution and 
vortexing for 60 seconds. Concentrations were corrected to 106 cells per ml using a 
spectrophotometer operating at specific wavelengths for the bacterium in question. The 
optical density (OD) is the turbidity created in the sample by the scattering of light by the 
microbial cells. If more cells are present, there will be more turbidity (light scattering), and 
therefore a higher concentration of microbes. The optical density is therefore proportional 
to the concentration of cells and can be used to standardise the amount of cells/ml (Widdel, 
2010).  Tryptone Soy agar (TSA) plates were prepared by dissolving 37.5 g of TSA powder 
(Lab M) in 1,000 ml of deionised water and poured into sterile petri dishes and allowed to 
dry in a laminar flow hood. 100 μl of the test suspension containing the pathogen was spread 
onto the TSA plates using a sterile plate spreader and was allowed to dry for 3-5 minutes in 
a laminar flow hood until no obvious sign of wetness was visible. The 10 mm cellulose plug 
was aseptically transferred to the pre-inoculated plates of Escherichia coli (NCIMB: 8879), 
Enterococcus hirae (NCIMB: 8191), Pseudomonas aeruginosa (NCIMB: 10421) and 
Staphylococcus aureus (NCIMB: 9518) and were incubated for 48 hours at 37 °C. After the 
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incubation period, the plates were removed and examined for areas of inhibition. The results 
were varying and indeterminate, but the SCOBY sample showed best action against E. hirae, 
with inhibition zones of up to 3 mm, which can be seen in figure 2.3 below. 
 
Figure 2.3: Antimicrobial effect of SCOBY on E. hirae. 
The pH of the SCOBY culture was measured and recorded as 3.5 ± 0.5. This low pH was 
due to the acids produced by the microbes during fermentation, which lowered the pH of the 
culture. To determine if it was the low pH that was inhibiting growth or if it was indeed 
microbial action, the experiment was repeated but once the sample of the cellulose layer had 
been collected, it was rinsed and soaked in a pH 7 phosphate buffer. Once the pH of the 
SCOBY culture had reached pH 7 ± 0.5, it was added to the pre-inoculated TSA plates as 
before and incubated. When the pH had been adjusted, there were no zones of inhibition. 
This confirmed that it was the low pH of the fluid in the cellulose layer that had probably 
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inhibited growth, not any specific anti-microbial action exhibited by the microbes present in 
the culture. As such, this line of investigation was not pursued. 
 
2.3.2: Isolating Antibiotic Producing Microbes from Soil Samples 
 
It was deemed important to attempt to isolate an antibiotic from an environmental sample 
rather than just purchase one from a laboratory supplier, as this would allow training on how 
to isolate an antibiotic from a culture, and eventually how to analyse the antibiotic using 
analytical techniques such as gas chromatography mass spectrometry (GCMS), liquid 
chromatography mass spectrometry (LCMS). To do this, a soil sample was taken from a 
garden environment and collected in a sterile bag and transferred to the laboratory under 
aseptic conditions and stored at 4 °C. The sample was taken from a grassy shaded area in a 
semi-urban area in the district of Wakefield, West Yorkshire, 10cm below the surface of top 
soil. To begin the search for an antibiotic producing microbe, the crowded plate technique 
was followed (Waksman, 1945). Briefly, 1 g of the soil sample was measured out and added 
to 9 ml of MRD to give an initial starting sample. Two 1 in 10 serial dilutions (1 cm3 sample 
added to 9 ml MRD) were carried out to give a sample concentration of 10-2 in relation to 
the initial starting sample. It was important that the microbes would not get too diluted, as 
crowded plates would allow the microbes to compete with each other and inhibition zones 
would be obvious. 100 µl of the dilutions were spread onto sterile TSA plates using a plate 
spreader and allowed to dry. The plates were incubated at room temperature (as they were 
collected during winter, so the traditional incubator temperature of 37 °C may be too high 
for some of the bacteria) until sufficient growth had occurred that the plates were completely 
covered in a lawn of bacteria; this was typically around 1-2 weeks. After this time period, 
the plates were examined for any areas of inhibition. Where inhibition had occurred, the 
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microbe assumed responsible was sub-sampled off the sample plate and streaked onto a fresh 
TSA plate. The streak plate process was repeated until the strain was isolated and pure, 
which was confirmed by a visual inspection of the plate and examining colonies via light 
microscopy. Phenotypic characteristics were examined using the naked eye (features such 
as colony shape, colour, speed of growth) to give a simple indication of the purity of the 
bacterial strains on the plate. The streak plate method was followed further until single 
colonies could be isolated. These colonies were incubated and were further assessed for their 
purity using other analytical techniques, such as Gram staining, and light microscopy 
analysis. Gram staining gave a good indication that all the cells present were of the same 
cell wall type, and although light microscopy does not give detailed insights into the very 
small cell components of bacterial cells, it gives a good indication of basic cell morphology 
such as shape. This gave further confidence that the isolated strains were pure and suitable 
for further downstream analyses.  
Once pure isolates of the potential antibiotic producers had been collected, they were 
screened against 4 pathogenic organisms: Escherichia coli (NCIMB: 8879), Enterococcus 
hirae (NCIMB: 8191), Pseudomonas aeruginosa (10421) and Staphylococcus aureus 
(9518), the same microbes used in the SCOBY experiments. The cross streak method 
(Velho-Pereira & Kamat, 2011) was used to examine any antimicrobial activity that might 
be exhibited by the collected isolates. A single colony of the isolate was spread vertically 
down the centre of the plate. The plate was then incubated at room temperature for 5-7 days, 
or until a band with a 1 cm width had grown. This allowed time for metabolites to diffuse 
through the agar, including any antibiotic if present. A single colony of each of the 4 
pathogenic test organisms was streaked perpendicularly across the plate towards the test 
isolate. The pathogenic organisms were streaked close to, but not touching the test isolate, 
and allowed to grow for a further 5-7 days at room temperature. After the incubation period, 
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the plates were examined for any inhibition zones. An example of a typical cross streak test 
can be seen in figure 2.4 below. 
 
Figure 2.4: An example of cross streak testing against antibiotic resistant bacteria, showing 
intermediate inhibition of E. coli and weak inhibition of E. hirae. 
Most antibiotics in use today have microbial origins. The Streptomyces genus produce more 
than 70 % of commercially available antibiotics (Kitani et al., 2011). Therefore, 
actinomycete isolation agar was prepared in an attempt to isolate bacteria from the 
Streptomyces genus. Streptomyces bacteria typically have a rough, white, leathery 
appearance and produce geosmin, a volatile metabolite which produces a typically earthy 
odour (Bizuye, Moges, & Andualem, 2013). Bacteria matching these phenotypic 
characteristics (i.e. having a rough, white, leathery appearance) were  carefully selected off 
the agar using a sterile inoculating loop and purified using the isolation method described 
previously and tested for antimicrobial activity, as with the crowded plate bacteria above. 
However, no Streptomyces bacteria were found that exhibited any antimicrobial activity. 
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2.3.3: Isolation Chip (iChip) 
 
As described previously, the iChip is a novel method for growing previously un-cultivable 
bacteria in a laboratory environment. The iChip is a multi-channel device made up of two 
exterior plates and a central interior plate. The central plate is submerged in molten agar 
containing an environmental sample and allowed to dry. The iChip is then assembled and 
incubated in-situ in an attempt to raise the in-vitro growth rate of microbes from 1 % to 
nearer 15 % (Nichols et al., 2010). The iChip assembly can be seen in figure 2.5 below. 
 
 
Figure 2.5: iChip assembly showing (A) the central plate being submerged in molten agar 
containing environmental sample, (B) how the iChip’s wells ‘’capture’’ bacteria in solidified 
agar plugs and (C) the assembly of the iChip containing suitable membranes allowing 
nutrients to diffuse into the agar from the external environment, but restricts the movement 
of bacteria (Ling et al., 2015). 
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An iChip style device was manufactured via 3-D printing by The Department of Forensic 
Engineering at the University of Huddersfield and was assessed for suitability in future 
experiments (see figure 2.6 below). Appropriate nuts and bolts to screw the iChip together 
were obtained along with 0.03 µm membranes. The membranes had to be small enough to 
restrict movement of bacterial cells, but still allow nutrients to move through from the 
external environment. The components of the iChip were sterilised by autoclaving and were 
aseptically transferred to sterile petri dishes until needed. It was important to test the 
effectiveness of the iChip’s seal; this was done by preparing the iChip containing only sterile 
agar and then incubating the iChip overnight in a broth containing Escherichia coli NCTC 
10418. The iChip was disassembled and the agar plugs in the central plate were examined 
for microbial growth by light microscope. The plugs examined remained sterile, so this 
proved that the membranes prevent movement of microbes from the external environment 
into the iChip and that the tightened nuts and bolts provided an adequate seal from the 
external environment. 
The iChip was prepared for microbial incubation by the method of Nichols et al., (2010). 
Briefly, 100 µg of soil was suspended in 100 ml MRD and vortexed until homogenous. 100 
ml of molten agar was prepared and stored in a sterile 100 ml falcon tube. 1 ml of the soil 
solution was pipetted into the molten agar. The central plate of the iChip was added and 
mixed slowly. The molten agar was allowed to cool and form plugs in the iChip’s central 
plate. The aim was to ‘’trap’’ bacteria in the wells of the central plate, so they can be 
incubated in situ. The 0.03 µm membranes were applied to each set of holes around the 
central plate (4 in total). Finally, the two outer plates are attached to the central plate and 
screwed tightly together with appropriate nuts and bolts to form a pressurised seal around 
the central plate. The iChip was incubated in situ in 10 cm3 of soil in a garden style 
environment, providing the microbial cells with the nutrients from their natural environment. 
Chapter Two: The Search for Novel Antimicrobials from Microbial Origins 
93 
 
The iChip was incubated for 7-10 days 10 cm below the surface in a grassy, shaded area 
next to St Paul’s Hall at the University of Huddersfield during the month of April 2016. The 
area was 10 m away from a main road and approximately 10 m away from the Applied 
Sciences building at the university, with a footpath through the area. In the area there are 
several mature tall trees, with a variety of wildlife including squirrels, jackdaws and other 
typical birds native to England. The iChip was buried 30 cm away from one of the trees, 
with the location marked and signed appropriately. After the incubation period in situ, the 
iChip was retrieved and transported back to the laboratory in sealed, sterile bag. The iChip 
was then washed vigorously in DNA grade water before being disassembled.  
 
 
Figure 2.6: Assembled 3-D printed iChip. 
The iChip was disassembled and agar plugs were removed by sterile unwound paper clips. 
The agar plugs were then examined under light microscope to look for microbial growth. 
Agar plugs that exhibited growth were aseptically transferred to agar plates and streaked 
across the plate using a sterile plate spreader. The plates were incubated and allowed to grow 
for 5-7 days until there was a lawn of bacteria covering the plate. 
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As in the crowded soil plate experiments, the crowded plates were examined for inhibition 
zones. The microbes presumed responsible for producing the inhibition zones were 
identified by placing the agar plate on a colony counting unit. Using the light from the colony 
counting unit, one could clearly see a single colony of microbes at the centre of each 
inhibition zone (see figure 2.11 below). It was therefore simple to identify the microbes 
which were exhibiting an antimicrobial effect on their neighbours. These colonies at the 
centre of each inhibition zone were carefully selected off the plate using a sterile inoculating 
loop and purified by using the streak plate method to obtain pure colonies, as described 
previously (Sanders, 2012). These isolates were examined for the antimicrobial activity 
against seven pathogenic organisms, specifically, β-lactamase producing bacteria. The 
pathogens were purchased from Public Health England (PHE) and included: the 
carbapenemase KPC-3 producing Klebseilla pneumoniae NCTC strain13438, the VIM-1 
producing Klebsiella pneumoniae NCTC strain 13440, the OXA-48 producing Klebsiella 
pneumoniae NCTC 13442, the NDM-1 producing Klebsiella pneumoniae NCTC 13443, 
methicillin resistant Staphylococcus aureus NCTC 12493, the IMP producing Escherichia 
coli NCTC 13476 and finally a β-lactamase negative Escherichia coli NCTC 10418. Over 
200 cross streak plates were prepared for potential antimicrobial producing organisms 
isolated from iChip testing. Once replicate testing had taken place, the initial number was 
reduced from over 200 organisms to 7 organisms that were observed to consistently inhibit 
the same pathogens upon repeats. 
Results of the cross streaking were recorded as showing weak inhibition (1-2 mm inhibition 
zones), intermediate inhibition (2-4 mm inhibition zones) or strong inhibition (>4 mm 
inhibition zones). An example of a cross streak test using the β-lactamase producing bacteria 
can be seen in figure 2.7 below. 
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Figure 2.7: An example of cross streak testing against antibiotic resistant bacteria, showing 
strong inhibition against Escherichia coli NCTCC 10418, Klebsiella pneumoniae NCTCC 
13340 and Klebsiella pneumoniae NCTCC 13343. 
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2.3.4: Polymerase Chain Reaction (PCR) 
 
The key concept of the iChip is that it facilitates the growth of previously unculturable 
bacteria. To test this hypothesis, polymerase chain reaction (PCR) took place to examine the 
specific strains of microbes that the iChip had cultivated. 
The 7 organisms were identified by polymerase chain reaction (PCR) experiments. PCR can 
be used to identify microbial organisms based upon their DNA sequence. DNA sequences 
are unique to individual strains and can be used to confidently identify the species and 
specific strain of an organism. PCR for microbial identification is a process which involves 
amplifying a target area of the 16S rDNA gene to a certain concentration so that the gene 
can be sequenced and the organism identified. Specific primers are used so that only the 
required region of the 16S rDNA gene is amplified. Although all organisms have a unique 
DNA sequence, there are conserved regions across all bacterial species, and this is also true 
in the 16S rDNA gene, as shown in figure 2.8 below. The variable region allows 
identification of the bacteria. 
 
Figure 2.8: Variable and conserved regions found in the 16S rDNA gene (Alimetrics, n.d.). 
A Mo Bio Ultra-Clean Microbial Isolation Kit was ran in accordance to the manufacturer’s 
instructions (Mo Bio, n.d.), but will be briefly described here. The sample is first prepared 
by adding appropriate amounts of initial bacterial sample, primer and polymerase/base 
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mixture into solution. The cells are ruptured in this process, releasing the DNA into the 
extracellular environment. The samples are centrifuged and filtered a number of times so 
that only the DNA is left in the sample. At this stage, the samples are run through an 
electrophoresis gel, which is created by dissolving 1 g of agarose powder in 100 ml of ultra-
pure water. The aim of the electrophoresis is to ensure that there is actually DNA present in 
the sample, without contamination, and that the preparation procedure to isolate the correct 
DNA from the bacteria has been a success. An example of an electrophoresis from the PCR 
process can be seen in figure 2.9 below. The lane on the far left hand side of the agarose gel 
was the reference ladder used for determining the size of the DNA fragment present in the 
PCR mixture. This contained reference DNA fragments, of which the molecular weight (and 
base pair [BP] length) is known and standardised, against which samples obtained from PCR 
were compared. The length of the 16s rDNA gene in the PCR experiment was approximately 
1500 BP; the obtained samples were compared to the reference marker in the ladder (which 
contained a 1500 BP marker), to give an indication to whether the PCR had been successful. 
DNA has a net negative charge owing to the phosphate backbone of the DNA chain 
(Yamasaki, Teramoto & Yoshikawa, 2001). The agarose gel works by separating 
components based on size. Smaller DNA fragments can traverse the viscous gel medium 
more quickly, so move closer to the positive anode, whilst the opposite is true for longer 
DNA fragments. This allows DNA fragments to be reliably separated based upon their  
length and compared to a reference ladder.  
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Figure 2.9: Example of electrophoresis ran on samples, clearly showing the PCR products 
being the desired length in the region of 1500 BP (owing to the tight banding to the 1500 
BP reference marker in the ladder), indicating successful PCR amplification for the region 
of interest. 
The first step in the PCR process is to separate the double helix strands of DNA in the 
denaturation process, which takes place at 95 °C. At this temperature, the DNA denatures 
and essentially unravels to form an upper (sense) and lower (anti sense) strands. This allows 
the primers present in the primer mix (myTaq) to begin pairing up to the exposed strands of 
DNA. The second process is the annealing process of the primers. Appropriate primers must 
be selected that will match the gene of interest to be amplified. In taxonomic identification, 
the fact there is a conserved region in the 16S rDNA across all bacterial species is exploited: 
an 8F1510R primer is used that will begin the amplification process in the conserved regions 
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of the 16S rDNA gene. The primer works from both the 8 forward position and the 1510 
reverse position on separate DNA strands (hence the name of the primer, 8F1510R). The 
annealing stage operates at 60 °C, which is cool enough to allow the reaction of the primers 
present in the primer mix to react and form pairs with the exposed bases on the strands of 
DNA. The final stage is the elongation stage; the temperature is raised to a value specific to 
the polymerase enzyme being used (72 °C in the current experiment) which binds the 
nucleotide bases to the rest of the DNA strand, completing the replication process. Normally, 
72 °C would cause enzymes to denature, but the polymerase typically used in PCR 
experiments is extracted from a strain of Thermus aquaticus, which are present in the hot 
springs of Yellowstone National Park, USA, which are capable of living at high 
temperatures (University of Utah, 2016). These 3 stages are repeated a total of 33 times to 
amplify the required 16s rDNA gene. The PCR schematic is shown in figure 2.10 below.  
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Figure 2.10: Overview of PCR Process (National Centre Biotechnology Information, 2014). 
Importantly, the primer mix used contains dideoxy nucleotides – also known as chain 
terminating nucleotides. These specific nucleotides are the same as regular nucleotides also 
contained in the primer mix, apart from the fact they lack a hydroxyl (OH) group on the 3’ 
carbon. The lacking OH group prevents other nucleotides bonding to the chain terminating 
nucleotide. This therefore terminates the sequencing of this chain, preventing the elongation 
of this specific chain of DNA. The dideoxy nucleotides present in the primer mix are 
approximately present at a 100 fold lower concentration than the regular nucleotides. The 
fact that there are billions of copies of the replicated DNA strand allows the statistical 
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inevitability that there will be a chain terminating dideoxy nucleotide present at every 
possible position in the replicated DNA strands. The dideoxy nucleotides are also labelled 
with a specific colour dye, which allows the specific nucleotides to be identified in 
downstream processing. After this process, the DNA samples were purified and corrected to 
appropriate concentration levels in DNA/RNA treated water. The replicated DNA strands 
were sent for external sequencing at Eurofins Laboratories in Wolverhampton, where the 
Sanger sequencing method was employed. The Sanger sequencing method takes advantage 
of the fact that there will be a dideoxy nucleotide base at every possible sequence in the 
DNA strand. The DNA samples are then ran through a capillary gel electrophoresis. The 
DNA strands exit the capillary gel electrophoresis tube in size order, as according to their 
molecular weight, with the DNA strands terminating after just one sequence exiting the gel 
first, and so on. The DNA strands are illuminated with a laser which allows the fluorescence 
emitted by the specific dye colour to be detected by a fluorescence detector. This therefore 
allows for the detection of the specific base at that position in the sequence. This process is 
repeated until all of the chains have been processed by the electrophoresis gel, allowing the 
complete DNA chain to be sequenced. The sequences were then compared to an academic 
database containing the DNA sequence of every characterised microbe. This allows analysis 
of the extracted DNA sequences and the percentage similarity gives an indication of the 
novelty of the microbe. Different academic sources may have different cut offs for defining 
a sample as a completely novel strain, but generally a similarity percentage of less than 97 
% can be grounds for claiming a completely novel, previously uncharacterised microbial 
strain (Fenollar, Roux, Stein, Drancourt, Raoult, 2006), (Srinivasan et al., 2015), (Reller, 
Weinstein, Petti, 2007). A similarity score of between 97 % and 99 % allows microbiologists 
to classify the genus, whilst a similarity score of more than 99 % allows classification to the 
species level (for example, a similarity score of more than 99 % would indicate a species 
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match, whereas a similarity score of between 97-99 % indicates a genus match). A match of 
less than 97 % allows a claim for a novel strain to be made and is the generally accepted cut 
off points in academic literature within the field of microbiology. 
 
2.3.5: Metabolomics 
 
Once the bacterial isolates showing antimicrobial activity had been identified by PCR 
experiments, the next stage of the experiment was to attempt to identify the metabolites 
being produced and investigate what may be causing antimicrobial activity. The samples 
were grown in Tryptone soy broth (TSB), which essentially contain the same ingredients as 
TSA, but contain fewer solidifying agents, so would remain in liquid state even at room 
temperatures. Samples were incubated for 7 days in an orbital incubator operating at 30 °C 
/ 100 RPM. After the incubation period, samples were centrifuged using a large rotor at 4°C 
/ 8,500 RPM for 20 minutes.  
The supernatant was collected and filter sterilised so the samples could be transported to 
non-class 2 laboratories and analysed.  The supernatant was added to equal volumes of 
various solvents, including ethyl acetate, dichloromethane and chloroform shaken 
vigorously and incubated once again in an orbital incubator overnight to allow the solvent 
to extract any potential antibiotic from the TSB supernatant. Along with solvent extraction 
taking place, the neat aqueous solution was freeze dried in an attempt to concentrate any 
potential antibiotic. After incubation, the solvent phase was collected using an extracting 
funnel and allowed to dry in a fume cabinet. The aqueous phase was also collected and 
stored separately. Once the solvent samples were dry, a yellow/brown gummy layer was 
collected. The first attempt to re-dissolve the samples used ultra-pure water, but after several 
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attempts the gummy brown layer remained un-dissolved. It was decided to try and use a 
different solvent; dimethyl sulfoxide (DMSO) was selected and seemed to work well to 
dissolve the gummy brown substance. A method to identify the metabolites was developed 
using an Agilent 6500 series LC-MS Q-TOF. A 1 µl injection was analysed over a 15 minute 
draw time using an Agilent Zorbax SB-C18 column. A jet stream electrospray ionisation 
source was used to ionise the sample, running in positive polarity mode. Samples were 
analysed in triplicate. De-ionised water was used as a system blank and a sterile sample of 
TSB was used as a sample blank. The rotary evaporated solvent extracts and the freeze dried 
aqueous solution were dissolved in DMSO and ran on LCMS-QToF in an attempt to identify 
any potential antibiotics. 
 
2.4: Results 
 
2.4.1: iChip Results 
 
The crowded plates created from the agar plugs of the iChip were examined for the presence 
of antimicrobial producing microbes, as identified by an inhibition zone. Visual inspection 
of the iChip crowded plates showed many zones of inhibition, as shown in figure 2.11 below. 
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Figure 2.11: Typical example of an iChip crowded plate. 
Over 200 antimicrobial producing microbes were isolated and purified as described 
previously and after repeated tests, these were narrowed down to 7 organisms. The PCR 
sequences of these organisms are discussed further in this chapter. 
 
2.4.1: Inhibition Testing Results 
 
Inhibition zones for the β-lactamase producing bacteria were graded as showing weak 
inhibition (1-2 mm inhibition zones) recorded as ‘1’, intermediate inhibition (2-4 mm 
inhibition zones) recorded as ‘2’, or strong inhibition (>4 mm inhibition zones) recorded as 
‘3’ (raw data tables can be found in the appendix). The 7 test organisms used were Klebsiella 
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pneumoniae 13438, Klebsiella pneumoniae 13440, Klebsiella pneumoniae 13443, 
Klebsiella pneumoniae 13442, Escherichia coli 13476, a strain of Methicillin Resistant 
Staphylococcus aureus and Escherichia coli 10418 as a β-lactamase negative control. 
The total inhibition scores were averaged, and the numerical values were used to create a 
heat map using RStudio and can be seen in figure 2.12 below. 
 
Figure 2.12: Heat map of inhibition scores. 
On figure 2.12 above, green colours indicate cross streak tests where strong inhibition was 
noted against the pathogenic strain, and red colours indicate where weak to no inhibition 
was recorded. As can be seen, the strongest inhibition was shown against E. coli NCTC 
10418 by almost all the antimicrobial producing test organisms. This is perhaps 
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unsurprising, as this was a β-lactamase negative control pathogen, perhaps indicating it lacks 
the defensive capability to protect itself from whatever the antimicrobial producing test 
organisms may be creating to exhibit their lethal effect on this organism. Practically no 
microbial inhibition was seen against E. coli NCTC 13476, which is an MBL, IMP 
producing microbe. Test organisms 5C, 2F1, 2F2 and 4A are largely ineffective against the 
other β-lactamase producing bacteria, but G1B1, S1B1 and 1B2 show medium to strong 
inhibition of these pathogenic microbes. G1B1 and 1B2 seemed to be strong inhibitors of 
these pathogenic, β-lactamase (including MBL) producing bacteria. 
2.4.2: Polymerase Chain Reaction Results 
 
After the purified PCR samples had been sequenced, the sequencing information was 
processed using National Centre for Biotechnology Information’s Basic Local Alignment 
Search Tool (BLAST) database (National Centre for Biotechnology, 2016). The figures 
below show the top matches for the isolated potential antibiotic producers when compared 
to the BLAST database. The sequences were then analysed using Molecular Evolutionary 
Genetics Analysis (MEGA) software (Molecular Evolutionary Genetics Analysis, 2016). 
The BLAST tool is a library containing the genetic information of many different microbial 
species and strains, against which the sequenced 16S rDNA gene can be compared and the 
closest matches can be given. 
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Figure 2.13 below shows the closest DNA BLAST matches for G1B1. 
 
Figure 2.13: Closest DNA BLAST matches for G1B1. 
Figure 2.14 below shows the closest DNA BLAST matches for S1B1. 
 
Figure 2.14: Closest DNA BLAST matches for S1B1. 
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Figure 2.15 below shows the closest DNA BLAST matches for 1B2. 
 
Figure 2.15: Closest DNA BLAST matches for 1B2. 
Figure 2.16 below shows the closest DNA BLAST matches for 2F1. 
 
Figure 2.16: Closest DNA BLAST matches for 2F1. 
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Figure 2.17 below shows the closest DNA BLAST matches for 2F2. 
 
Figure 2.17: Closest DNA BLAST matches for 2F2. 
Figure 2.18 below shows the closest DNA BLAST matches for 4A. 
 
Figure 2.18: Closest DNA BLAST matches for 4A. 
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Figure 2.19 below shows the closest DNA BLAST matches for 5C. 
 
Figure 2.19: Closest DNA BLAST matches for 5C. 
The DNA of the isolated potential antibiotic producers was compared using MEGA to see 
if any of the organisms were genetically identical. Samples G1B1, S1B1 and 1B2 were 
compared, as they were all found to be Pseudomonas baetica and their morphology appeared 
similar. After analysis on MEGA it appeared that samples G1B1 and S1B1 were genetically 
identical over the extracted 16S rDNA gene, but 1B2 was different. Also, samples 2F1, 2F2 
and 4A all appeared to have similar morphology, so were also compared on MEGA. Samples 
2F1 and 2F2 appear to be genetically identical, whilst 4A was different. Therefore, for the 
purpose of future experiments, it will be assumed that samples G1B1 and S1B1 are the same, 
and samples 2F1 and 2F2 are also identical. 
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2.4.3: Metabolomics 
 
All 7 samples were prepared for LC-MS analysis as described in the methods section. The 
rotary evaporated solvent extracts were analysed along with the freeze dried aqueous 
sample. The LC-MS analysis identified 1,915 unique compounds across all the samples. The 
sample information was extracted from Agilent Technologies’ MassHunter Workstation 
Qualitative Analysis Software into Agilent Technologies’ chemometric analysis software 
Mass Profiler Professional. Figure 2.20 below is an example of the data obtained from the 
LCMS QToF experiments and shows the initial volcano plot showing all the compounds 
identified by the Q-TOF, grouped together by sample in the aqueous freeze dried sample. 
 
Figure 2.20: Initial volcano plot showing compounds identified grouped by sample. 
Samples could then be compared against the blank to see how many unique compounds were 
in the sample. Figure 2.21 below shows sample 1B2 compared against the TSB blank. 
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Figure 2.20 above shows the relative abundance of unique compounds identified in the 
LCMS assay, colour coded with blue colours showing compounds that are lower intensity, 
towards yellow, orange and red colours that represent compounds that are highly abundant 
in the sample. Blue colours represent lower abundance compounds. Lines that go vertically 
from the X axis indicate compounds that are unique to that specific sample, whereas lines 
that go horizontally indicate compounds that are present in all of the samples. Lines that go 
vertical from the X axis from one sample and then go across only over a few are present in 
those specific compounds.  
 
Figure 2.21: Sample 1B2 compared against the TSB blank. 
Figure 2.21 above shows all the compounds present the TSB blank and sample 1B2. The 
blue lines represent compounds that are at overall relative low abundance, whilst the yellow-
red lines represent an increase in overall relative compound abundancy. The lines coming 
from the origin on the primary Y axis are compounds that are only present in the 1B2 sample, 
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whereas lines coming from the origin on the secondary Y axis represent compounds that are 
only present in the broth blank. The primary and secondary Y axis represents the abundance 
of the compound in that specific sample. For example, a line originating from 5 on the 
primary Y axis that goes to a higher position on the secondary Y axis represent compounds 
that are present in both 1B2 and the broth blank, but are more abundant in the broth blank. 
Figure 2.21 shows a large number of compounds that are only present in both 1B2 and the 
broth blank. However, the fact that there are no blue lines on the secondary Y axis shows 
that there are no compounds present in the broth blank in a low abundance which are not 
present in the test sample (1B2), but the opposite is true for the test sample. This means that 
there are many more compounds present in the test sample at a lower abundance than are 
not present at all in the broth blank. It is highly probable, that if any antibiotic is being 
produced, it is one of these compounds that is coloured blue and comes from the origin on 
the primary Y axis. However, this compound is present amongst a slew of other metabolites. 
Further work is needed to try and reduce this number down to a more reasonable amount, 
where a realistic chance is possible for the antibiotic to be characterised from the LCMS 
data. 
 
2.5: Discussion and Conclusion 
 
The results from the cross streak testing from antibiotic producing bacteria isolated from the 
iChip crowded plates indicate that 7 potential antibiotic producing bacteria have been 
identified. Three strains in particular (G1B1, S1B1 and 1B2) seemed to show good inhibition 
against β-lactamase producing pathogens. Of particular interest is inhibition of K 
pneumoniae 13443, a Gram negative metallo-β-lactamase producer (NDM-1). A surface pH 
Chapter Two: The Search for Novel Antimicrobials from Microbial Origins 
114 
 
probe was used to measure the pH of the agar in the inhibition zones and showed a pH of 
8.2. Although this is not optimum for growth of K. pneumoniae, it should not be inhibitory. 
Also, the fact that other strains of K. pneumoniae grew on these plates indicates that, 
hopefully, there is a compound that the test microbe is producing that is inhibiting growth, 
and it is not just that (for example) an acidic substance is being produced that inhibits growth. 
This theory can be supported by the fact that E. coli 10418 experienced the most inhibition 
out of any test pathogen. E. coli 10418 is a negative control for β-lactamase production, so 
the observation that it is inhibited the most suggests that it is because it cannot protect itself 
against whatever potential antibiotic compounds the test organism is producing, but some 
of the other β-lactamase positive pathogens can.  
The closest match to test organisms G1B1, S1B1 and 1B2 was Pseudomonas baetica, as it 
was the closest match on the BLAST search and also when examining the phylogenetic tree. 
Pseudomonas baetica was described as a novel fish pathogen as recently as 2012 (López et 
al., 2012). It is not known for producing antibiotics, so perhaps this could be a novel 
discovery and further metabolomics of the test microbes that showed good results against 
the β-lactamase producing pathogens is certainly worth exploring. It is known that 
Pseudomonas spp. can produce antibiotics, including: 1-phenazinecarboxylic acid, 2, 4-
diacetylphloroglucinol, pyrrolnitrin, phenazine and pyoluteorin (Raaijmakers, Weller & 
Thomashow, 1997). However, the formulas and molecular weights of these samples were 
not found when checking the metabolomics results in Agilent’s MassHunter software, 
further indicating that perhaps a novel metabolite may be inhibiting the test pathogens. 
Samples 2F1 and 2F2 appear to be the same organism, according to the PCR results. Samples 
2F1, 2F2, 4A and 5C all had negligible inhibitory effects against the test β-lactamase 
producers, although they had good results against the non β-lactamase producing bacteria in 
the first round of antibiotic susceptibility testing. Future work will most likely focus on 
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working with bacteria that showed good inhibition against the β-lactamase producing 
bacteria, such as 1B1G, 1B1S and 1B2. 
The results from the LC-MS identified 1,915 compounds. The results from 1B2 showed over 
400 differences from the blank TSB sample when analysed at p <0.01 and 16 fold difference. 
This represents a good result in one way, because it shows that the LC-MS method 
developed is capable of identifying a large amount of compounds from the samples, but over 
400 compounds is far too many to try and identify and quantify. 
There is possibly a huge potential for discovery of novel microbial strains and novel 
antimicrobials using the iChip. As stated earlier, the vast majority of microbes present in the 
environment are unculturable in laboratory conditions. Secondary metabolites of the 
remaining culturable organisms have been described as a long over-mined source of 
antimicrobials, with the chance of discovering a novel antimicrobial metabolite estimated to 
be 10-7 (Nichols et al., 2010).  
In an attempt to reduce the number of compounds found in the sample, isolates G1B1, S1B1 
and 1B2 were incubated in Tryptone Soy Broth at 30 °C in a rotating incubator for 7 days. 
The samples were centrifuged and the supernatant was collected and filter sterilised. The 
supernatant was subject to freeze drying which resulted in the production of a brown powder 
for each sample. The freeze dried product was collected and subjected to antimicrobial 
testing using the streak plate method described previously. This was attempted in the hope 
that the antimicrobial the isolates produce was a secondary metabolite, as most antibiotics 
are from microbial sources; and the freeze drying would concentrate the compounds 
responsible for the inhibition seen. However, the freeze dried isolate showed no signs of 
inhibition, as was seen in the cross streak testing. This indicates that perhaps the compound 
is not stable enough to survive the freeze drying process, or that perhaps the compound is 
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not produced whilst the bacteria grows in a broth. Further work is needed to attempt to 
isolate the antibiotic. 
The work done in this chapter found a previously little described strain of Pseudomonas 
baetica, not previously known for producing antimicrobials (López et al., 2007), (López, 
Navas, Thanantong, Herran, Sparagano, 2012). Previous interest in this microbe had mostly 
only been concerned with its pathogenicity towards fish, specifically wedge sole. This 
isolate exhibited repeated inhibition in subsequent cross streak tests against β-lactamase 
producing bacteria. LCMS analysis of the isolate revealed over 400 unique compounds not 
identified in blank samples. Further work is needed to reduce this amount to a manageable 
figure, where identification of specific compounds responsible for causing the inhibition 
may be possible. Further work could include more statistical analysis involving Agilent 
Technologies’ Mass Profiler Professional; more blank samples could be prepared against 
which the test sample could be compared to “subtract” blank metabolites (i.e. metabolites 
which are not involved in any sample inhibition). Blank samples could be taken such as TSA 
dissolved in a suitable solvent, and then areas around the pathogen growing on TSA, and 
then areas around the Pseudomonas baetica growing on TSA. These metabolites could be 
logged as “blank” metabolites. Then, the test could be repeated but agar taken directly from 
the zone of inhibition on TSA plates where Pseudomonas baetica and test pathogens are 
incubated together. These “blank” metabolites could then be “subtracted” from the total 
metabolites in the test sample. This would then account for metabolites produced without 
the presence of an inducer (the pathogen, in the case of the antibiotic producing 
Pseudomonas baetica). Although the blank TSB was accounted for in the current 
experiment, passive metabolites were not. Single bacterial strains are capable of producing 
thousands of unique metabolites (Sajed et al., 2016), therefore being able to “subtract” 
several insignificant passive metabolites would be a helpful step in the experimental 
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procedure towards reducing the number of unique compounds found in the test sample. Also, 
as shown here, the potential for novel microbes incubated using the iChip is huge and 
represents a promising way of eventually identifying novel antimicrobials. 
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3.1: Introduction 
 
As discussed in the general introduction, there are existing inhibitors of the SBLs. However, 
there are only four approved for clinical use; clavulanic acid, sulbactam, tazobactam, and 
more recently avibactam (figure 3.1 below). With the exception of avibactam, the existing 
inhibitors typically only inhibit class A and C SBLs. The combination of β-lactam antibiotics 
with SBL inhibitors has been utilised to give previously susceptible β-lactam antibiotics 
renewed activity against SBL producing bacteria. 
 
 
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
123 
 
 
Figure 3.1: SBL inhibitors approved for clinical use; the β-lactam containing clavulanic acid, 
sulbactam and tazobactam and the non-β-lactam diazabicyclooctane avibactam. 
Bacteria have developed resistance for every antibiotic introduced into the clinic so far, so 
the development of novel SBL inhibitors is of the greatest importance in order to increase 
the susceptibility of ESBL producing bacteria to existing β-lactam antibiotics.  
In an effort to combat the ever increasing threat posed by β-lactamases, inhibitors have been 
developed with the intention of being used in conjunction with β-lactam antibiotics to restore 
antibiotic activity to previously susceptible antibiotics. Examples of β-lactam β-lactamase 
inhibitor combinations (BLBLIC) include: ceftazidime-avibactam, ceftolozane-tazobactam, 
amoxicillin-clavulanate and ampicillin-sulbactam (Toussaint & Gallagher, 2015). Data 
show that BLBLIC produce lower minimum inhibitory concentrations (MIC) than treatment 
without β-lactamase inhibitors (Reading & Cole, 1977), (Jones, Barry, Thornsberry & 
Wilson, 1985), and can be as powerful as carbapenems – our most potent antibiotics of ‘’last 
resort’’, held in reserve for only the most severe bacterial infections. BLBLIC therefore 
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represent an alternate treatment pathway for serious infections caused by extended spectrum 
β-lactamase producing bacteria – drugs of ‘’last resort’’, (such as carbapenems and 
polymyxins), can be reserved for the most severe infections, therefore limiting bacterial 
exposure to such drugs, thereby reducing the chance for resistance to arise to said drugs; 
whereas BLBLIC can be used to extend and prolong the life of our existing β-lactam 
antibiotic arsenal. Development of novel β-lactam antibiotics has been scarce in recent 
times, and existing discovery platforms have yielded insignificant results. Developing novel 
SBL inhibitors for use in conjunction with β-lactam antibiotics is an attractive development 
option for medicinal chemists, in order to restore the functionality of existing β-lactam 
antibiotics. 
Whilst clavulanic acid and the related inhibitors sulbactam and tazobactam have been in 
clinical use for some time, they are good inhibitors of class A SBLs but are generally poorer 
inhibitors of class C and D enzymes. The newer inhibitor, avibactam, has a wider range of 
activity than the existing SBL inhibitors, being able to inhibit enzymes from class A, C and 
some D. Vaborbactam is also a novel, non-β-lactam SBL inhibitor, but only has activity 
against class A and C SBLs. Therefore the need for the development of a novel β-lactamase 
inhibitor with action against all 3 classes of SBLs is of great clinical significance. 
Given the frequency of administration of BLBLIC, as well as the fast generation times of 
bacteria, it is perhaps unsurprising that there are reports describing resistance of bacteria to 
BLBLIC medication. Avibactam has been approved for clinical use alongside the 
cephalosporin antibiotic ceftazidime in a BLBLIC marketed as Avycaz and has been shown 
to be effective against infections mediated by SBL producing bacteria (Mosley, Smith, 
Parke, Brown, Wilson & Gibbs, 2016). Whilst BLBLIC resistance was initially described in 
the combination of amoxicillin and clavulanic acid, there are concerning reports that 
resistance has already been noted against avibactam/ceftazidime (Shields, Nguyen, Press, 
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Chen, Kreiswirth & Clancy, 2017).  The mechanism of resistance to BLBLIC is primarily 
through the hyper-production of β-lactamase enzymes that simply overwhelm the inhibitor 
and antibiotic, resulting in a net hydrolysis compared to inhibition (Martinez, Vicente, 
Delgado-Iribarren, Perez-Diaz & Baquoro, 1989), (Wu, Shannon & Phillips, 1994), (Wu, 
Shannon & Phillips, 1995), by modification of outer membrane proteins, decreasing the 
permeability of the cell membrane (Reguera, Baquero, Perez-Diaz & Martinez, 1991), as 
well as variations of the β-lactamase which is less susceptible to covalent inhibition by the 
commercially available inhibitors (Bonomo & Rice, 1999), (Nicolas-Chanoine, 1997). 
Diazabicyclooctane inhibitors such as avibactam, relebactam and vaborbactam are 
promising developments in the campaign against antibiotic resistance, as previous inhibitors 
were all based on the β-lactam scaffold. These are novel inhibitors in the sense that they do 
not contain a β-lactam group, and a represent a significant step forward in the development 
of SBL inhibitors. Up until avibactam, all SBLs had operated using a β-lactam scaffold, and 
limited development options. Since the introduction of avibactam, there has been the 
development of further non-β-lactam inhibitors entering into clinical trials. These include 
the diazabicyclooctanes relebactam, nacubactam, zidebactam and the boronic acid 
vaborbactam, the latter has recently passed clinical trials in 2017 for use in conjunction with 
meropenem for use against carbapenemase producing Klebsiella pneumoniae (Hecker et al., 
2015). Although vaborbactam has only been recently introduced into the clinic, the concept 
of using boron derived electrophilic agents to inhibit SBLs is not new. Work in the early 
1970s showed that an SBL from Bacillus cereus was reversibly inhibited by borate ions 
(Kiener & Waley, 1978). The structures of these inhibitors are seen in figure 3.2 below. 
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Figure 3.2: The non-β-lactam SBL inhibitors in clinical development and the recently 
approved vaborbactam. 
Development of non-β-lactam SBL inhibitors is a significant step forward in the battle 
against antibiotic resistance, owing to the novelty of their structures and explores a fresh 
avenue of research previously restricted to β-lactam containing compounds. 
History has taught us that antibiotic resistance will eventually overcome any treatment we 
can produce, so the development or the expansion of knowledge regarding novel inhibitors 
is a desperate priority. Clearly, β-lactamase inhibitors are a desirable addition for medicinal 
chemists in order to extend the life and dwindling effectiveness of our current β-lactam 
antibiotics. However, over the course of the last 70 years, the evolutionary pressure forced 
onto microbes has afforded them with many mechanisms of resistance. Bacteria are able to 
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combat β-lactamase inhibitors by hyper-production of the enzyme (Wu, Shannon & Phillips, 
1994), or by producing strains of β-lactamases that are resistant to inhibitors (Chaïbi, Sirot, 
Paul & Labia, 1999). With the ever looming threat of resistance, novel antimicrobials 
including novel β-lactamase inhibitors are needed.  
 
3.2: Chapter Aims 
 
This study aimed to produce novel inhibitors derived from avibactam based on the 
mechanism of action. Here, four such novel inhibitors are reported and their inhibitory 
activity is discussed. 
It is known that inactivation of the β-lactamases by avibactam occurs by acylation of the 
active site serine residue (Wang et al., 2016). This acyl enzyme complex is not readily 
further hydrolysed and is relatively stable, leading to termination of catalytic activity of the 
β-lactamase enzyme, resulting in inhibition. The aim of this project was to investigate the 
possibility of generating the acyl enzyme from derivatives of avibactam, for example, the 
ring opened carbamate ester. The ester function may act as a substrate for the enzyme, 
displacing the alcohol and so generating the same acyl enzyme complex. An overview of 
the intended reaction scheme is shown below in figure 3.3. 
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Figure 3.3: Avibactam and proposed inhibitor mechanisms. 
Carbamates are half ester/half amide derivatives of carbonic acid and are more reactive than 
amides but less reactive than esters. Carbamates derived from carbamic acid have long been 
used as a pesticide owing to the fact they inhibit the two forms of acetylcholinesterase 
(AChE) found in mammals – AChE and butyrylcholinesterase (BuChE) (Bajda, Latka, 
Hebda, Jonczyk & Malawska, 2018), (Chiou, Huang, Hwang & Lin (2009). Cholinesterases 
are responsible for the termination of impulse response in controlling muscles by efficiently 
catalysing the hydrolysis of the neurotransmitter acetylcholine at synapses into choline and 
acetic acid (Colovic, Kristic, Pasti, Bondzic & Vasic, 2013). Acetylcholine is released from 
the pre-synaptic neuron into the synapse to transmit the nerve impulse across the synaptic 
cleft by binding to receivers on the post synapse neuron, which causes sodium channels on 
the post synaptic neuron, generating an action potential and causing muscle contraction. 
After the acetylcholine is released from the receiving neuron, it is hydrolysed by AChE into 
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its substituents (acetic acid and choline). Acetic acid diffuses through the synaptic cleft, 
whereas the choline is taken back up into the presynaptic neuron by a sodium ion dependent 
choline transporter, where it is used to resynthesize acetylcholine (Titus, Revest & 
Shortland, 2010). Acetylcholine and the nerve transmission pathway is obviously a very 
important mechanism within mammals, and therefore represent an important therapeutic 
target for a variety of medications (Mehta, Adem & Sabbagh, 2012). Indeed, recent work 
has highlighted the link between decreased levels of acetylcholine and progression of 
Alzheimer’s disease, leading to dementia (Ayllon, Small, Avila & Valero, 2011), 
(McGleenon, Dynan & Passmore, 1999), (Tabet, 2006). Obviously, as acetylcholinesterase 
is responsible for catalysing the hydrolysis of acetylcholine which therefore leads to a 
decrease in physiological concentrations of the neurotransmitter, inhibitors of 
acetylcholinesterase has been of interest to the pharmaceutical community. Carbamates are 
well known inhibitors of acetylcholinesterase; an example of which is rivastigmine, which 
contains a carbamate group capable of binding covalently with the serine active site of the 
acetylcholinesterase and has a very slow turnover in which it is only very slowly removed 
by hydrolysis of the enzyme carbamate complex (Yanovsky et al., 2012). Rivastigmine is 
used in the treatment and prevention of Alzheimer’s disease, the mechanism of action is to 
inhibit acetylcholinesterase, helping to prevent the hydrolysis of the neurotransmitter 
acetylcholine.  
Although carbamates show therapeutic potential in the treatment and prevention of 
Alzheimer’s, historically they have a rather more sinister use. Carbamate inhibitors have 
been heavily used in agriculture as insecticides, fungicides, herbicides, biocides and 
pesticides for common pests (Struger, Grabuski, Cagampan, Sverko & Marvin, 2016). 
Carbamates are often preferred compared to traditional organophosphates owing to the 
latter’s toxicity (Queensland Department of Health, 2002). Levels of acetylcholine in 
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mammals is closely regulated via the previously mentioned actions of AChE. If this enzyme 
is inhibited in mammals, it can cause rapid onset of symptoms including paralysis leading 
to death arising from the interruption of normal nerve transmissions (Risher, Mink & Stara, 
1987). 
X-ray crystallography studies have shown AChE to have a serine group in its active site 
(Dvir, Silman, Harel, Rosenberry & Sussman, 2010), (Johnson et al., 2003). Knowing that 
carbamates can act as effective inhibitors of AChE (McHardy, Wang, McCowen & Valdez, 
2017), a serine enzyme, it was hoped that the synthesised carbamates based on avibactam 
may show inhibitory activity for SBL enzymes. 
 
3.3: Methods 
 
All chemicals used were of reagent grade and acquired from Sigma Aldrich unless otherwise 
stated. 
 
3.3.1: Synthesis of Carbamate Inhibitors 
 
Four derivatives were synthesised based on the schemes below in figures 3.4 and 3.5 to give 
a variety of carbamates with leaving groups. 
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Figure 3.4: Overview of the synthesis of the carbamates of avibactam. 
The alcohol (ROH) used in each instance was: methanol (MeOH), trifluoroethanol 
(CF3CH2OH), hexafluoroisopropanol (CF3)2CHOH (HFIP) and hexafluoroacetone hydrate 
(CF3)2C(OH)2 (HFA) was used as per the scheme below. 
 
 
Figure 3.5: Overview of the synthesis of the HFA analogue. 
For the synthesis of all the derivatives, triethylamine (TEA) was utilised as a base to enhance 
the nucleophilicity of the alcohol, for attack at the carbonyl carbon on the β-lactam ring of 
avibactam to cause ring opening. It is unlikely that these weakly basic conditions would lead 
to any epimerisation of the chiral centres. Table 3.1 below shows the expected structure, 
formula, and molecular weight (MW) of each compound. 
 
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
132 
 
Table 3.1: Information and structures of carbamate inhibitors. Further analytical data is 
given in the methods section. 
Compound Name pKa of 
ROH 
Structure in negative 
ionisation mode 
Mass to 
Charge 
(M/Z)  
Formula 
Methyl Carbamate 
(MA) 
16 
 
296.0561 C11H20N3O6S
- 
Trifluoroethyl 
Carbamate (TA) 
12.4 
 
364.0439 C9H13F3N3O6S
- 
Hexafluoroisopropanol 
(HFIP) 
9.3 
 
432.0318 C10H12F6N3O6S
- 
Hexafluoroacetone 
Hydrate (HFA) 
6.58 
 
447.03 C10H12F6N3O8S
- 
Avibactam N/A 
 
264.0296 C7H10N3O6S
- 
 
One equivalent of TEA base was added to one equivalent of the avibactam starting material 
in the alcohol as the solvent. The reaction mixture was stirred under reflux in a N2 
atmosphere. Samples were periodically taken to monitor the disappearance of avibactam and 
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the appearance of the product which was analysed by LCMS and will be described more 
fully in the LCMS method section. Typically, the reaction would be complete after 36 hours. 
Once avibactam could no longer be seen by the LCMS detection method, the sample was 
rotary evaporated under reduced pressure to form a dry powder. The powder was kept under 
N2 and stored at -20 °C. 
 
3.3.2: Liquid Chromatography Mass Spectrometry (LCMS) Analysis Methods of the 
Carbamate Inhibitors 
 
An Agilent 1260 LC system coupled to an Agilent 6545 Quadrupole Time of Flight Mass 
Spectrometer (QToF-MS) system was utilised for LCMS analysis of the carbamate 
inhibitors, with the method of Beaudoin & Gangl (2016) utilised to provide acceptable 
LCMS parameters. The carbamates were dissolved in pH 7 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer and sonicated prior to LCMS analysis and 
made to a concentration of 100 ppm. The mobile phases used were LCMS water 0.1 % 
formic acid on pump line A and LCMS acetonitrile (ACN) 0.1 % formic acid on pump line 
B. An ACE 5 C18-AR (3 µm, 150 x 4.6 mm) column maintained at 30 °C was used to 
provide retention of the inhibitors. The binary pump flow rate was 0.8 ml with an injection 
volume of 5 µl. The elution method was as follows: 3 % B for 1 minute, then a linear increase 
from 3 to 50 % B in 1.4 minutes, followed by another linear increase from 50 to 99 % B in 
1.6 minutes, hold at 99 % B for 0.5 minutes, then a return to 3 % B for 3.5 minutes, followed 
by an equilibration time of 10 minutes before the next sample was injected. 
The mass spectrometer employed a jet stream electrospray ionisation (JS-ESI) and the 
conditions were as follows: gas temperature, 320 °C; gas flow, 8 L/min; nebuliser. 35 psig; 
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sheath gas temp, 350 °C; ion polarity, negative; nozzle voltage, 1000 V; fragmentor voltage, 
175 V. 
 
3.3.3 UV Analysis and Kinetics Determination 
 
It was necessary to develop a method to determine both the rates of hydrolysis of the 
carbamates and the rates of inhibition of the SBLs by the carbamates, and the rates of 
antibiotic hydrolysis by the SBLs.  
The hydrolysis of the carbamates in pH 14 sodium hydroxide (NaOH) was measured by 
recording a decrease in absorbance at 305 nm for the HFIP carbamate, 221 nm for the TFA 
carbamate and 235 nm for the MA carbamate. A baseline blank consisting of NaOH (1 M) 
corrected to pH 14 using a calibrated pH probe was first taken. 0.1 mM solutions of each 
carbamate were prepared and then added to the NaOH and the UV spectra were recorded 
over a period of 12 hours to deduce the hydrolysis of the carbamates as monitored by a loss 
in absorbance at the already mentioned wavelengths.  
The rate of hydrolysis of SBLs against various β-lactam antibiotic substrates was first 
measured as a control (initial antibiotic substrates used included benzylpenicillin and 
cephalosporin based antibiotics such as cephalothin and cefpirome). These were considered 
blanks, against which the activity of inhibition would be compared to give insights into the 
kinetics of inhibition of the SBLs by the carbamates. The various SBLs used were prepared 
in appropriate buffer and used in nM range concentration solutions. This solution was placed 
into an Agilent Technologies Cary 4000 Series UV Vis Spectrophotometer thermostatted to 
30 °C controlled by Cary Win UV Scan/Kinetics software. The instrument was zeroed in the 
presence of enzyme and buffer, but with the absence of antibiotic substrate. Appropriate 
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wavelengths were used to monitor for the decrease in absorbance of each antibiotic used, 
with 240 nm being used for benzylpenicillin and 260 nm being used for the cephalosporin 
based substrates. A 40 mM stock solution of substrate antibiotic was used with a final 
concentration in the cuvette being 0.2 mM. As soon as the substrate was added to the cuvette, 
the solution was shaken and immediately placed in the UV instrument so the loss of 
absorbance of the antibiotic as it was hydrolysed by the SBL could be measured. Penicillin 
was found to have a very high Km compared to the cephalosporin based antibiotic used, 
cephalothin. Therefore, after initial experiments cephalothin was used as the substrate of 
choice to measure hydrolysis/inhibition, as it had a lower Km and was easier to use to deduce 
kinetic information. An example of the data produced by these experiments is shown in 
figure 3.6 below. 
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Figure 3.6: Hydrolysis of cephalothin by SBL P99, showing initial rate (zero order slope) 
and first order decay. 
The zero-order slope corresponds to the saturation of the enzyme and the rate of reaction is 
independent of the concentration of substrate. These straight line slopes are proportional to 
enzyme concentration and hence are a simple and accurate way to measure enzyme activity. 
The experiments measured the rate of hydrolysis of a substrate antibiotic by a selected SBL 
enzyme, using the loss of absorbance as a tool to deduce the concentration of the active 
enzyme. An overview of this reaction can be seen in the following Michaelis—Menten 
kinetics scheme: 
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𝑅𝑎𝑡𝑒 =  
𝑘𝑐𝑎𝑡 [𝐸][𝑆]
𝐾𝑚 + [𝑆]
 
When [S] is greater than Km, the rate is equal to:  
𝑅𝑎𝑡𝑒 =  𝑘𝑐𝑎𝑡[𝐸] 
Saturation kinetics are zero order with respect to the substrate and are independent of the 
concentration of substrate. However, when [S] is less than Km, the rate equation changes to 
the following: 
𝑅𝑎𝑡𝑒 =  
𝑘𝑐𝑎𝑡
𝐾𝑚
 [𝐸][𝑆] 
 
The reaction is first order with respect to the substrate: 
𝑘𝑜𝑏𝑠 =  
𝑅𝑎𝑡𝑒
[𝑆]
=  
𝑘𝑐𝑎𝑡
𝐾𝑚
[𝐸] 
and the rate (change in concentration of substrate divided by change in time) changes with 
the concentration of substrate. 
A time dependent UV method was designed to monitor for inhibition of SBLs. The rate of 
decrease in absorbance of cephalothin, a β-lactam antibiotic, in the presence of a β-lactamase 
is measured. All assays were performed in 0.1 M pH 7.0 HEPES buffer with ionic strength 
(I) = 1 M with KCl, prepared using ultra-pure water (UPW) from a Millipore Milli-Q 
Gradient device. The pH of the buffer was checked using a calibrated Mettler Toledo Inlab 
Routine Pro pH Measurement instrument with a FE20/FG2 probe.  
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A cephalothin stock solution was made by dissolving 16.74 mg into 1 ml of pH 7.0 HEPES 
buffer (0.1 M). 10 µl of this stock solution was transferred to the 2ml test solution in the 
cuvette to give a final test concentration of 0.2 mM. The inhibitor stocks were made fresh 
on the day of experiments and were kept in melting ice when not kept refrigerated. For the 
MA carbamate, 29.61 mg was dissolved in 1 ml pH 7.0 HEPES buffer (0.1 M) to create a 
100 mM stock. For the TA carbamate, 3.64 mg was dissolved into the same buffer to create 
a 10 mM stock for use in further experiments. For the HFIP carbamate, 6.48 mg was 
dissolved in 100 ml of the same buffer to create a 150 µM stock. For the HFA carbamate, 
6.71 mg was dissolved in 100 ml of the same buffer to create a 150 µM stock. Finally, for 
avibactam 3.96 mg was dissolved in 100 ml of the same buffer to create a 150 µM stock. 
SBLs were provided in frozen form from the University of Oxford Schofield group, in µM 
concentration stocks. Upon receipt, the enzymes were diluted and aliquoted appropriately in 
pH 7.0 HEPES buffer (0.1 M) and stored at -20 °C until needed. Further information 
regarding enzyme production can be found in chapter six. 
In each experiment, a 2 ml quartz cuvette was used containing 5 nM enzyme and 0.2 mM 
cephalothin and varying concentrations of the inhibitor. These concentrations provided a 
reasonable absorbance change and so were deemed suitable. A scan of the entire wavelength 
(190 nm - 800 nm) was collected for the hydrolysis of cephalothin using the Scan 
application, and 260 nm was deemed a suitable wavelength to monitor the hydrolysis (loss) 
of cephalothin. The system was blanked using a solution containing everything except the 
analyte (cephalothin) and reactions were commenced by the addition of cephalothin to the 
solution containing the inhibitor and enzyme. The initial rate of the loss of absorption at 260 
nm was used as a measurement of the concentration of active enzyme and so as a tool to 
determine the rate of inhibition. The faster the loss of enzyme activity the faster the rate of 
inhibition. Time dependent inhibition experiments were performed by creating a 20 ml stock 
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solution of enzyme, to which an inhibitor was added and a stopwatch started. Samples were 
taken periodically to which cephalothin was added, to allow the monitoring of hydrolysis. 
The enzyme and inhibitor were incubated at room temperature for varying amounts of time 
to see if the reaction between the enzyme and inhibitor could be time dependent. An example 
of the data obtained from the time dependent inhibition experiments can be seen in figure 
3.7 below. 
 
Figure 3.7: Example of data from the time dependent inhibition experiments. 
As native enzyme is inhibited, its concentration as an active catalyst decreases and so the 
rate of the enzyme catalysed hydrolysis of cephalothin decreases. The initial slopes of 
enzyme with inhibited samples over time can be compared against the initial rate of the 
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control sample (antibiotic and enzyme with the absence of inhibitor) and plots of these slopes 
against time give the rate of inactivation of the enzyme. 
 
3.3.4: pH Dependence of the Rate of Inactivation Inhibition of SBLs by the Carbamate 
Inhibitors and pH Dependence of the Rates of Hydrolysis of Substrates by SBLs 
 
The pH dependence of the rate of inhibition of the enzymes by the carbamate inhibitors was 
compared to that for the hydrolysis of the substrates by SBLs was investigated. This was 
accomplished by following the method described previously, but carrying out the 
inhibition/hydrolysis experiments in different pH buffers. All buffers were made to 0.1 M 
with ionic strength made constant to 1 M maintained by KCl. Formic acid (pKa 3.75) was 
used as the buffer for pH levels between 3-4.5, 2-(N-morpholino)ethanesulfonic acid (pKa 
6.21) (MES) was used as the buffer for pH levels between 5-6.5, HEPES was employed as 
the buffer for pH levels between 7-8.0, and 
tris(hydroxymethyl)methylamino]propanesulfonic acid (pKa = 8.51 (TAPS) was used as the 
buffer for pH levels between 8.5-9. Kinetic data were interpreted using GraphPad Prism 7 
and Microsoft Excel. 
 
3.3.5: Triple Quadrupole Analysis of Carbamate Inhibitors 
 
An Agilent Technologies 1260 high pressure liquid chromatography system coupled to an 
Agilent Technologies 6495 Triple Quadrupole (QqQ) Mass Spectrometer was utilised to 
probe for any avibactam present to ensure it was not the cause of inactivation. Samples were 
made up to 10 nM along with a 10 nM avibactam standard. The mobile phase on line A was 
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LCMS water 0.1 % formic acid, and the line B mobile phase was LCMS ACN 0.1 % formic 
acid. The composition of the mobile phase was 50/50, with a flow rate of 0.4 ml/min. A zero 
dead volume was used instead of a column. The instrument was set up to monitor for the 
negative adduct of avibactam, with a single ion monitoring (SIM) of 264.1. The parameters 
for the QqQ were as follows: gas temperature, 300 °C; gas flow, 5 L/min; fragmentor 
voltage, 135 V in negative polarity mode. 
 
3.3.6: Gas Chromatography Mass Spectrometry Monitoring for Loss of Alcohol 
 
To further the evidence that it was not any residual avibactam remaining in the carbamates 
which is responsible for the inhibition, a gas chromatography mass spectrometry (GCMS) 
experiment was designed to monitor for the loss of alcohol, after inactivation of the enzyme. 
It was anticipated that the production of alcohol would result from the covalent acylation of 
the active serine site of the enzymes, giving rise to inactivation. To monitor for the loss of 
alcohol, an experiment was designed which would allow for the time dependent inhibition 
of the enzyme, and the production of alcohol. 100 µM of inhibitor was added to 1 µM 
enzyme and allowed to react for 30 minutes. Appropriate blanks were taken against which 
the amount of alcohol in the experimental sample could be compared. Butanol was used to 
extract the alcohol for GCMS analysis. An Agilent Technologies single quadrupole GCMS 
system was used. 1 µL of sample was injected onto a HP5 column. The initial oven 
temperature was 35 °C with a 5 °C/minute ramp to 80 °C held for 1 minute.  
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3.4: Results and Discussion 
 
3.4.1: LCMS Analysis of Carbamates 
 
The samples were run on a LCMS instrument as described in the methods section. 
Appropriate blanks were run and the expected mass for each compound was extracted from 
the total ion chromatogram (TIC) to indicate whether or not the correct compound had been 
synthesised. 
The extracted ion chromatogram (EIC) for the predicted MW of each compound was 
extracted from the TIC from each sample. Each sample was run in positive and negative 
ionisation mode, with negative ionisation mode providing the best response for each sample. 
Unfortunately, it was not possible to fully characterise the hexafluoroacetone hydrate 
analogue compound via LCMS, and further work is required for this sample to fully 
elucidate its structure. 
 
Figure 3.8: EIC of 296.0561 for MA. 
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Figure 3.9: EIC of 364.0439 for TA. 
 
Figure 3.10: EIC of 432.0318 for HFIP analogue. 
 
Figure 3.11: EIC of 264.0294 for avibactam. 
In figures 3.9 and 3.10 there were two peaks present. This is a common occurrence in HPLC 
and LCMS and is known as peak splitting; causes can range from poor method design to 
instrument issues (such as HPLC pump issues), to issues with sample preparation. In the 
case of this experiment, it was due to the sample being too concentrated, which was 
confirmed by the instrument indicating that the ion detector was overloaded due to the 
column being saturated with sample, resulting in an irregular peak shape. The samples in 
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the above figures were made to a high concentration (10 µM) in order to search for any trace 
evidence of remaining avibactam starting material. Despite being unable to find the mass of 
447.03 for the hexafluoroacetone hydrate analogue, the sample showed very effective 
inhibition of SBLs (which will be discussed later). Avibactam’s M/Z was searched for in the 
TIC and no avibactam was found. The QToF instrument was capable of identifying 
avibactam with a 1 µL injection of a 10 nM standard. This means that if there was any 
avibactam in the sample, it must be considerably less than the 10 nM standard. This result, 
along with further experiments to be discussed shortly, suggest that there is no avibactam in 
the synthesised compounds, meaning that the inhibition must be due to the synthesised 
compounds. 
Further work is required to fully characterise these compounds, and future experiments 
could include QqQ analysis. QqQ analysis essentially fragments the compounds using an 
electronic voltage and then looks for the pieces of the compounds remaining. The software 
then ‘’pieces’’ the remaining structures together to collate a fingerprint of the molecule. The 
masses of the daughter ions provided from fragmenting the molecule and the way in which 
the structure fragments are used to identify the structure of the compound.  
 
3.4.2: QqQ Analysis of Synthesised Compounds for Avibactam Detection 
 
As mentioned, it was important to ensure that the inhibition seen with the synthesised 
compounds was due to them, and not due to any remaining avibactam from the synthesis 
reaction. The LCMS QToF samples looked relatively clean and to contain just the 
synthesised compounds. Another way to check for the presence of avibactam was to check 
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using QqQ; the results of which are seen below, and will be discussed further in the 
discussion. 
Figure 3.12 below shows the TIC for the avibactam standard. 
 
Figure 3.12: TIC of avibactam standard on QqQ, showing a clearly abundant ion of 264.1. 
This m/z of 264.1 was then searched for in the two derivatives of avibactam. Using single 
ion monitoring (SIM) of the QqQ, a higher sensitivity can be achieved in comparison to 
other LCMS instruments, including the Q-TOF. Figure 3.13 below shows the TIC for 264.1 
in the two derivatives made up to 500 µM, and a water/ACN blank. 
 
Figure 3.13: TIC of SIM of 264.1 in the two derivatives and a water/ACN blank, showing 
an instrument response of 103. 
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The three samples shown in figure 3.13 above are a water/ACN blank, the MA sample and 
the TA sample. The SIM analysis of these three samples gave a response of 103 on the QqQ 
instrument. For comparison, the TIC of SIM of 264.1 of 10 nM avibactam is shown below 
in figure 3.14. 
 
Figure 3.14: TIC of SIM of 264.1 of 10 nM avibactam, showing an instrument response of 
106. 
The results for the SIM analysis of avibactam’s M/Z in a 10 nM avibactam standard gave a 
response of 106 on the QqQ instrument. Clearly from the results, 10 nM of avibactam 
contains much more avibactam than either of the 500 µM synthesised compounds. The peaks 
of the TA and MA samples appear as a flat line on the avibactam sample. This is further 
proof that there is no avibactam in the synthesised samples. In the experiments, it has clearly 
been shown that there is no detectable avibactam present in the carbamate inhibitors, as 
shown by the QqQ and LCMS experiments. This therefore can only mean that it cannot be 
avibactam that is inhibiting the enzymes, and must be the synthesised carbamates. 
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3.4.3: Liberation of Alcohol  
 
Another theory to support the observation that it is the synthesised carbamates inhibiting the 
SBLs rather than any remaining avibactam is whether or not the ROH is produced after the 
synthesised compounds were incubated with the enzyme. If the ROH was detected, then it 
confirms that the predicted reaction between the carbamate and the enzyme had taken place 
and the ROH was liberated as predicted. As a control, the same experiment as above was 
carried out under exactly the same conditions but with no enzyme present. 
To investigate this, the TA inhibitor (100 µM) was incubated with SBL CTX-M-15 (1 µM) 
for 20 minutes. The alcohol (if present) was then extracted into butanol and ran on GCMS.  
First, a blank of butanol and a TA spike were run as described in the methods section.  
 
Figure 3.15: Trifluoroethanol (1 mM) spike in butanol (10 cm3) 
The first peak at 2.27 minutes gave the following prominent ions. 
 
Figure 3.16: Prominent ions for peak at 2.27 minutes. 
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These spectral parameters were ran against the National Institute of Standards and 
Technology Mass Spectral database tool and identified trifluoroethanol with a strong match, 
as can be seen in figure 3.17 below. 
 
Figure 3.17: Strong match for trifluoroethanol. 
The peak at 2.27 minutes was therefore confirmed as trifluoroethanol. A 500 µM solution 
of the trifluoroethanol carbamate derivative was prepared in 0.1 M HEPES buffer at pH 7. 
The sample was extracted with butanol and this blank sample was run on GCMS. It was 
important to detect whether any free trifluoroethanol was detected in a blank sample 
consisting of just the carbamate in the absence of enzyme under the same conditions for 20 
minutes. The TIC of this sample can be seen below. 
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Figure 3.18: Overview of TIC for the blank inhibitor sample. 
If the area corresponding to the known retention time of trifluoroethanol is expanded (around 
2.27 minutes as from figure 3.15 above), one can clearly see that there is no trifluoroethanol 
present in this blank sample (see figure 3.19 below, confirming no trifluoroethanol present 
in the blank inhibitor sample). Therefore, there is no ring closure of the carbamate to 
generate avibactam and alcohol under these reaction conditions. 
 
Figure 3.19: Expanded area of TIC of inhibitor blank, showing noticeable lack of peaks 
around 2.27 minutes, indicating no trifluoroethanol was present in the control reaction. 
CTX-M-15 was added to make a final solution of 500 µM TA and 5 µM CTX-M-15 in 0.1 
M HEPES buffer at pH 7.0. The enzyme and inhibitor were incubated together for 20 
minutes, and the sample was extracted with butanol and ran on GCMS. 
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Figure 3.20: Incubated TA and inhibitor samples. 
Looking at figure 3.20 above, one can clearly see there is a noticeable peak present in the 
incubated TA/enzyme sample; the same peak is clearly not present in the control reaction. 
This indicates that trifluoroethanol is liberated after the reaction between the inhibitor and 
enzyme commences, which suggests that it is the synthesised inhibitor responsible for the 
noticed inhibition. 
Furthermore, this was confirmed by spiking the same sample with trifluoroethanol, which 
resulted in the trifluoroethanol peak seen in the inhibited enzyme sample having a much 
higher response on the GCMS.  
The fact that there was no trifluoroethanol detected in the TA control sample, but there was 
a noticeable peak for trifluoroethanol noticed in the presence of the enzyme/TA sample 
indicates that trifluoroethanol must be being liberated due to a reaction with the enzyme. 
The logical conclusion is that the trifluoroethanol is liberated from the TA when the 
inhibition of the enzyme commences. This is further proof that the inhibition is due to the 
carbamate, and not because of any avibactam that may be present in the sample.  
The GCMS experiment worked well to show that there was no reformation of avibactam 
(due to the fact there was no liberation of alcohol in the blank inhibitor sample) in the time 
frames relevant to the inhibition experiments and also showed that alcohol was liberated 
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from the inhibitor upon the inhibition reaction with the enzyme. However, GCMS as an 
analytical technique is not as sensitive as LCMS, and a high concentration of enzyme was 
required in the reaction to facilitate the liberation of enough alcohol to facilitate a response 
via GCMS. Knowing that the inhibitors probably followed the same reaction mechanism, it 
was deemed unnecessary to sacrifice more enzyme to test this same reaction on the other 
inhibitors. 
 
3.4.4: Detection of Avibactam via LCMS in the Carbamate Derivatives 
 
Further work was carried out to demonstrate the lack of avibactam starting material in the 
synthesised inhibitors. The kinetic data (which will be discussed shortly), indicated that there 
was a very fast reaction between the carbamates and the SBL enzymes they inhibited, with 
the vast majority of inhibition taking place within the first 5 minutes of the reaction 
commencing. If it could be shown that there was no avibactam reformation in this time 
frame, then it would be further proof that it was the carbamates responsible for inhibition, 
and not any left-over avibactam from the synthesis reaction, or recyclisation of the inhibitors 
to reform avibactam. 
It was first deemed necessary to deduce the limit of detection for avibactam for the 
instrument being used. The work was carried out on an Agilent Technologies 1200 LC 
system coupled to an Agilent Technologies 6210 Time of Flight (TOF) Mass Spectrometer. 
A series of avibactam standards were made with set concentrations down to 0.1 nM. A 50 
nM avibactam standard was used to give the m/z for avibactam on the TOF instrument. The 
response for this concentration can be seen below in figure 3.21. 
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Figure 3.21: TOF Response for 50 nM Avibactam standard. 
The system provided a small, but noticeable peak which correlated with the expected m/z of 
avibactam in negative ionisation mode. This peak was not present in an ultra-pure water 
(UPW) blank. 
Lower concentrations were run down to 0.1 nM and a response for avibactam could still be 
seen down to the 1 nM level, so if no avibactam could be seen in the synthesised inhibitor 
samples, then any avibactam present must be below this figure. 
Next, a 10 µM sample for the HFIP carbamate analogue was prepared and run using the 
same method and conditions. At this concentration, the instrument detected a response for 
the EIC of the m/z of the HFIP analogue, but detected absolutely no response for the EIC of 
the m/z of avibactam. This means that if there was any avibactam present in the synthesised 
compound, it must be below 1 nM. It is important to take into consideration the fact that the 
HFIP and HFA carbamates were used at a maximum concentration of 50 nM in the enzyme 
kinetic experiments (which will be discussed shortly). If no avibactam was detected in the 
10 µM sample of the synthesised inhibitor, then there will certainly be no avibactam in the 
50 nM sample of the inhibitor. This is further proof that it is the carbamate derivatives which 
are responsible for inhibition. It is also worth noting that, in any case, the concentration of 
any avibactam present must also be lower than the enzyme concentration used in the 
experiments; which is further proof that it is the carbamate derivatives responsible for 
inhibition, not any residual avibactam. 
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After determining the limits of detection for the instrument with regards to avibactam, 
attention turned to proving that there was no recyclisation of the carbamate compounds to 
form avibactam. A 50 nM solution of the HFIP derivative was prepared in a 0.1 M pH 7 
HEPES buffer solution at 25 °C, the same experimental conditions that the kinetics 
experiments were performed. Samples were taken after 30 minutes to monitor for the 
presence of avibactam. The instrument response from this experiment can be seen in figure 
3.22 below. 
 
Figure 3.22: TIC of 30 minute HFIP sample. 
The m/z for avibactam and HFIP were extracted from the TIC. The instrument found no 
avibactam, and HFIP still had a detectable response, as seen below in figure 3.23. 
 
Figure 3.23: EIC for the m/z of HFIP in the 50 nM sample after incubation for 30 minutes. 
This confirmed that there was no detectable recyclisation of avibactam from the carbamates 
in the time frame for which inhibition was seen in the kinetic experiments. This is further 
proof that inhibition must be due to the synthesised inhibitors and not due to avibactam. 
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In summary, there is no avibactam present from the synthesis of the inhibitors, as seen from 
the clean LCMS traces and the QqQ data. It is also confirmed that the inhibition of the 
enzyme occurs concurrent with the expulsion of the alcohol leaving group in the inhibitors, 
as seen from the GCMS data showing the liberation of trifluoroethanol after incubation of 
the inhibitor with CTX-M-15. Finally, it is shown that there is no recyclisation of avibactam, 
as seen from the timed LCMS experiment with the HFIP sample stored in 0.1 M HEPES 
buffer at 25 °C for 30 minutes. After this period, no avibactam was found within the 
detectable limits of the instrument. It can therefore be concluded that the synthesised 
carbamates provide a novel inhibition of the SBLs.  
 
3.4.5: Kinetics of Hydrolysis of Substrate by SBLs and Inhibition and pH Dependence 
 
The four synthesised carbamates were tested for their inhibition against common SBLs from 
classes A and C. The enzymes tested for inhibition from class A were TEM-1, and the classes 
from class C were AmpC, P99 and CTX-M-15. Also, three of the synthesised carbamates 
were subjected to hydrolysis in pH 14 NaOH to elucidate their hydroxide rate constant. This 
could be compared to the pKa of their alcohol leaving group to give more information of 
their effectiveness as inhibitors. 
 
3.4.5.1: Kinetics of Hydrolysis of Carbamate Inhibitors 
 
The hydrolysis of the carbamate inhibitors in 1 M pH 14 NaOH at 25 °C was deduced as 
monitored by the loss of absorbance at certain wavelengths, as discussed in the methods 
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section. The change in absorbance was recorded over a period of time and the natural 
logarithm of the absorbance infinity value – absorbance time value gave a straight line 
corresponding to the observed pseudo first-order rate constant. As these kinetic runs were 
performed in 1 M NaOH these rate constants also give the second-order values. Figure 3.24 
below shows the Bronsted plot for the second-order rate constants (M-1s-1) for the hydroxide 
ion catalysed hydrolysis for three of the carbamates (MA, TA and HFIP) against the pKa of 
the leaving group alcohol. 
 
Figure 3.24: Bronsted Plot of the second-order rate constants for the hydroxide-ion catalysed 
hydrolysis of carbamates against the pKa of the alcohol. 
As can be seen from figure 3.24 above, as the acidity of the alcohol increased, the hydroxide 
ion rate constant for hydrolysis is also increased. This gives an indicator to the effectiveness 
y = -1.01E-01x - 3.94E+00
R² = 9.99E-01
-5.8
-5.6
-5.4
-5.2
-5
-4.8
-4.6
9 10 11 12 13 14 15 16 17
lo
g 
k O
H
pKa of ROH
Bronsted Plot of the Second-Order Rate Constants for the Hydroxide-
Ion Catalysed hydrolysis of Carbamates Against the pKa of the 
Alcohol
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
156 
 
of the carbamates as an inhibitor. It was confirmed that the more effective inhibitors had 
higher hydroxide rate constants. Unfortunately, due to time constraints, the hydroxide rate 
constant of the HFA carbamate was unable to be confirmed. However, it has the lowest pKa 
of the carbamates, so it is predicted that it would have an even greater hydroxide rate 
constant than the other inhibitors. 
The slope of the line in fig 3.24 gives the Bronsted βlg value which in this case is -0.1. This 
is a surprisingly low value. For comparison the βlg hydroxide-ion catalysed hydrolysis of 
esters PhCH2CO2R is -0.4. The effective charge on the alcohol oxygen in carbamates is +0.8 
and so the observed βlg for alkaline hydrolysis is compatible with rate-limiting breakdown 
of the tetrahedral intermediate as seen in figure 3.25 below: 
 
Figure 3.25: Alkaline hydrolysis of carbamates showing rate-limiting step of the 
breakdown of the tetrahedral intermediate. 
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3.4.6: Kinetics of Inhibition of AmpC, P99, TEM-1 and CTX-M-15 by Methyl ester 
carbamate and Trifluoroethyl ester Carbamate Derivatives  
 
The MA and TA only provided modest inhibition as compared to the more acidic alcohol 
derivatives, containing leaving groups with lower pKas. As such, the results of the kinetics 
data for the MA and TA derivatives will only be discussed briefly, with the results of the 
more acidic alcohols being explained in more detail. 
To determine the kinetics of inhibition, blank samples consisting of enzyme and substrate 
(cephalothin) were performed using changes in the UV spectra as described in the methods 
section. Samples were taken at specified time intervals and the initial slopes of each sample 
were recorded. These samples served as blank determinations, and would be used to 
compare against the inhibition initial slopes. This ratio of active enzyme to inactive enzyme 
gives the percentage of active enzyme remaining after times incubated with the inhibitor. 
The percentage active enzyme remaining figures were plotted against the incubation time to 
give a graph displaying pseudo first order kinetics. 
The percentage active enzyme remaining were converted to concentration of enzyme 
remaining, and the natural logarithm of these values were plotted against incubation time to 
give a straight line graph, as shown in figure 3.26 below. 
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Figure 3.26: Natural logarithm of concentration of active enzyme remaining against 
incubation time for inhibition of AmpC (5 nM) by the TA carbamate (10 µM). 
The slope of the graph above in figure 3.26 can be interpreted as the observed pseudo first-
order rate constant for the inhibition (kobs). This was repeated for each experiment between 
the enzyme and carbamates, with different concentration of carbamates used. These kobs 
values were then plotted against carbamate concentration the slope of which gives the 
second-order rate constant (M-1s-1) for inhibition, as seen below in figure 3.27. 
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Figure 3.27: Observed pseudo first-order rate constants, kobs, for the inhibition of CTX-M-
15 (10 nM) by trifluoroethanol analogue (TA) at varying inhibitor concentrations. 
This method of data collection/analysis was repeated for different inhibitors and enzyme 
combinations, the results of which are shown below in table 3.2. 
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Table 3.2: Kinetic results of inhibition of SBLs by MA and TA carbamate derivatives. 
Enzyme 
Carbamate 
Derivative 
Concentration 
(µM) 
kobs (s
-1) ki (M
-1s-1) 
TEM-1 
MA 
25 3.13 x 10-4 
14.32 
50 7.16 x 10-4 
100 9.90 x 10-4 
150 1.13 x 10-3 
250 2.72 x 10-3 
TA 
0.5 3.41 x 10-4 
1016.48 
1 5.39 x 10-4 
1.5 6.84 x 10-4 
2.5 1.83 x 10-3 
3.75 3.07 x 10-3 
5 5.08 x 10-3 
AmpC 
MA 
250 2.51 x 10-4 
2.01 
500 5.58 x 10-4 
1000 1.19 x 10-3 
1500 3.02 x 10-3 
TA 
5 1.51 x 10-4 
36.6 8 2.93 x 10-4 
10 4.76 x 10-4 
CTX-M-
15 
MA 
500 9.5 x 10-4 
3 1000 3 x 10-3 
1250 3.49 x 10-3 
TA 
1 1.97 x 10-4 
314.6 2.5 7.70 x 10-4 
5 1.57 x 10-3 
P99 
MA 250 2.41 x 10-4 
0.96   500 4.54 x 10
-4 
  1000 9.84 x 10
-4 
TA 
1 1.03 x 10-4 
105.45 5 4.46 x 10-4 
10 1.05 x 10-3 
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The synthesised TA and MA samples were tested for their inhibition of TEM-1 AmpC, 
CTX-M-15 and P99.  
For inhibition of AmpC, the data showed modest inhibitory effects, with ki of the MA 
analogue being 2 M-1s-1, but the TA had a higher ki in the region of 40 M
-1s-1, making it a 
more effective inhibitor. AmpC SBLs are produced by many of the Enterobacteriaceae, so 
producing novel inhibitors of these enzymes is of great clinical interest.  
The data for the inhibition of P99 by MA and TA showed similar kinetics to the inhibition 
of AmpC. This was to be expected, as AmpC and P99 are both class C SBLs, and MA and 
TA are predicted to inhibit the enzymes in the same way. However, it was encouraging to 
see that inhibition was observed with a different enzyme. This suggested that the two 
inhibitors were novel inhibitors of SBLs. To further confirm this, it was decided to test the 
two inhibitors against an SBL from a different class. Class A SBL TEM-1 was acquired and 
similar inhibition testing took place. 
With regards to TEM-1, only modest rates of inhibition were noticed by the synthesised 
inhibitors. However, it was noticed that TEM-1 had relatively high rates of inhibition as 
compared to the other enzymes, with ki being in the region of 10
3 M-1-s-1 for the TA 
carbamate. 
Finally, for CTX-M-15, modest inhibition was noticed with the TA/MA synthesised 
inhibitors.  
Now that inhibition had been observed across different classes of SBLs, work commenced 
in trying to improve the modest inhibitory effects of the TA and MA. The effectiveness of 
the MA and TA carbamates was limited by the pKa of the alcohol leaving groups. MeOH 
has a pKa of 16, which showed the lowest activity of any synthesised inhibitor. The pKa of 
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CF3CH2OH was lower, at 12.4, and was seen to be a more effective inhibitor. Therefore, 
alcohols with lower pKas were identified, and used to synthesise two further compounds: 
Hexafluoroisopropanol (HFIP) with a pKa of 9.3 and hexafluoroacetone hydrate (HFA) with 
a pKa of 6.58. It was predicted that these alcohols having lower pKas would serve as better 
leaving groups, and therefore act as better inhibitors of SBLs. HFIP and HFA inhibitors were 
prepared as described in the methods section and were screened for their effectiveness 
against CTX-M-15. 
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3.4.7 Kinetics of Inhibition of CTX-M-15 by Hexafluoroisopropanol and 
Hexafluoroacetone Hydrate Carbamate Derivatives 
 
The two carbamates synthesised with the more acidic alcohols (hence providing leaving 
groups with lower pKas) were also tested for their inhibition against SBL CTX-M-15. As 
will be seen shortly, the inhibition of CTX-M-15 by these enzymes was much more efficient 
than with either of the MA or TA carbamates. Their results will be discussed in more detail, 
as their results are of much more clinical relevance. 
 
Figure 3.28: Percentage active β-lactamase CTX-M-15 remaining after incubation with 
HFIP carbamate at 10:1 (50 nM) and 1:1 (10 nM) concentration with enzyme. 
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It was noted immediately from figure 3.28 that HFIP was a much more effective inhibitor 
than either of the two previously tested inhibitors. This is thought to be due to the lower pKa 
of the alcohol leaving group, making the HFIP a more efficient inhibitor. As for the previous 
inhibition experiments with the less acidic alcohol leaving groups, the experiments were 
conducted in 20 ml pH 7.0 HEPES buffer (0.1M) using 0.2 mM cephalothin as a substrate 
for hydrolysis. For the 50 nM experiment, 6.67 µl was taken from the 150 µM HFIP stock 
solution and added to the 20 ml test solution containing 5 nM CTX-M-15 to create a 50 nM 
test concentration where as for the 10 nM experiment, 1.33 µl was taken and added to the 
20 ml test solution to create a final 10 nM concentration. 
 
Figure 3.29: Natural logarithm of concentration active enzyme remaining against incubation 
time for inhibition of CTX-M-15 (5 nM) by the hexafluoroisopropanol analogue (50 nM) at 
10:1 concentration with enzyme. 
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The pseudo first-order rate constant for this inhibition as seen from figure 3.29 was 5.12 x 
10-3s-1 corresponding to a second-order rate constant ki of 1.02 x 10
5 M-1s-1. It was noted that 
the HFIP carbamate derivative was an extremely good inhibitor of CTX-M-15. The 
experiment was therefore repeated at a lower concentration of inhibitor, with 1:1 
concentration with enzyme in what would be a second-order reaction process. 
 
Figure 3.30: Second-order plot for inhibition of CTX-M-15 (10 nM) by HFIP carbamate (10 
nM) at 1:1 concentration with enzyme. 
The ki from the HFIP reaction with CTX-M-15 under second-order conditions where the 
concentration of the reactants A and B were equal gives ki = 3.75 x 10
5 M-1s-1, as seen from 
figure 3.30 above. This makes the HFIP inhibitor an extremely effective inhibitor of CTX. 
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result in no inhibition) was known. The early readings deviate from the line of best fit 
somewhat. This is likely due to the inhibition reaction happening so quickly, that with the 
current method design it was difficult to accurately capture data at these early points of the 
reaction. A stopped flow experiment would be a way to overcome this difficulty for future 
work. This is unlikely to be of any mechanistic significance, as data from the LCMS 
inhibitor experiments suggested the compounds were pure and there was no 
recyclisation/further reactions to form other compounds. The next analogue to try was the 
HFA inhibitor, which was synthesised with the lowest pKa alcohol of all the inhibitors. 
 
Figure 3.31: Percentage active CTX-M-15 remaining after incubation with HFA carbamate 
at 100:1 (1 µM), 10:1 (100 nM) and 1:1 (10 nM) concentration with enzyme. 
As can be seen from figure 3.31 above, the percentage activity remaining for CTX-M-15 
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as compared to the original inhibitors with higher pKa alcohol leaving groups. As for the 
previous inhibition experiments with the less acidic alcohol leaving groups, the experiments 
were conducted in 20 ml pH 7.0 HEPES buffer (0.1M) using 0.2 mM cephalothin as a 
substrate for hydrolysis. For the 1 µM experiment, 133.33 µl was taken from the 150 µM 
HFA stock solution and added to the 20 ml test solution containing 10 nM CTX-M-15 to 
create a 1 µM test concentration where as for the 100 nM experiment, 13.33 µl was taken 
and added to the 20 ml test solution to create a final 10 nM concentration and finally for the 
10 nM experiment, 1.33 µl was added to the 20 ml test solution to give a final inhibitor 
concentration of 10 nM. 
 
Figure 3.32: Second-order plot for inhibition of CTX-M-15 (10 nM) by HFA carbamate (10 
nM) at 1:1 concentration with enzyme. 
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The data from the inhibition experiments with HFA indicate that HFA had a ki = 1.23 x 10
6 
M-1s-1, as seen from figure 3.32 above. This shows that HFA is the most effective inhibitor 
of the SBLs out of all the compounds synthesised. There was a slight offset result at 1800 
seconds which may increase the slope slightly, but clearly HFA was the most effective 
inhibitor tested. This is in line with figure 3.33 below, the Bronsted Plot showing the pKa of 
the leaving group against the ki calculated from the inhibition experiments for the inhibition 
of CTX-M-15, where there is clearly a correlation between the pKa
 of the alcohol leaving 
group decreasing and log ki increasing. 
 
Figure 3.33: Bronsted plot for the carbamate inhibitors and the inhibition of CTX-M-15. 
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inhibitor. The corresponding βlg = 0.64, which is much greater than that of 0.1, which is 
observed for the alkaline hydrolysis of the carbamates. 
Carbamates are much less reactive than esters. The second order rate constants for the 
alkaline hydrolysis of carbamates are generally very low, for example, for the rate constant 
for simple carbamates is 4.5 x 10-6 M-1s-1 giving a half-life of about 50,000 years at pH 7 
(Adams & Baron, 1965). Therefore, the reaction of the avibactam carbamate derivatives 
with the β-lactamases must be enzyme catalysed. 
The effective charge on the alkoxy oxygen of carbamates is + 0.8 due to resonance, as seen 
in figure 3.34 below: 
 
Figure 3.34: Charge of the alkoxy oxygen of carbamates. 
The slope of the Bronsted plot gives a βlg = 0.64 which indicates rate-limiting formation of 
the tetrahedral intermediate, as seen in figure 3.35 below: 
 
Figure 3.35: Rate-limiting formation of the tetrahedral intermediate between the carbamate 
and enzyme. 
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The Bronsted βlg for the alkaline hydrolysis of esters is – 0.4, which has been interpreted as 
rate-limiting attack of hydroxide-ion upon the carbonyl carbon (Barton, Laws & Page, 
1994). 
The HFA derivative was such an effective inhibitor, the ki for avibactam was determined to 
see if the HFA inhibitor was a more effective inhibitor than the current market leader. 
 
Figure 3.36: Percentage active CTX-M-15 (10 nM) remaining after incubation with 
avibactam (10 nM) at 1:1 concentration with enzyme. 
As can be seen from figure 3.36 above, avibactam showed similar inhibitory action to the 
two more acidic inhibitors that were synthesised. As for the previous inhibition experiments, 
the experiment took place in 20 ml pH 7.0 HEPES buffer (0.1 M), using 0.2 mM cephalothin 
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as the substrate. 1.33 µl of the 150 µM avibactam stock solution was added to the 20 ml test 
sample to give an inhibitor concentration of 10 nM. 
 
Figure 3.37: Second-order plot for inhibition of CTX-M-15 (10 nM) by avibactam (10 nM) 
at 1:1 concentration with enzyme. 
The ki of the inhibition of CTX-M-15 by avibactam was 5.02 x 10
5 M-1s-1, as seen in figure 
3.37 above. Not only does this mean that our HFIP carbamate derivative is a comparable 
inhibitor to avibactam (with a ki of 3.75 x 10
5 M-1s-1), but the HFA derivative (with a ki of 
1.23 x 106 M-1s-1) surpasses the performance of avibactam at inhibiting CTX-M-15. If, as 
expected, the mechanism of inhibition is observed amongst different classes of SBLs, the 
data suggest that a novel inhibitor has been synthesised that is of superior performance to 
the current market leader, avibactam. The line of best fit in figure 3.32 can be subject to 
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some scrutiny owing to the result at 1800 seconds, but even if this result is removed, the 
HFA inhibitor is in the region of a two fold better inhibitor than avibactam. The work 
detailed here lays the foundations of future work, where a number of similar analogues could 
be synthesised and screened for their inhibition against emerging important SBLs. 
Furthermore, the fact that the HFA carbamate derivative is a noticeably better inhibitor of 
CTX-M-15 than avibactam suggests, once more, that it is indeed the synthesised compounds 
that are responsible for inhibiting the enzymes, and not residual avibactam left over from 
the synthesis reaction. 
Table 3.3 below summarises the relevant results of the inhibition work carried out with 
HFIP, HFA and avibactam. 
Table 3.3: Summary of the relevant ki data of the results of the inhibition of CTX-M-15 by 
HFIP, HFA and avibactam. 
Inhibitor Concentration (nM) ki (M-1s-1) 
Hexafluoroisopropanol 
Carbamate (HFIP) 
10 3.75 x 105 
Hexafluoroacetone Hydrate 
Carbamate (HFA) 
10 1.23 x 106 
Avibactam 10 5.02 x 105 
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3.4.8: Kinetics of Hydrolysis of Substrates by SBLs and pH Dependence 
 
To further investigate the mechanism of inhibition and catalysis of hydrolysis of β-lactams 
by SBLs, the effect of pH on both the catalysed hydrolysis and inhibition was investigated 
to see whether they were similar or different.  
The pH profiles for hydrolysis were ascertained by using three SBLs (P99, CTX-M-15 and 
AmpC) at set pH levels to catalyse the hydrolysis of cephalothin and monitoring the 
hydrolysis via changes in the UV at 260 nm. The solutions were buffered at set pH with the 
ionic strength (I) maintained by KCl. The reaction was allowed to go to completion at each 
pH to for each enzyme. A representative example will be shown for each enzyme to show 
how the pH profiles were obtained.  
3.4.8.1: pH Dependence of the Hydrolysis of Cephalothin Catalysed by P99 
 
An example of the P99 catalysed hydrolysis of cephalothin can be seen in figure 3.38 below.  
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Figure 3.38: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.0 in HEPES 
Buffer (0.1 M) 
From these hydrolysis graphs (which were repeated for each enzyme at 0.5 pH intervals, 
which can be seen in the general methods section), one can obtain a variety of information 
regarding the kinetics of the reaction between the enzyme and substrate. The total change in 
absorbance divided by the substrate concentration gives Δε. The slope of the initial straight 
line portion of the zero order section of the graph can be divided by (Δε x [E]) to give kcat 
(s-1). This information will be summarised in tables for each enzyme shortly. 
The latter part of the hydrolysis reaction corresponds to enzyme catalysis below saturation 
and follows first order kinetics.  This portion of the graph can be imported into GraphPad 
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Prism (GraphPad Software, California USA) and curve fit against a first order decay 
equation to give kobs, an example of which is seen below in figure 3.39. 
 
Figure 3.39: First order curve fit of the hydrolysis of cephalothin (0.2 mM) by P99 (5 nM) 
in pH 7.0 HEPES buffer (0.1 M). 
In figure 3.39 above, the black triangles represent the experimental data obtained in the 
hydrolysis experiments and the red line is the curve fit obtained from GraphPad Prism. This 
curve fit gave kobs. This was repeated for every hydrolysis reaction (the results of which can 
be seen in the methods section). The kobs value can be divided by the enzyme concentration 
to give kcat/Km (M
-1s-1). 
Using the data analysis methods described previously, various kinetic parameters were 
deduced from the hydrolysis graphs for the enzyme catalysed hydrolysis of cephalothin over 
various pH by P99 which can be seen in table 3.4 below. 
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Table 3.4: Kinetic parameters of the hydrolysis of cephalothin (0.2 mM) over various pH at 
30 °C with I = 1 M (KCl) by β-lactamase P99 (5 nM). 
 
The kcat/Km was plotted against pH to give the following graph. 
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Figure 3.40: kcat/Km for the hydrolysis of cephalothin (0.2 mM) by P99 (5 nM) at various 
pH. 
The P99 β-lactamase catalysed hydrolysis of cephalothin as seen above in figure 3.40 shows 
the typical bell-shaped pH-rate profile indicative of two important ionisable groups on the 
enzyme controlling activity. One of these must be ionised for maximal activity and the other 
unionised as per the scheme below: 
 
From figure 3.40 above, pKa
1 is 6.40 and pKa
2 is 8.85. For this class C β-lactamase the low 
pKa is thought to be due to Tyr-150 which is H-bonded to Lys-315 and Lys-67 acting as a 
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general base (Page, Vilanova & Layland, 1995). The accepted hydrolysis scheme for class 
C β-lactamases can be seen below in figure 3.41: 
 
Figure 3.41: Accepted hydrolysis scheme for class C β-lactamases. 
 
3.4.5.4.2: CTX-M-15 pH Dependence of Hydrolysis of Cephalothin 
 
These pH rate profiles for the hydrolysis of β-lactams by β-lactamase enzymes were repeated 
for other classes of β-lactamases; additional data (such as the absorbance graphs and kobs 
curve fits) can be seen in section 6.10 in the general methods section. The kinetic data for 
CTX-M-15 can be seen in table 3.5 below. A representative example will be shown and 
briefly discussed for CTX-M-15. The CTX-M-15 catalysed hydrolysis of cephalothin at pH 
5.5 is shown below in figure 3.42. 
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Figure 3.42: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 5.5 in 
MES Buffer (0.1 M) 
The first order portion of the graph was imported into GraphPad Prism to allow curve fitting 
against a first order decay equation and kobs to be obtained, as shown below in figure 3.43 
below. 
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Figure 3.43: First order curve fit of the hydrolysis of cephalothin (0.2 mM) by CTX-M-15 
(5 nM) in pH 5.5 MES buffer (0.1 M). 
This process was repeated at 0.5 pH intervals from pH 4.0 to 9.0 for CTX-M-15. Using the 
data analysis methods described previously, various kinetic parameters were deduced from 
the hydrolysis graphs for the enzyme catalysed hydrolysis of cephalothin over various pH 
by CTX-M-15 which can be seen in table 3.5 below. 
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Table 3.5: Kinetic parameters of the hydrolysis of cephalothin (0.2 mM) over various pH at 
30 °C with I = 1 M (KCl) by β-lactamase CTX-M-15 (5 nM). 
pH [E] 
(nM) 
Zero 
Order 
Slope 
Δε kobs (s-1) kcat (s-1) kcat/Km 
(M-1s-1) 
Km (M) 
4.0 5 3.34 x 10-3 7.21 x 103 1.13 x 10-3 92.65 2.26 x 105 4.10 x 10-4 
4.5 5 1.09 x 10-2 7.72 x 103 1.23 x 10-2 282.38 2.46 x 106 1.15 x 10-4 
5.0 5 1.72 x 10-2 7.52 x 103 2.23 x 10-2 457.45 4.46 x 106 1.03 x 10-4 
5.5 5 1.77 x 10-2 7.69 x 103 2.84 x 10-2 460.34 5.68 x 106 8.10 x 10-5 
6.0 5 1.78 x 10-2 7.38 x 103 3.10 x 10-2 482.34 6.20 x 106 7.78 x 10-5 
6.5 5 1.94 x 10-2 7.56 x 103 3.32 x 10-2 513.23 6.64 x 106 7.73 x 10-5 
7.0 5 1.94 x 10-2 7.28 x 103 3.33 x 10-2 532.97 6.66 x 106 8.00 x 10-5 
7.5 5 1.67 x 10-2 7.19 x 103 3.25 x 10-2 464.53 6.50 x 106 7.14 x 10-5 
8.0 5 1.24 x 10-2 7.72 x 103 3.08 x 10-2 321.24 6.16 x 106 5.21 x 10-5 
8.5 5 7.98 x 10-3 7.40 x 103 2.37 x 10-2 215.68 4.74 x 106 4.55 x 10-5 
9.0 5 5.00 x 10-3 7.80 x 103 1.58 x 10-2 128.21 3.16 x 106 4.06 x 10-5 
 
Much like for P99, the kcat/Km was obtained using the kobs from the hydrolysis experiments 
and plotted against pH to give the following pH profile. 
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Figure 3.44: kcat/Km for the hydrolysis of cephalothin (0.2 mM) by CTX-M-15 (5 nM) at 
various pH. 
For CTX-M-15 β-lactamase the pH profile as seen above in figure 3.44 for hydrolysis of 
cephalothin again shows the typical bell-shaped profile. For this enzyme pKa
1 and pKa
2 are 
4.75 and 8.95 respectively determined from the hydrolysis reaction.  
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3.4.8.2: AmpC pH Dependence of Hydrolysis of Cephalothin 
 
The pH profile experiments were repeated for AmpC. As before, a representative example 
of how the kinetic data were obtained will be shown. Figure 3.45 below shows the AmpC 
catalysed hydrolysis of cephalothin at pH 6.0. 
 
Figure 3.45: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.0 in MES 
Buffer (0.1 M) 
The first order portion of the graph was imported into GraphPad Prism to allow curve fitting 
against a first order decay equation and kobs to be obtained, as shown below in figure 3.46 
below. 
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Figure 3.46: First order curve fit of the hydrolysis of cephalothin (0.2 mM) by AmpC (5 
nM) in pH 6.0 MES buffer (0.1 M). 
This process was repeated at 0.5 pH intervals from pH 5.5 to 8.5 for AmpC. Using the data 
analysis methods described previously, various kinetic parameters were deduced from the 
hydrolysis graphs for the enzyme catalysed hydrolysis of cephalothin over various pH by 
AmpC which can be seen in table 3.6 below. 
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Table 3.6: Kinetic parameters of the hydrolysis of cephalothin (0.2 mM) over various pH at 
30 °C with I = 1 M (KCl) by β-lactamase AmpC (5 nM). 
pH [E] 
(nM) 
Zero 
Order 
Slope 
Δϵ kobs (s-1) kcat (s-1) kcat/Km Km 
5.5 5 2.44 x 10-3 6.51 x 103 8.96 x 10-3 74.96 1.79 x106 4.18 x 10-5 
6.0 5 2.67 x 10-3 6.94 x 103 1.77 x 10-2 76.95 3.54 x106 2.17 x 10-5 
6.5 5 3.12 x 10-3 6.97 x103 2.68 x 10-2 89.53 5.36 x 106 1.67 x 10-5 
7.0 5 3.64 x 10-3 6.71 x 103 3.62 x 10-2 108.49 7.24 x 106 1.50 x 10-5 
7.5 5 4.44 x 10-3 7.02 x 103 4.91 x 10-2 126.50 9.82 x 106 1.29 x 10-5 
8.0 5 3.30 x 10-3 6.83 x 103 8.39 x 10-2 96.63 1.68 x 107 5.76 x 10-6 
8.5 5 3.35 x 10-3 6.67 x 103 3.6 x 10-2 100.45 7.2 x 106 1.4 x 10-5 
 
As for P99 and CTX-M-15, the absorbance and curve fit graphs from which the kinetic data 
above was deduced can be seen in section 6.10 of the general methods section. kcat/Km was 
plotted against pH to give the following pH profile. 
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Figure 3.47: kcat/Km for the hydrolysis of cephalothin (0.2 mM) by AmpC (5 nM) at various 
pH. 
AmpC has a rather strange pH profile as seen above in figure 3.47, which was confirmed by 
repeat experiments. It was perhaps that the stock of enzyme used may have been 
compromised in some way, giving unexpected results. These results were then compared 
with the dependence of the ki by the carbamates ki to give some insight into the mechanisms 
of catalysis/inhibition 
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3.4.9: pH Dependence of Inhibition of SBLs 
 
The effect of pH on the inhibition of the SBLs was also investigated in a similar manner to 
the pH dependent hydrolysis experiments. As for the pH dependence of the hydrolysis of 
substrates by β-lactamases, a representative example of how the data was obtained for each 
enzyme will be shown. For all experiments, the same concentration stock solutions as 
described previously were used. Blanks were recorded over a period of time relevant for the 
inhibition experiments for each enzyme and a negligible loss of enzyme activity was 
recorded (<5%). 
3.4.9.1: pH Dependence of Inhibition of P99 by TA Carbamate and Avibactam 
 
As with the inhibition experiments, the first step was to obtain a blank sample at a set pH 
where no inhibitor was present, against which inhibition could be compared. In this sample, 
there was only the β-lactamase P99 (5 nM) and the substrate cephalothin (0.2 mM). This 
would serve as a reference against which inhibited samples could be compared against to 
measure remaining enzyme activity. An example of one of the blank reactions (at pH 8.5) is 
shown in figure 3.48 below. 
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Figure 3.48: P99 catalysed hydrolysis of cephalothin at pH 8.5 without inhibitor present. 
The slope of the zero order portion of the graph in figure 3.48 above serves as a reference 
point, against which  inhibition rates can be compared (as in chapter 3.4.6) and can be seen 
in figure 3.49 below.  
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Figure 3.49: Zero order section of the graph in figure 3.48, giving a zero order slope of 7.03 
x 10-3 
The zero order slope of the blank sample (where no inhibitor was present, only β-lactamase 
P99 and antibiotic substrate cephalothin) was 7.03 x 10-3 and served as a reference against 
which inhibited samples can be compared to offer an insight into enzyme activity. The zero 
order slopes of inhibited samples were compared against the “blank” zero order slope (where 
there was no inhibition as no inhibitor was present), from which the amount of inhibited 
enzyme can be calculated. 
The inhibitor (TA) was added to the β-lactamase P99 in 20 cm3 pH 8.5 TAPS buffer to give 
final concentrations of TA (10 µM) and P99 (5 nM) and a timer was started. At specified 
time intervals, a sample was taken and cephalothin was added (100 µL from a 40 mM stock 
y = -7.03E-03x + 1.60E+00
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
0 5 10 15 20 25 30 35 40 45
A
b
so
rb
an
ce
Time (Seconds)
Zero Order Section of The Hydrolysis of Cephalothin (0.2 mM) by β-
Lactamase P99 (5 nM) in pH 8.5 TAPS Buffer (0.1 M) at 30 °C with I = 
1 M (KCl) as Monitored by the Loss of Absorbance at 260 nm
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
190 
 
solution to give a final cephalothin concentration of 0.2 mM) and the hydrolysis of 
cephalothin was measured. The rate of hydrolysis as compared to the blank sample where 
there was no inhibitor added gave an indication to the rate of inhibition and the total un-
inhibited enzyme remaining. The percentage active enzyme remaining was deduced by 
dividing the zero order slope of the inhibited sample by the zero order slope of the blank 
sample. For example, the hydrolysis graph of the inhibition sample at 20 minutes (1200 
seconds) inhibition time gave the following absorbance graph as shown in figure 3.50 below. 
 
Figure 3.50: Zero order section of the P99 catalysed cephalothin hydrolysis after inhibition 
by TA after 1200 seconds incubation time at pH 8.5. 
Figure 3.50 above gave a zero order slope of 2.797 x 10-3. When this is divided by the blank 
zero order slope of 7.03 x 10-3, it gives a result of 0.3979, indicating 39.79% enzyme activity 
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was remaining. This corresponded to an enzyme concentration of 1.99 x 10-9 M. This process 
was repeated at various time points until there was minimal enzyme activity remaining. The 
concentration enzyme remaining at the recorded time points were then converted to their 
natural logarithm and plotted against time in seconds. This gave a straight line graph as seen 
below in figure 3.51. 
 
Figure 3.51: Natural logarithm of concentration of active enzyme remaining against 
incubation time for inhibition of P99 (5 nM) by TA (10 µM). 
The slope of the graph above in figure 3.51 (3.42 x 10-4 s-1) can be interpreted as the observed 
pseudo first-order rate constant for the inhibition (kobs). This result can be divided by the 
inhibitor concentration (10 µM) to give the second order rate constant of 34.2 M-1s-1. 
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This process was repeated at 0.5 pH intervals from pH 5.5 to pH 9 to create the following 
pH profile as seen in figure 3.52 below. 
 
Figure 3.52: ki for the inhibition of P99 (5 nM) by TA (10 µM) at various pH. 
This process was repeated but avibactam was used as the inhibitor instead of TA, as seen in 
figure 3.53 below. The pH-rate profiles for the inhibition of P99 β-lactamase by the 
carbamate derivatives (figure 3.52 above) and avibactam (figure 3.53 below) are almost 
identical to that for hydrolysis of β-lactams. The pKa1s of the two important ionisable groups 
are 5.90 and 6.05 for TA carbamate and avibactam respectively; where-as the pKa
2 values 
are 8.75 and 8.30 respectively. 
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Figure 3.53: ki  for the inhibition of P99 (5 nM) by avibactam (50 nM) at various pH. 
The predicted scheme for the inactivation of SBLs by avibactam and our carbamate 
inhibitors is shown below in figure 3.54: 
 
Figure 3.54: Predicted inactivation of SBLs by avibactam and our carbamate inhibitors. 
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3.4.9.2: pH Dependence of Inhibition of CTX-M-15 by TA Carbamate and Avibactam 
 
The process for testing the pH dependent inhibition of P99 with our TA carbamate and 
avibactam was repeated with other SBL enzymes. As before, a representative example will 
be shown and briefly explained to show how the data for the pH profiles was obtained. 
As for P99, the first step was to obtain a blank sample without inhibitor present, against 
which inhibited samples could be compared, as seen in figure 3.55 below. 
 
Figure 3.55: CTX-M-15 catalysed hydrolysis of cephalothin at pH 6.5 without inhibitor 
present. 
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The zero order slope of the above graph in figure 3.55 serves as a reference against which 
inhibited samples can be compared to give an insight into the amount of inhibited enzyme. 
The zero order slope can be seen below in figure 3.56. 
 
Figure 3.56: Zero order section of the graph in figure 3.55, giving a zero order slope of 
1.8598 x 10-2. 
As before, the inhibitor was added to the enzyme and a timer was started. Cephalothin was 
added at various time points and the hydrolysis was monitored. The rate of hydrolysis in the 
inhibited samples was compared to the blank sample and the amount of inhibited enzyme 
was calculated. An example of CTX-M-15 inhibition by TA after 900 seconds can be seen 
in figure 3.57 below. 
 
y = -1.8598E-02x + 1.7560E+00
R² = 9.9854E-01
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 5 10 15 20 25 30 35 40 45 50
A
b
so
rb
an
ce
Time (Seconds)
Zero Order Section of The Hydrolysis of Cephalothin (0.2 mM) by β-
Lactamase CTX-M-15 (5 nM) in pH 6.5 MES Buffer (0.1 M) at 30 °C 
with I = 1M (KCl) as Monitored by the Loss of Absorbance at 260 nm
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
196 
 
 
Figure 3.57: Zero order section of the CTX-M-15 catalysed cephalothin hydrolysis after 
inhibition by TA after 900 seconds incubation time at pH 8.5. 
Figure 3.57 gave a zero order slope of 2.521 x 10-3. When this was divided by the blank zero 
order slope of 1.8598 x 10-2, it gave a result of 0.1356, indicating 13.56% enzyme activity 
was remaining. This corresponded to an enzyme concentration of 6.78 x 10-10 M. This 
process was repeated at various time points until there was minimal enzyme activity 
remaining. The concentration enzyme remaining at the recorded time points were then 
converted to their natural logarithm and plotted against time in seconds. This gave a straight 
line graph as seen below in figure 3.58. 
y = -2.521E-03x + 1.592E+00
R² = 9.999E-01
0.8
1
1.2
1.4
1.6
1.8
2
0 10 20 30 40 50 60 70 80 90
A
b
so
rb
an
ce
Time (Seconds)
Zero Order Section of the Hydrolysis of Cephalothin (0.2 mM) by β-
Lactamase CTX-M-15 (5 nM) After Inhibition by TA (5 µM) for 900 
Seconds in pH 6.5 HEPES Buffer (0.1 M) at 30 °C with I = 1 M (KCl) as 
Monitored by the Loss of Absorbance at 260 nm
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
197 
 
 
Figure 3.58: Natural logarithm of concentration of active enzyme remaining against 
incubation time for inhibition of CTX-M-15 (5 nM) by TA (5 µM). 
As with P99, the slope of the graph above in figure 3.58 (2.504 x 10-3 s-1) can be interpreted 
as the observed pseudo first-order rate constant for the inhibition (kobs). This result can be 
divided by the inhibitor concentration (5 µM) to give the second order rate constant of 500.8 
M-1s-1. 
This process was repeated at 0.5 pH intervals from pH 4.0 to pH 9.0 to create the following 
pH profile as seen in figure 3.59 below. 
 
 
y = -2.504E-03x - 1.903E+01
R² = 9.991E-01
-20.8
-20.6
-20.4
-20.2
-20
-19.8
-19.6
-19.4
-19.2
-19
0 100 200 300 400 500 600 700
ln
[E
] t
Time (Seconds)
Natural Logarithm of Enzyme Remaining (ln[E]t) Against Incubation 
Time After Inhibition of β-Lactamase CTX-M-15 (5 nM) by TA (5 µM) 
in pJ 6.5 HEPES Buffer (0.1 M) at 30 °C and I = 1 M (KCl)
Chapter Three: Novel Avibactam Analogues as Novel Inhibitors of Serine-β-Lactamases 
198 
 
 
Figure 3.59: ki for the inhibition of CTX-M-15 (10 nM) by TA (5 µM) at various pH. 
This process was repeated with avibactam as the inhibitor.  
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Figure 3.60: ki for the inhibition of CTX-M-15 (5 nM) by avibactam (50 nM) at various pH. 
The typical bell-shaped profile of the hydrolysis of cephalothin by CTX-M-15 is mirrored 
in those for inhibition of the enzyme by the TA carbamate (figure 3.59 above) and avibactam 
(figure 3.60 above). For this enzyme, the pKa
1s are both 4.45, and for pKa
2s they are 8.65 
and 8.80 for the TA carbamate and avibactam respectively. For hydrolysis of cephalothin 
pKa
1 = 4.75 and pKa
2 = 8.95. 
So again, for the inhibition of CTX-M-15 it appears that the same catalytic machinery is 
used for both hydrolysis and inhibition. The general base is probably Glu-166 (Po, Chan & 
Chen, 2017), (Delmas, Chen, Prati, Robin, Shoichet & Bonnet, 2008). 
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3.4.9.3: pH Dependence of Inhibition of AmpC by TA Carbamate 
As with P99 and CTX-M-15, the pH dependence of inhibition was investigated with the TA 
carbamate. A representative example will be briefly explained here before the pH profile is 
explained in further detail. 
First, a blank sample consisting of just the enzyme and substrate was obtained, as in figure 
3.61 below. 
 
Figure 3.61: AmpC catalysed hydrolysis of cephalothin in pH 6.5 MES buffer. 
The zero order portion of figure 3.61 above serves as a blank reference, against which 
inhibition rates can be deduced. 
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Figure 3.62: Zero order section of AmpC catalysed hydrolysis of cephalothin in pH 6.5 MES 
buffer. 
Figure 3.62 above gives a zero order slope of 3.12 x 10-3, which can be used as a reference 
to compare enzyme activity, or amount of inhibition. As before, the inhibitor (in this case, 
TA carbamate in 10 µM final concentration) was added to the enzyme sample (AmpC with 
a  final concentration of 5 nM) and a timer was started. Samples were taken at various time 
points and the zero order slopes were recorded and compared against the blank zero order 
slope (cephalothin and enzyme only) to give an indication to the amount of enzyme activity, 
and therefore the amount of enzyme which is inhibited. 
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Figure 3.63: Zero order section of the AmpC catalysed cephalothin hydrolysis after 
inhibition by TA carbamate after 120 seconds at pH 6.5. 
Figure 3.63 gave a zero order slope of 1.33 x 10-3. When this was divided by the blank zero 
order slope of 3.12 x 10-3, it gave a result of 0.4263, indicating 42.63% enzyme activity was 
remaining. This corresponded to an enzyme concentration of 8.53 x 10-10 M. This process 
was repeated for various time points until there was minimal enzyme activity remaining. 
The concentration enzyme remaining were then converted to their natural logarithm and 
plotted against time in seconds. This gave a straight line graph as seen below in figure 3.64. 
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Figure 3.64: Natural logarithm of concentration enzyme remaining (AmpC) after inhibition 
by TA carbamate. 
The slope of the graph above in figure 3.64 (1.51 x 10-4 s-1) can be interpreted as the observed 
pseudo first-order rate constant for the inhibition (kobs). This result can be divided by the 
inhibitor concentration (10 µM) to give the second order rate constant of 15.10 M-1s-1. 
This process was repeated at 0.5 pH intervals from pH 5.5 to pH 9 to create the following 
pH profile as seen in figure 3.65 below. 
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Figure 3.65: ki for the inhibition of AmpC (2 nM) by TA (10 µM) at various pH. 
As can be seen from figure 3.65 above, kcat/Km and ki for pH dependent hydrolysis of 
cephalothin and the inhibition of AmpC correlate with each other on their dependence upon 
pH. This suggests that there is active-site directed inhibition. The close similarity between 
the kcat/Km for the hydrolysis of cephalothin by AmpC and the inhibition of AmpC by TA 
suggests that the catalytic apparatus used for hydrolysis of β-lactams is the same for 
inhibition of the enzyme by the TA carbamate derivative. 
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3.4.10: Hydrolysis and Inhibition Conclusions 
 
The carbamate derivatives are good time-dependent inhibitors of classes of serine β-
lactamases. There is a good relationship between the second order rate constants for 
inhibition and the pKa of the leaving group alcohol generating a Bronsted βlg value = 0.59, 
consistent with rate limiting formation of a tetrahedral intermediate. The carbamate with the 
best leaving group, hexafluoroacetone hydrate (HFA), is a better inhibitor than avibactam 
itself. The pH-rate profiles for hydrolysis and inhibition by the carbamates and avibactam 
are all similar, indicating that the same catalytic machinery is used for these different 
processes. The pKas for the hydrolysis and inhibition for each experiment are shown below 
in table 3.7. 
Table 3.7: pKas for the hydrolysis and inhibition for each pH dependent experiment in 
chapter 3. 
Enzyme Hydrolysis 
pKa1 
Inhibition 
pKa1 TA 
Inhibition 
pKa1 Avi 
Hydrolysis 
pKa2 
Inhibition 
pKa2 TA 
Inhibition 
pKa2 Avi 
P99 6.40 5.90 6.05 8.85 8.75 8.30 
CTX-M-
15 
4.75 4.45 4.45 8.95 8.65 8.80 
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Chapter Four: Other Novel β-Lactamase Inhibitors 
4.1: Introduction 
 
4.1.1: Ellagic Acid 
 
Ellagic acid is a polyphenolic phytochemical (Vattem & Shetty, 2005) present in various 
fruits and vegetables (Corbett, Daniel, Drayton, Field, Steinhardt & Garrett, 2010), with 
pomegranate juice being a traditional rich source of this polyphenol (Usta, Ozdemir, 
Schiariti & Puddu, 2013). Ellagic acid is a highly symmetrical molecule which contains a 
fused four ring system, with four phenolic groups (Priyadarsini, Khopde, Kumar & Mohan, 
2002). Polyphenols are naturally derived products, produced as secondary metabolites by 
plants, and play an essential role in plant physiology (Beart, Lilley & Haslam, 1985), and 
also assist in the prevention of infection from plant pathogens (Daglia, 2012). Ellagic acid 
contains a 𝛿-lactone as a possible acylating residue and an acidic phenol thus possessing the 
two fundamental requirements of an inhibitor of serine β-lactamases. However, before 
discussing those aspects, it is worth reviewing their general biological activities. 
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Figure 4.1: Structure of ellagic acid 
Ellagic acid (as seen above in figure 4.1) has long been a molecule of biological and 
pharmaceutical interest due to its antioxidant properties (Talcott, Talcott & Percival, 2003). 
In chemical terms, antioxidants are compounds capable of reacting and “neutralising” free 
radicals, by acting almost as an electron “sponge”. Free radicals are reactive oxygen and 
nitrogen species that have an unpaired electron in their outer shell, making them highly 
reactive (Lobo, Patil, Phatak &Chandra, 2010). Antioxidants such as phenols are capable of 
transferring H atoms (via electron and proton transfer) to the active free radical to generate 
a neutral species and a stabilised phenol radical: 
 
Free radicals are capable of causing cell damage by reacting indiscriminately with cell 
components. Free radicals are capable of oxidising many compounds, including components 
of human cells. Whilst this can lead to cell damage, a key concern of free radicals is that 
they may ultimately lead to cell mutations, and possibly cancer (Thyagarajan & Sahu, 2017). 
Antioxidants therefore spare cells from damage, by undergoing oxidation by free radicals 
themselves, saving cells from being potentially damaged. Ellagic acid and similar 
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compounds are important components of a healthy diet, and have been shown to be stable 
under physiological conditions, and are therefore capable of reaching various parts of the 
digestive system intact (Usta et al., 2013). 
Furthermore, ellagic acid has been shown to have anti-inflammatory effects (Favarin et al., 
2013). Inflammation occurs when the immune system responds to threats, such as foreign 
pathogens which may be introduced from wounds. Inflammation also occurs where there 
has been damage to tissue, such as a blow to a joint and has familiar characteristics, such as 
pain, redness, swelling and heat. Inflammation encourages healing by promoting blood flow 
to the source of the injury, allowing white blood cells and other immune responses to reach 
the damaged area and promote healing (Koh & DiPietro, 2011). Whilst inflammation has 
been shown to be essential for healing (Landen, Li & Stahle, 2016), immune system 
responses can sometimes incorrectly trigger inflammation where there is no threat posed by 
an invading pathogen, in what is referred to as chronic inflammation. Chronic inflammation 
is typically brought on by a combination of host factors (for example, the specific health of 
the individual) including age and genetic predisposition to inflammation and lifestyle factors 
such as smoking, poor diet and a sedentary lifestyle (Garn et al., 2016). In chronic 
inflammation, the immune system continues producing an immune response (the traditional 
redness, swelling and pain etc.) even after the immune threat has been eliminated, or even 
in the complete absence of a threat to the immune system. Unrestrained, the immune system 
continues to produce macrophages and other white blood cells which, in the absence of a 
foreign pathogen, begin to attack surrounding healthy tissue and organs. This chronic 
inflammatory response can be a prerequisite to some of the most notorious challenges of our 
age, including cancer, diabetes and arthritis (Chang & Yang, 2016). The protective activity 
afforded to ellagic acid and other polyphenols has generally been attributed to their 
antioxidant, free radical scavenger and metal chelator properties. Also, polyphenols have 
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been shown to be capable of inhibiting physiologically important enzymes such as digestive 
enzymes including α-glucosidase and pancreatic α-amylase, helping to decrease blood sugar 
levels (McDougall & Stewart, 2005), (Gu, Hurst, Stuart & Lambert, 2011) and also 
pancreatic lipase, reducing the amount of fat absorbed during digestion (Glisan, Sae-Tan, 
Grove, Yennawar & Lambert, 2014). 
Additionally, naturally occurring polyphenols (including ellagic acid) have been 
investigated for their antibacterial properties (Daglia, 2012), (Coppo & Marchese, 2014), 
(Sanhuenza, Melo, Montero, Maisey, Mendoza, Wilkens & 2017). Flavan-3-ols, flavanols 
and tannins have received the most attention from the scientific community due to their 
wider spectrum of activity and antibacterial potency, and the fact they are able to operate 
synergistically with antibiotics to improve their potency as evidenced by a decrease in 
minimum inhibitory concentrations (MICs) for β-lactam antibiotics combatting clinically 
important strains of Enterobacteriaceae, including Escherichia coli and Staphylococcus 
aureus (Haghjoo, Lee, Habiba, Tahir, Olabi & Chu, 2013). Figure 4.2 below shows some 
common polyphenols and their applications as antimicrobial agents. 
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Figure 4.2: classes of polyphenols and their typical applications as antimicrobial agents 
(Daglia, 2012). 
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Ellagic acid is a derivative of tannins and is produced biosynthetically by the hydrolysis of 
tannins (Zhang, Wang & Xu, 2014). Indeed, the effectiveness of polyphenols as antibacterial 
agents has prompted research into their suitability as natural preservatives for food products, 
owing to the strong public demand to reduce the amount of synthetic materials used in food 
production and storage (Vaguero, Fernandez, Nadra & Saad, 2010) and also as novel 
antibiotics owing to the prevalence of resistance to conventional therapies (Jayaraman, 
Sakharkar, Lim, Tang & Sakharkar, 2010), (Saavedra, Borges, Dias, Aires, Bennett, Rosa 
& Simoes, 2010). 
Mechanisms of action for polyphenols as antibacterial agents are not fully understood. It is 
thought that owing to the structural similarity with some existing antibiotics that they will 
operate in mechanistically similar circumstances. For example, it has been suggested that 
some polyphenols are able to interfere with cell membrane and wall production, resulting in 
destabilisation of the membrane and eventual cell death, showing a similar mechanism of 
action to existing β-lactam antibiotics (Heinonen, 2007). Additionally, polyphenols have 
been shown to act as chelating agents, being capable of binding metal ions including iron 
and zinc. Metal depletion causes severe limitations to bacterial growth, resulting in bacterial 
cells being unable to reproduce and grow (Dixon, Xie & Sharma, 2005). Also, it has been 
shown that polyphenols are able to inhibit extracellular enzymes essential for normal 
bacterial cell function and growth, leading to cell death (Pimia, 2004). Finally, polyphenols 
have been shown to have activity against not only bacteria, but fungi and viruses also, 
including herpes, influenza and flu viruses (Ho, Cheng, Weng, Leu & Chiu, 2009). 
Susceptible strains of fungi to polyphenols include Candida albicans, Candida parapsilosis 
and Microsporum gypseum (Hirasawa & Takada, 2004). An example of the mechanism of 
action for viral inhibition is by preventing the attachment of viral particles to their target 
receptor cells, preventing transmission of the virus to host cells (Nakayama, Suzuki, Toda, 
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Okubo, Hara & Shimamura, 1993) and also by modification to the membrane of the viral 
particles, resulting in a decrease of viral activity (Song, Lee & Seong, 2005). The mechanism 
of action of antifungal polyphenols is not fully understood and is in area of developing 
research as more and more polyphenols are screened for their antimicrobial properties, but 
it is thought that polyphenols can disrupt healthy spore formation, and interruptions of cell 
membrane permeability, resulting in the lack of reproduction of fungal cells and lysis of the 
cell due to altered membrane permeability (Yang & Jiang, 2015). 
As analytical tools and extraction methods improve, the number of identified and 
characterised polyphenols has increased, with over 8,000 phenolic compounds identified 
(Dai & Mumper, 2010) and over 4,000 flavonoids described (Tsao, 2010). There is a rich 
opportunity for the investigation of these compounds and into their potential benefits as use 
for novel therapies concerned with the previously mentioned health ailments. Ellagic acid 
has only relatively recently been recognised as having biologically relevant activities and as 
such investigation into its potential uses as a pharmaceutical agent is beginning to increase.  
Ellagic acid has not been subject to much research within the field of microbial 
chemotherapy, with interest only slowly accumulating in the compound since 2010. A 2010 
study by Ghudhaib, Hanna & Jawad explored the use of ellagic acid as an antimicrobial 
agent. Their research concluded that ellagic acid provided lower MICs than the existing 
antibiotics gentamycin and streptomycin for important pathogenic strains of bacteria, 
including the Gram-negative β-lactamase producing pathogen Klebsiella pneumoniae. 
Another study by Panichayupakaranant, Tewtrakul & Yuenyongsawad (2010) tested the 
antibiotic activities of pomegranate rind, containing 13 % v/v ellagic acid. They found the 
MIC of ellagic acid against Staphylococcus aureus to be in the range of around 10 µg, which 
is in a similar region to existing antibiotics including the BLBLIC amoxicillin/clavulanate, 
which has an MIC of 8 µg (Rubin, Ball & Trejo, 2011). Finally, a more recent study by De 
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and colleagues (2018), investigated the use of ellagic acid as an antibacterial agent against 
the problematic stomach ulcer causing Gram-negative pathogen Helicobacter pylori. H. 
pylori is a troublesome pathogen, capable of producing β-lactamases (Tseng et al., 2009) 
and therefore possibly resistant to many existing antibiotics dependent upon the strain. The 
results from this study showed that ellagic acid was capable of inhibiting all the strains of 
H. pylori infected, with MICs in the range of 5-30 mg/ml. Whilst this range is higher than 
the classic antibiotic used in H. pylori suspected infections (amoxicillin) with MICs of 
around 1 µg/ml (Kim, Kim, Jung, Kim, Kim & Song, 2004), it is still interesting that ellagic 
acid was capable of inhibiting all strains with modest MICs. Furthermore, ellagic acid aided 
in the healing and restitution of gastric mucosal damage caused by H. pylori. These studies 
show that ellagic acid has a huge potential for development as a novel antimicrobial product. 
Clearly, a naturally occurring compound that is shown to reduce the occurrence of chronic 
inflammation with anti-oxidant and antibacterial properties is of significant interest to the 
pharmaceutical community. Indeed, ellagic acid has been labelled as a super-nutrient owing 
to these properties. However, the question of whether ellagic acid is capable of inhibiting β-
lactamases has so far not been investigated. Ellagic acid is a potential acylating agent and a 
metal-ion chelator. Therefore, there is a potential for ellagic acid to be an SBL inhibitor, and 
perhaps also an MBL inhibitor. Investigations into the antibacterial activity of ellagic acid 
have shown its potential to be a future novel antimicrobial agent. If this molecule also 
possessed a β-lactamase inhibiting ability, it would make it an ideal candidate for 
investigations and development as a dual action novel antimicrobial and β-lactamase 
inhibiting agent, perhaps making it a resistance proof antibiotic. It could also be used in a 
synergistic fashion with other existing β-lactams, as has been shown with other polyphenols; 
the ellagic acid could exhibit modest antimicrobial capability, but then also act as a protector 
of the β-lactam antibiotic by inhibiting β-lactamases produced by the target bacteria. This 
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co-administration could help lower MICs, as shown with other polyphenols. In this chapter, 
the MBL and SBL capability of ellagic acid will be investigated, along-side other interesting 
molecules, including another plant derived compound (urolithin A), and an existing lipase 
inhibitor (orlistat). 
 
4.1.2: Urolithin A 
 
Urolithin A is also a plant based metabolite (Zhao, Shi, Guo, Zhao, Song & Yang, 2018), 
similar to ellagic acid, and is found from similar sources including fruits and nuts 
(Paivarinta, Pajari, Torronen & Mutanen, 2009). Like ellagic acid, it contains a δ-lactone 
and acidic phenolic groups. Urolithins are formed after elagitannins are hydrolysed to ellagic 
acid under physiological conditions in vivo, and ellagic acid is then gradually metabolised 
by the intestinal microbiota to produce different types of urolithins (Landete, 2011). When 
unabsorbed elagitannins and ellagic acid reach the colon in the latter part of the digestive 
system, they are metabolised by gut microbiota to yield a variety of urolithins (Villalba, 
Beltran, Espin, Selma, Barberan, 2013). There are four main types of urolithin: urolithin A, 
B, C and D (Espin, Larrosa, Teresa & Barberan (2013). The subject of this chapter will be 
urolithin A. Urolithin D is produced from ellagic acid upon the opening of a lactone ring 
and removal of a carboxyl group. Urolithin D then loses 1, 2 or 3 hydroxyl groups via 
dihydroxylation to form urolithin C, urolithin A and urolithin B respectively (Kang, 
Buckner, Shay, Gu & Chung, 2016). 
In terms of its chemical nature, urolithin A is a benzocoumarin, being a combination of 
coumarin and isocoumarin, as seen in figure 4.3 below. 
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Figure 4.3: Structure of urolithin A, showing similarities between coumarin and isocoumarin 
(Espin, Larrosa, Conesa & Barberan, 2013). 
As urolithin A is a metabolite of ellagic acid, it is perhaps unsurprising that the associated 
health benefits of both molecules are fairly similar. Urolithin A has been shown to have 
antioxidant properties, although it is not as capable an antioxidant as other polyphenols such 
as ellagic acid (Biolonska, Kasimsetty, Khan & Ferreira, 2009). Additionally, urolithin A 
has been shown to have anti-inflammatory properties, also similar to ellagic acid. In a study 
by Gimenez-Bastida et al., (2012), urolithin A at relevant physiological concentrations (µM 
range) was shown to exhibit anti-inflammatory activity in the progression of atherosclerosis 
(an inflammatory disease affecting the arteries [Fana & Montagnana, 2018]), moderately 
inhibiting monocyte adhesion to endothelial cells, thereby preventing the progression of the 
disease.  
Furthermore, urolithin A has been shown to exhibit anticarcinogenic effects, which has been 
one of the most heavily investigated health effects of this compound (Heber, 2008). 
Conventional cancer therapies are associated with severe side effects, which can often be 
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debilitating, such as pain, diarrhoea, and often infection brought about by a weakened 
immune system for those patients undergoing chemotherapy (Pearce, Haas, Vuney, Pearson, 
Haywood, Brown & Ward, 2017).  Therefore, the demand for alternative therapies that 
avoids these side effects is of great interest to the scientific community. Urolithin A has been 
shown to inhibit cancer related enzymes and modulate certain genes associated with cancer. 
For example, Zhang et al., (2016) found that urolithin A modulated ER alpha-dependent 
gene expression, which resulted in the inhibition of endometrial cancer proliferation. Also, 
in a study probing the effects of urolithins on bladder cancer cells, Liberal, Carmo, Gomes, 
Cruz and Batista (2017) found that urolithin A impaired the proliferation of bladder cancer 
cells, and induced apoptosis (cell death) of cancer cells. An important aspect of this study is 
that urolithin A had selective effects against cancer cells, and did not interfere with the 
growth of normal, healthy cells. Furthermore, urolithin A has been shown to be effective at 
inhibiting the growth of cancer cells in the colon, which is perhaps of greater relevance than 
cancer of other areas, as it is in the colon where ellagic acid is metabolised to form urolithin 
A, and can reach bioactive concentrations (Espin et al., 2013). Urolithin A alongside ellagic 
acid and urolithin B, were shown to prevent the cell cycle of caco-2 cancer cells in the colon 
through gene modulation of those genes involved in cell cycle regulation (Sarrias, Espin, 
Barberan & Conesa, 2009). Finally, many studies have shown urolithin A to be capable of 
controlling prostate cancer tumour growth (Gonzalez, Ciudad, Pulido & Noe, 2016), 
(Stanislawska, Piwowarski, Granica & Kiss, 2018), (Poudel, Vadhanam & Burliston, 2014), 
(Vicinanza, Zhang, Henning & Heber, 2013), (Stanislawska, Granica & Kiss, 2015) making 
it a promising candidate for a future chemopreventative agent for prostate cancer. The 
typical mechanisms of action for urolithin as an anti-prostate cancer agent included: 
modulating genes involved with cancerous cell growth and inducing apoptosis of cancer 
cells. 
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It is understood that intestinal absorption of elagitannins and ellagic acid is quite low, which 
results in an abundant source of elagitannins and ellagic acid for biosynthesis of urolithins, 
which have a much higher bioavailability for absorption in the intestine (Cerda, Llorach, 
Ceron, Espin, Barberan, 2003). This suggests that it is the urolithins which may be the actual 
bioactive molecules and the source of the health benefits from polyphenols as discussed in 
the previous sub chapter, and the health benefits rely on the effect of the metabolites 
produced by the gut microbiota. 
 
4.1.3: Orlistat 
 
Orlistat is an approved gastric and pancreatic lipase inhibitor drug developed by Roche, 
marketed under the trade name Xenical in the United States and Alli in the United Kingdom 
(Drew, Dixon & Dixon, 2007). Dietary fat must be broken down into smaller fatty acid 
chains and glycerol by digestive lipase, before being capable of absorption in the digestive 
tract. Orlistat’s intended mechanism of action is to inhibit digestive lipase enzymes by 
binding covalently to the active site, resulting in a reduction in activity of lipase enzymes, 
thereby decreasing the amount of dietary fat absorbed in the intestinal tract; ultimately 
leading to a reduction in the amount of calories consumed (Heck, Yanovski & Calis, 2012). 
Lipase enzymes in the digestive system rely on a catalytic triad of serine, histidine and an 
aspartic acid residue to catalyse the hydrolysis of dietary fat (Brumlik & Buckley, 1996). In 
terms of its chemistry, orlistat is a diastereomeric molecule with four chiral centres, 
containing a β-lactone group (Heck, Yanovski & Calis, 2012). Orlistat’s structure can be 
seen in figure 4.4 below. 
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Figure 4.4: Chemical structure of orlistat. 
Interestingly, although the main focus of orlistat has been its capability as a digestive lipase 
inhibitor, it has also been shown to be an effective inhibitor of the fatty acid synthase 
enzyme. This enzyme is associated with tumour progression in prostate cancer (Kridel, 
Axelrod, Rozenkrantz & Smith, 2004). 
Kinetic data show that orlistat is the most effective lipase inhibitor currently on the market, 
with IC50 values lower than other polyphenol natural products with known lipase inhibiting 
activity, as shown in a study by Gonzalez et al., (2017). IC50 (also known as the half maximal 
inhibitory concentration), is a measure of the effectiveness of an inhibitor binding to an 
enzyme. The lower an IC50, the more potent is the inhibitor and it is the most commonly 
used metric as a measure of an inhibitor’s effectiveness (Kalliokoski, Kramer, Vulpetti & 
Gedeck, 2013).  
Despite their similarity to β-lactams, there has been little research into the use of lactones as 
β-lactamase inhibitors. The work of Gal et al., (2000) describes the activity of a γ-lactone 
acting as a β-lactamase inhibitor. γ-Lactones are structurally similar to β-lactones, with the 
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only difference being that the oxygen is part of a five member ring in gamma lactones, as 
opposed to a four member ring in β-lactones. A literature review found no references to β-
lactones being employed as β-lactamase inhibitors. 
It is hypothesised, that owing to the fact that orlistat is an efficient inhibitor of digestive 
lipases, and the fact that these enzymes have a serine in their active site, and also the fact 
that previous work has shown gamma lactones to be capable of inhibiting β-lactamases, that 
orlistat may perhaps show inhibitory activity against SBLs. It is known that β-lactones can 
act as both acylating and alkylating agents, as seen below in figure 4.5: 
 
Figure 4.5: β-lactones acting as acylating and alkylating agents. 
 
4.1.4: Chapter Four Aims 
 
As discussed, three potential novel β-lactamase inhibitors have been identified and will be 
assessed for their suitability as inhibitors and for their antibiotic capability. Furthermore, as 
ellagic acid has 4 ionisable groups, the effect of pH on the activity of potential β-lactamase 
inhibition by ellagic acid will also be determined. 
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4.2: Methods 
 
4.2.1: UV Methods 
 
The UV methods for detection of inhibition were much the same as the methods used in 
chapter three. Briefly, stock solutions of the potential inhibitors were created in MeOH for 
ellagic acid and ACN for orlistat and urolithin A. A 1 mM ellagic acid stock solution was 
created in MeOH by dissolving 3.02 mg of ellagic acid in 1 ml MeOH and sonicating for 20 
minutes. The inhibition experiments for ellagic acid were conducted in the usual buffers for 
the respective pH but supplemented with 10 % MeOH to aid solubility of ellagic acid. For 
example, for the inhibition experiments with ellagic acid at pH 8.5, the buffer would be 20 
ml pH 8.5 TAPS buffer (0.1 M) with 10 % MeOH (18 ml aqueous TAPS buffer and 2 ml 
MeOH) with ionic strength maintained to 1 M with KCl. Similarly, for orlistat and urolithin 
A, a different solvent composition was required. 4.96 mg of orlistat was dissolved in 1 ml 
ACN to create a 10 mM stock solution. For urolithin A, 2.28 mg was dissolved in 1 ml ACN 
to create a 10 mM stock solution. For both of these inhibitors, the inhibition experiments 
were conducted in pH 7.0 HEPES buffer (0.1 M) with 10 % ACN (18 ml pH 7.0 HEPES 
buffer and 2 ml ACN) maintained to 1 M ionic strength with KCl.  
Appropriate blanks containing the same concentrations of solvent (10% MeOH/ACN) were 
taken to see if they had any effect on the activity of the enzyme and much like for the other 
time dependent blanks, enzyme activity loss was negligible (<5%). The hydrolysis of the 
antibiotic cephalothin was used as a tool to measure the concentration of the enzyme through 
inhibition/hydrolysis rates of the enzyme. 
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The enzyme was thawed slowly in melting ice and was added to the stock solution of the 
potential inhibitors and a stopwatch was started. Samples were taken at intermittent intervals 
after incubation of the potential inhibitor with various β-lactamases and pipetted into a 1 
cm3 cuvette. The cuvette was then placed in a UV cell thermostatted to 30 °C, and the 
instrument was then blanked at 260 nm (a good wavelength for cephalothin) with the 
contents of the UV cell (buffer, solvent, inhibitor and enzyme). Cephalothin solution was 
added and the instrument began recording the absorbance at 260 nm. The rates of hydrolysis 
were determined from the initial slopes of absorbance against time. These initial slopes gave 
the percentage of active enzyme remaining and were converted to concentration values. A 
graph of the natural logarithm of the concentration of active enzyme remaining against 
incubation time in seconds, gave a straight line graph, the slope of which was kobs for the 
inhibition reaction. 
The stability of the enzyme over the time periods used for the inhibition studies was 
determined from observing the initial slopes of the change in absorbance in the hydrolysis 
of cephalothin. This was to ensure that any change in the rate of hydrolysis reflects inhibition 
of the enzyme and not any ‘natural’ loss of activity of the enzyme. 
For the pH dependent analysis of ellagic acid, the method was much the same except the pH 
and the buffer used was altered dependent upon the requirements of the pH levels. The 
following buffers were used depending upon the pH required: pH 4-5: acetic acid, pH 5.5-
6.5: 2-(N-morpholino)ethanesulfonic acid, pH 7.0-8.0: HEPES, pH 8.5-9.0 TAPS. 
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4.2.2: Microbiological Methods 
 
The antibiotic potential of the three compounds was qualitatively tested. Tryptone soya agar 
(TSA) plates were prepared and maximum recovery diluent (MRD) solutions containing 
different antibiotic resistant strains of bacteria were spread over the surface of the agar using 
a sterile plate spreader and were placed in a sterile laminar flow hood until the surfaces were 
dry. Six wells were created in the agar plates by using a sterile 10 mm cork borer. A 10 µM 
solution of each of the compounds was prepared and 50 µL was pipetted into each well and 
allowed to diffuse through the agar before being placed in an incubator at 37 °C. Appropriate 
blanks containing the diluent (MeOH/ACN) were also prepared to ensure the concentration 
of solvent used had no effect on microbial growth. 
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4.3: Results and Discussion 
 
4.3.1: Inhibition Results 
 
All of the compounds tested showed inhibition with differing degrees of effectiveness. 
 
4.3.1.1: Ellagic Acid β-Lactamase Inhibition and Microbial Inhibition Results 
 
 
Figure 4.6: Percentage active CTX-M-15 (10 nM) remaining after incubation with ellagic 
acid (1 µM). 
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Figure 4.6 above shows a dramatic decrease in the activity of CTX-M-15 when inhibited 
with 1 µM of ellagic acid, with the activity exponentially decreasing to a negligible amount.  
 
Figure 4.7: Natural logarithm of concentration of active CTX-M-15 (10 nM) enzyme 
remaining after inhibition with ellagic acid (1 µM). 
Clearly, as seen from figure 4.7 above, ellagic acid has an inhibitory effect on the CTX 
enzyme with a kobs of 1.11 x 10
-3 M-1s-1, giving a second order rate constant ki = 1.11 x 10
3 
M-1s-1. An experiment with 10-fold less ellagic acid was undertaken, with the concentration 
of ellagic acid being 100 nM, only 10 x the concentration of the enzyme. 
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Figure 4.8: Percentage active CTX-M-15 (10 nM) remaining after incubation with ellagic 
acid (100 nM) at 1:10 concentration with enzyme. 
Figure 4.8 above shows the activity decrease of CTX-M-15 after incubation with ellagic 
acid in a 1:10 concentration ratio of enzyme to inhibitor. Clearly, there is time-dependent 
inhibition occurring. However, the activity of the enzyme does not appear to go to zero 
which is perhaps indicative of an equilibrium process. The concentration of ellagic acid is 
100-fold less than in the previous 10 µM experiment. 
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Figure 4.9: Natural logarithm of concentration active enzyme remaining against incubation 
time for inhibition of CTX-M-15 (10 nM) by ellagic acid (100 nM). 
The loss of enzyme activity by ellagic acid gives a pseudo first-order rate kobs of 3.21 x 10
-4 
M-1s-1, corresponding to a second-order rate constant for inhibition ki = 3.21 x 10
3 M-1s-1, as 
seen from figure 4.9 above. 
At this point, appropriate enzyme blanks were ran over a similar amount of time as the 
inhibition experiments to ensure that it wasn’t simply the CTX-M-15 losing activity over 
the time period of the experiment. These experiments confirmed that CTX-M-15 remained 
active over this time period, with a negligible loss of activity (<5 %). This showed that the 
enzyme activity decrease with ellagic acid must be due to the inhibitory action of ellagic 
acid, and not any natural loss of enzyme activity. 
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Finally, another way to investigate if the ellagic acid is indeed inhibiting the enzyme through 
a chemical reaction is to investigate the UV profile of the reaction between the ellagic acid 
and the enzyme. The CTX—M-15 enzyme was used at a concentration of 800 nM and 
ellagic acid inhibitor at a concentration of 8 µM were incubated over a two-hour period and 
repeated UV scans took place. If there was a difference in the UV profile of the incubated 
enzyme and inhibitor over time, it was further proof that some sort of reaction was taking 
place. 
 
Figure 4.10: UV scans of CTX-M-15 (800 nM) and ellagic acid (8 µM) in pH 7.0 HEPES 
(0.1 M) at 30 °C with I = 1 M (KCl). 
In figure 4.10 above, the blue spectra are the first scan of 8 µM ellagic acid incubated with 
800 nM CTX-M-15 in 0.1 M HEPES buffer with 10 % MeOH at 30 °C, and the red line is 
a scan after 16 hours. As can be seen, the UV profile clearly changes after this time, 
Chapter Four: Other Novel β-Lactamase Inhibitors 
235 
 
indicating that some sort of reaction is taking place. At 275 nm the absorbance is roughly 
0.3112, and it decreases to 0.281 after 2 hours, roughly representing a 10 % drop. The 
amount of enzyme compared to ellagic acid (800 nM compared to 8 µM) is also a 1:10 ratio, 
so this corroborates the theory that most of the enzyme present is reacting with the ellagic 
acid. This is further evidence that it is the ellagic acid reacting with the enzyme in an 
inhibition reaction, causing the UV profile to change. 
This experiment was repeated with a different SBL enzyme, TEM-1, but the concentrations 
of ellagic acid to enzyme were present in a 1:1 ratio. 
 
Figure 4.11: UV scans of TEM-1 (70 µM) and ellagic acid (70 µM) in pH 7.0 HEPES (0.1 
M) at 30 °C with I = 1 M (KCl). 
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In figure 4.11 above, the red spectrum is the initial scan and the pink spectrum is a UV scan 
after 2 hours reaction time. One can clearly see there is a lot more of reaction between the 
ellagic acid and enzyme. This is because there is a lot more enzyme present, so one would 
expect there to be a more dramatic change in the UV profile as more ellagic acid is reacted 
with by the higher concentration of enzyme. The fact that an increase in the amount of 
enzyme increases the change seen in the two UV spectra confirms that there is a reaction 
taking place between the enzyme and the ellagic acid. When taking into consideration the 
other inhibition results, it is beyond doubt that the ellagic acid is inhibiting the SBLs it has 
been tested against.  
 
4.3.1.2: Inhibition Studies with a Metallo-β-Lactamase 
 
After establishing that ellagic acid showed potential as an SBL inhibitor, it was possible that 
it may act as an MBL inhibitor, owing to its ability to act as a chelating agent for metal ions. 
Ellagic acid was examined for any inhibitory activity against NDM-1 MBL up to a 
concentration of 10 mM, but no inhibition was recorded. 
 
4.3.1.3: pH Dependence of Inactivation of CTX-M-15 by Ellagic Acid 
 
The effect of pH on the inhibitory action of ellagic acid on CTX-M-15 was investigated, 
similar to pH dependent inhibition experiments in chapter 3. Ellagic acid has 4 ionisable 
groups; therefore it was necessary to establish how many of the 5 forms of ellagic acid 
showed inhibitory activity. Appropriate buffer solutions were prepared at various pH levels 
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using a calibrated pH probe, and the inhibition experiments for ellagic acid and CTX-M-15 
were repeated at different pH levels over physiologically relevant levels.  
The literature revealed the 4 pKas of ellagic acid as: 6.5, 7.45, 9.61 and 11.50 (United States 
National Library of Medicine, 2008). Using these values, a graph showing the speciation 
plot of ellagic acid was constructed. 
 
Figure 4.12: Speciation plot of ellagic acid, EH4 is the undissociated species, EH3
-, EH2
2-, 
EH3- and E4- are the mono-, di-, tri- and tetra-anions respectively. 
The speciation plot in figure 4.12 above shows the abundance of each of the 4 ionisable 
forms of ellagic acid at various pH levels. The obtained ki for the inhibition of CTX-M-15 
by ellagic acid at various pH levels can be seen in figure 4.13 below. 
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Figure 4.13: ki for the inhibition of CTX-M-15 (10 nM) by ellagic acid (100 nM) over 
various pH. 
This can then be superimposed over the speciation plot for ellagic acid to give an indication 
of the ionised forms of ellagic acid responsible for the inhibition, as seen below in figure 
4.14. 
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Figure 4.14: Speciation plot of ellagic acid superimposed with ki over physiologically 
relevant pH levels. 
The kis for the inhibition of CTX-M-15 by ellagic acid were recorded over physiologically 
relevant pH levels. It was initially intended to go above pH 9.0, but unfortunately the enzyme 
does not operate at these relatively extreme pH levels. As can be seen from figure 4.14 
above, the ki for the inhibition of CTX-M-15 by ellagic acid follows the emergence of the 
mono- and di-anions forms of ellagic acid. This indicates that ellagic acid is active as an 
inhibitor when it has these negative charges, and some deprotonation of the molecule is 
required for it to be able to inhibit with the serine active site of CTX-M-15. The requirement 
for a negative charge on the inhibitor is compatible with that for substrates and reflects the 
interaction with a positively charged residue (Lys-240) on the enzyme. 
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Using the fundamentals of the Henderson-Hasselbach equation and the data available in the 
speciation plot, one can determine the fraction of the specific ion of ellagic acid present at a 
specific pH. For example, at pH 6.0, the following is true for EH3
-: 
𝐾𝑎
𝐻++𝐾𝑎
  
10−6.5
10−6.0+ 10−6.5
=
0.316 × 10−6
1.316 ×10−6
= 0.24 × 100 = 24 %  
Therefore, at pH 6.0 the amount of ellagic acid present is 24 % in the EH3
-
 form. This 
calculation can be repeated for the other ionic forms at other pH levels. 
The approximate values of the second-order rate constants for the anionic species can be 
estimated from:  
ki
tot = ki
EH3
- + ki
EH2
2- 
At pH 6.0 there is ‘no’ EH22- but 24 % EH3-: 
ki
tot = 5.6 x 103 = 0.24 ki
EH3
- 
Therefore, ki
EH3
- = 2.33 x 104 M-1s-1 
At pH 7.5 ki
tot = 1.20 x 10-4 M-1s-1 and the fraction of EH2
2- present is 0.5 (50 %) whilst the 
fraction of EH3
- present is 0.45 (45 %). 
ki
tot = 1.20 x 104 = 0.45 x 2.33 x 104 + 0.5 ki
EH2
2- 
1.20 x 104 – 1.05 x 104 = 0.5 kiEH2
2- 
ki
EH2
2- = 0.30 x 104 M-1s-1 
ki
EH2
2- = 3.0 x 103 M-1s-1 
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Therefore, the mono-anionic species is almost 10-fold a better inhibitor than the di-anionic 
ellagic acid. 
It appears that both the mono and di-anionic species of ellagic acid are effective inhibitors. 
It would be useful to study the effectiveness of ellagic acid with an electron-withdrawing 
group para to the departing phenol group to improve the rate of acylation: 
 
Possible electron withdrawing groups could be -NO2 or -F. 
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4.3.1.4 Urolithin A Inhibition Results 
 
Urolithin A was tested for any β-lactamase inhibitory activity. As can be seen from figure 
4.15 below, Urolithin A only had very modest inhibitory activity against CTX-M-15, and as 
such does not represent a good candidate for future novel inhibitor development. 
 
Figure 4.15: Percentage active CTX-M-15 (10 nM) remaining after incubation with urolithin 
A (10 µM). 
When one considers the structure of urolithin A (as seen again in figure 4.16 below), it is 
perhaps unsurprising that it has a lower inhibitory activity than that of ellagic acid. 
Specifically, the pKa of the phenols will give ellagic acid a higher value than that of ellagic 
acid, which also means that the phenols will not be ionised, meaning that inhibition will be 
less likely to occur. Also, there is not the correct geometrical relationship between the 
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carbonyl group and the phenol to bind well to the active site of the β-lactamase enzyme, 
which means you will not be able to achieve the same binding shown by ellagic acid. 
 
Figure 4.16: Structure of urolithin A. 
 
4.3.1.5: Orlistat Inhibition Results 
 
The inhibitory effects of orlistat against SBL CTX-M-15 were investigated, in much the 
same way as ellagic acid. Orlistat (as seen in figure 4.17 below) is a lipophilic molecule with 
limited solubility however the solubility of orlistat was determined and was found to be 
soluble in a 10 % solution of ACN in pH 7.0 HEPES (0.1 M) buffer solution. Appropriate 
blanks were run with CTX-M-15 in this solution to ensure the added ACN had no effect on 
enzyme activity.  
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Figure 4.17: Chemical structure of orlistat. 
There was negligible loss in enzyme activity over 30 minutes for CTX-M-15 in the 10 % 
ACN buffer solution. This means that any loss of activity in the actual experiments must be 
due to the actions of orlistat behaving as an inhibitor. Orlistat was found to be a weak 
inhibitor of CTX-M-15, as can be seen in figure 4.18 below. 
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Figure 4.18:  Percentage active CTX-M-15 (10 nM) remaining after incubation with  orlistat 
(10 µM). 
10 µM was the lowest concentration at which a reasonable amount of inhibition was noticed, 
making orlistat a weak inhibitor of CTX-M-15. The pseudo first-order rate constant from 
figure 4.18 was kobs 7.73 x 10
-4s-1 corresponding to a second-order rate constant of 77.3 M-
1s-1. 
To help confirm that orlistat was indeed acting as an inhibitor, the experiments were repeated 
but with a much higher concentration of orlistat. If orlistat was acting as an inhibitor, there 
should be a lower amount of active enzyme over the same time period as in the 10 µM 
experiment. 
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Figure 4.19: Percentage active CTX-M-15 (10 nM) remaining after incubation with orlistat 
(100 µM). 
As can be seen from figure 4.19 above, there is much more inhibition than the 10 µM sample, 
this data gives a kobs = 5.35 x 10
-3s-1, corresponding to a second-order rate constant = 53.5 
M-1s-1, which is in reasonably good agreement with 10 µM data and confirmed the inhibition 
was due to orlistat. 
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4.3.2: Microbial Inhibition by Ellagic Acid 
 
As discussed in the introduction to this chapter, polyphenols and ellagic acid in particular 
have received attention owing to their ability to inhibit microbial pathogens. To qualitatively 
investigate this, various plates of pathogenic bacteria, some capable of producing β-
lactamases, were prepared according to the methods section. The results can be seen in 
figures 4.20-4.22 below. 
 
Figure 4.20: Inhibition of Klebsiella pneumoniae NCTC 13443 by ellagic acid with a MeOH 
blank. 
As can be seen from figure 4.20 above, there is a clear inhibition zone around the ellagic 
acid (EA) well. Klebsiella pneuomoniae is also an NDM-1 metallo-β-lactamase producing 
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microbe. It is of therefore significant clinical interest if ellagic acid is capable of both SBL 
enzymes and MBL producing bacteria, perhaps representing a potential future treatment 
development option for infections SBL/MBL producing microbes. 
 
Figure 4.21: Inhibition of Escherichia coli NCTC 13476 by ellagic acid. 
As can be seen in figure 4.21 above, there is a clear area of inhibition around the ellagic acid 
well in the agar plate. Escherichia coli NCTC 13476 is also an MBL producing microbe, 
producing Imipenemase (IMP). The fact that ellagic acid is capable of inhibiting growth of 
this microbe along with Klebsiella pneuomoniae 13476 (also an MBL producing microbe) 
is further proof that ellagic acid is capable of inhibiting growth of problematic Gram 
negative MBL producing bacteria and warrants further research as a potential treatment of 
infections caused by MBL producing bacteria. 
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Figure 4.22: Inhibition of Escherichia coli NCTC 10418 by ellagic acid. 
Finally, ellagic acid was tested for its inhibition against Escherichia coli NCTC 10418, 
which is a non-β-lactamase producing bacteria. As can be seen from figure 4.22 above, 
ellagic acid also had inhibitory activity against this pathogen. Urolithin A and orlistat were 
also assessed for their microbial inhibitory activity, but unfortunately possessed no antibiotic 
ability. 
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4.4: Chapter Four Conclusion 
 
Three novel inhibitors of SBLs have been identified and their effectiveness as inhibitors has 
been determined. Ellagic acid, a plant polyphenol, urolithin A, a plant metabolite and 
orlistat, an existing dietary lipase inhibitor used as a weight loss aid. Out of the three novel 
inhibitors, ellagic acid showed the most promise for future development as a β-lactamase 
inhibitor. It was shown that the mono-anionic species of ellagic acid was the most effective. 
Whilst urolithin A and orlistat also showed SBL inhibitory action, urolithin A only exhibited 
very modest activity, whilst orlistat was a more effective inhibitor. This is perhaps not too 
surprising, as digestive lipase enzymes are known to have a serine in their active site, as do 
SBL enzymes (Ranjbar, Zibaee & Sendi, 2014), (Rouseel et al., 1999), (Chater, Wilcox, 
Houghton & Pearson, 2015). Table 4.1 below summarises the inhibitors and the calculated 
kis. 
Table 4.1: Summary of calculated kis for the novel inhibitors discussed in chapter 4. 
Inhibitor ki (M
-1s-1) 
Ellagic Acid Mono-Anion 2.33 x 104 
Ellagic Acid Di-Anion 3.00 x 103 
Urolithin A <20 
Orlistat 65.4 
 
Ellagic acid was not only the most effective inhibitor, it also showed effectiveness at 
inhibiting several problematic Gram-negative pathogens, including MBL producing 
Klebsiella pneumoniae and Escherichia coli. Enterobacteriaceae such as these pathogens 
are associated with increased morbidity and mortality worldwide (Zowawi, Balkhy, Walsh 
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& Paterson, 2013), (Babu, Visweswaraiah & Kumar, 2014). Therefore, ellagic acid 
represents an interesting, novel antimicrobial agent, which is capable of inhibiting SBLs and 
also inhibiting MBL producing bacteria.  
Further work was concluded on ellagic acid, investigating the effect of pH on the inhibitory 
actions against CTX-M-15. The outcomes of this work suggest that out of the 4 ionisable 
forms of ellagic acid, only two are effective as SBL inhibitors. Future work with ellagic acid 
could include nitrating the molecule to further its effectiveness as an SBL inhibitor.  
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Chapter Five: Summary and Concluding Remarks 
 
5.1 Introduction 
 
Antibiotic resistance is an unavoidable inevitability owing to the genetic drivers of resistance 
present in all bacteria, pathogenic and non-pathogenic alike. The greatest contributor to 
antibiotic resistance is overwhelmingly the capability of bacteria to produce antibiotic 
cleaving enzymes, β-lactamases. β-Lactamases are capable of efficiently catalysing the 
hydrolysis of β-lactam antibiotics, thereby rendering them useless in combatting microbial 
infections. β-Lactam antibiotics are the most widely used and relied upon class of antibiotics 
by a great deal, owing to their efficacy and limited side effects. The dissemination of β-
lactamase encoding genes throughout pathogenic bacteria represent the greatest threat to β-
lactam antibiotics, which have long been our weapon of choice in the fight against 
pathogenic infections. Unfortunately, we have been unable to replicate the success of β-
lactam antibiotics into novel classes of antimicrobial treatments. The antibiotic production 
pipeline has been drying up since the “golden era” of discovery of antibiotics in the 1950-
1970s. The goal of developing a completely novel class of resistance-proof synthetic 
antibiotics has not been achieved. Antibiotics are expensive to research, time consuming to 
develop, and as they are treatment for acute infections, they do not give a great return relative 
to the high investment needed to get from concept to approved drug. Pharmaceutical 
companies have therefore been moving away from novel antibiotic research, instead 
concentrating resources on developing treatments for more lucrative chronic diseases such 
as cancers or diabetes. The development of novel antibiotics has therefore been somewhat 
neglected in recent decades; although there has been a recent rekindling of interest owing to 
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the disturbing dearth of novel antibiotics. The bleakness of a post-antibiotic reality is 
becoming a more concerning threat within the scientific community. 
The work detailed in this thesis has aimed to go some way to providing insights into ways 
of culturing bacteria perhaps as a pathway to discover novel antibiotics. Novel β-lactamase 
inhibitors have also been synthesised and discussed, and the pH dependent nature of 
hydrolysis of antibiotics by SBLs and their inhibition by novel inhibitors has also been 
explored. Also, novel compounds acting as SBL inhibitors have been identified, and their 
applications for future development have also been highlighted. 
 
5.2: The Search for Novel Antimicrobials from Microbial Origins   
 
It is well known that the vast majority of microbes will not grow in laboratory conditions. 
The vast majority of our existing classes of antibiotics have originated from screening 
platforms investigating the metabolites of bacteria for antibiotic capabilities, mainly spurred 
on by Fleming’s serendipitous discovery of the anti-microbial properties of Penicillium. 
Microbial sources of novel antibiotics have been described as over-mined and long depleted. 
However, when one considers that around 98 % of bacteria in situ are un-culturable in vitro, 
many scientists have explored ways of trying to increase the in vitro growth rate in order to 
explore the metabolites of potentially novel bacteria, doing so would re-vitalise the 
“Waksman Platform of Discovery” – a method employed during the golden era of antibiotic 
discovery to identify antimicrobial producing bacteria from environmental samples.  
The work in this chapter explored one such method for increasing the in vitro growth rate of 
bacteria. The “iChip” is a multi-welled plastic device traps bacteria in agar plugs for 
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incubation in situ until colonies are well established. After this point, the whole unit is 
transferred back to the laboratory and disassembled and agar plugs exhibiting growth are 
incubated. This process identified one such microbe which repeatedly showed inhibition of 
clinically relevant SBL/MBL producing bacteria. PCR was carried out to identify the strain 
of the specific microbe, and it was identified as Pseudomonas baetica, a little described 
strain of bacteria whose only noticeable trait was that it was pathogenic to wedge sole – a 
species of fish popular for consumption in Spain. LCMS analysis took place on a broth of 
Pseudomonas baetica and identified over 400 unique compounds. Clearly, this was far too 
many to try and realistically quantify with the time and resources available, but it showed 
that the iChip and LCMS could be used as tools to potentially isolate novel antimicrobial 
producing bacteria and then to identify the antibiotic using LCMS. 
 
5.3: Novel Avibactam Analogues as Novel Inhibitors of Serine Beta Lactamases 
 
In an attempt to combat the greatest threat to β-lactam antibiotics, β-lactamase enzymes, 
pharmaceutical companies have developed β-lactamase inhibitors (BLIs). BLIs represent a 
way of inhibiting β-lactamases produced from β-lactamase producing enzymes, thereby 
preventing hydrolysis of the β-lactam ring present in β-lactam antibiotics to their microbial 
killing mechanism. BLI’s are paired with existing β-lactam antibiotics in an attempt to 
restore their antimicrobial killing capability. Historically, there has been three clinically 
approved BLI: tazobactam, sulbactam and clavulanic acid. Owing to the dearth of novel 
antibiotics, interest has increased in recent years around novel BLIs, in an attempt to extend 
the life of existing β-lactam antibiotics and help combat infections causes by antibiotic 
resistant bacteria.  
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The work in this chapter looked at avibactam, a novel β-lactamase inhibitor and novel 
carbamate derivatives of avibactam. The work predominantly revolved around 4 carbamate 
inhibitors which were shown to have inhibitory effects towards SBLs. The work showed 
that the leaving groups of the carbamate derivatives could be altered to result in more 
effective inhibition. More acidic alcohols were introduced as leaving groups and it was 
found that as the pKa of the alcohol used as a leaving group decreased, the inhibitory 
effectiveness of the carbamate derivatives increased. The most effective carbamate 
derivative, the hexafluoroacetone derivative (HFA) had a higher ki than avibactam itself, 
whilst the second most effective inhibitor (the hexafluoroisopropanol [HFIP]) carbamate 
derivative had a ki comparable to that of avibactam. 
The work in this chapter also explored the pH dependency of hydrolysis of antibiotics 
catalysed by different SBLs and the inhibition of these SBLs. The work concluded that the 
catalytic machinery used in both the hydrolysis of antibiotics and inhibition of the enzymes 
were the same, owing to the similar bell shaped curves obtained from these experiments 
(kcat/Km for enzyme catalysed hydrolysis of cephalothin and ki for the inhibition of these 
enzymes by the carbamate inhibitors/avibactam). 
 
5.4: Other Novel β-Lactamase Inhibitors 
 
The work in this chapter investigated three potential novel β-lactamase inhibitors, ellagic 
acid, urolithin A and orlistat. All three were investigated owing to their structural 
characteristics, as it was predicted that they had the necessary features essential for being 
able to inhibit SBLs. 
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Ellagic acid, a polyphenol with supposed health benefits, was found to be the most effective 
inhibitor out of the three compounds tested. Urolithin A (a plant derived metabolite) and 
orlistat (a dietary lipase inhibitor). Urolithin A and orlistat had only modest inhibitory 
effects. Ellagic acid has great potential for future development, as the molecule can be 
nitrated which will, in theory, improve its ability as an inhibitor of SBL enzymes. 
All three of the compounds were also tested for their ability to inhibit microbial pathogens. 
Out of the three tested, only ellagic acid showed any inhibitory activity against the pathogens 
tested, which included MBL producing bacteria. Ellagic acid clearly shows potential as a 
dual microbial pathogen and SBL inhibitor, which could present an interesting future 
development option. 
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Chapter Six: General Methods 
 
6.1: Sourcing of Materials 
 
All materials used were obtained from Fisher Scientific, Loughborough, Leicestershire 
Sigma Aldrich, Gillingham, Dorset or Fluorochem, Hadfield, Derbyshire and were of 
analytical reagent grade or higher. 
Ultra-pure water refers to water purified from a Milli-Q Millipore Gradient ultra-pure water 
system. 
6.2: Preparation of Tryptone Soy Agar 
 
Tryptone soy agar powder was obtained from LabM, Heywood, Lancashire, and the typical 
formulation was as follows:  
Table 6.1: Ingredients of tryptone soy agar powder. 
Ingredient Amount (g) 
Tryptone 15 
Soy peptone 5 
Sodium chloride 5 
Agar No. 2 12 
 
37 g of powder was weighed into a clean 1 L Schott bottle in a decontaminated laminar flow 
hood. 1 L of deionised water was added and was swirled to mix with the powder. The bottle 
was sealed and autoclave tape was placed across the lid and the bottle was then placed into 
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a Prestige Medical Autoclave Classic 12 litre benchtop autoclave and sterilised at 121 °C at 
15 psi for 15 minutes. Once the autoclave cycle had finished, the autoclave tape was 
inspected and the molten agar was placed in a Precision (Thermo Fisher) water bath at 50 
°C and allowed to cool until the bottle was warm to the touch. Once the bottle was cool 
enough to handle but the agar was still molten, the bottle was transported to a laminar flow 
hood and 9 cm agar plates were prepared by aseptically pouring the molten agar into the 
plates and swirling gently to ensure the agar would solidify evenly. The plates were allowed 
to cool and harden for 30 minutes and were then stored inverted in a sealed bag at 4 °C until 
needed. 
 
6.3: Preparation of Tryptone Soy Broth 
 
Tryptone soy broth powder was obtained from LabM and the ingredients were as follows: 
Table 6.2: Ingredients of tryptone soy broth powder. 
Ingredient Amount (g) 
Tryptone 17 
Soy peptone 3 
Sodium chloride 5 
Dipotassium phosphate 2.5 
Dextrose 2.5 
 
30 g of powder was weighed into a clean 1 L Schott bottle in a decontaminated laminar flow 
hood. 1 L of deionised water was added and was swirled to mix with the powder. The bottle 
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was sealed and autoclave tape was placed across the lid and the bottle was then placed into 
a Prestige Medical Autoclave Classic 12 litre benchtop autoclave and sterilised at 121 °C at 
15 psi for 15 minutes. Once the autoclave cycle had finished, the autoclave tape was 
inspected and the broth was allowed to cool until the bottle was warm to the touch. Once the 
broth had cooled to room temperature it was ready to use in further experiments or was 
stored at 4 °C until needed. 
 
6.4: Polymerase Chain Reaction 
 
6.4.1: Extraction 
 
For the extraction of DNA from microbial origins for PCR analysis, a MO-BIO PowerSoil 
DNA Extraction Kit was used (MO-BIO, Carlsbad, CA, US), as according to the 
manufacturer’s instructions. Several inoculating loops of pure isolate were added to a 
PowerBeads tube and vortexed. 60 µL of cell lysing solution (C1) was added to the 
PowerBeads tube and vortexed briefly. The PowerBead tubes containing sample and cell 
lysing solution were then attached to a MO-BIO horizontal vortex machine and operated at 
maximum velocity for 10 minutes. The tubes were then centrifuged for 30 seconds at 10,000 
g. 400 µl of the supernatant was collected and transferred to a new, clean, 2 ml collection 
tube. 250 µl of solution C2 was then added to remove non-DNA and other non-essential 
materials from the sample and was vortexed for 5 seconds to mix with the sample and then 
incubated for 5 minutes at 4 °C. The sample was centrifuged after incubation for 1 minute 
at 10,000 g. 600 µl of supernatant was then collected and transferred to a new, clean, 2 ml 
collection tube, with care being taken to avoid disturbing the pellet. 200 µL of C3 solution 
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was then added to further remove any non-DNA and other inorganic material from the 
sample and a further incubation period of 5 minutes at 4 °C. The samples were then 
centrifuged at room temperature for 1 minute at 10,000 g, with the supernatant being 
transferred to a new 2 ml collection tube. 1200 µl of solution C4 was added to the sample 
and then vortexed for 5 seconds. The salt content of C4 solution aids in the aggregation 
(accumulation and clumping together of) of the DNA, which allows it to be more efficiently 
loaded onto a spin filter, which acts as a silica membrane column to aid in the purification 
of the sample – the DNA is collected on the spin filter whilst any non-DNA material is eluted 
via centrifugation. The sample is centrifuged at 10,000 g for 1 minute through the spin filter 
and the flow through is discarded each time. This process is repeated at least three times 
with the rest of the supernatant. 500 µl of solution C5, an ethanol based wash solution is 
then added to the spin filter and centrifuged, which helps eliminate any non-DNA material 
from the sample following centrifugation at 10,000 g for 60 seconds. After the C5 solution 
flow through is discarded, the centrifugation step is repeated to ensure the elimination of 
any remaining non-DNA material, and the flow through is discarded once more. Now the 
pure, clean DNA is on the spin filter, it needs to be eluted for further down-stream 
processing. The spin filter is transferred to a new 2 ml collection tube and 30 µL of C6 
solution is added to the spin filter. The sample is centrifuged for 1 minute at 10,000 g which 
elutes the DNA from the spin filter. The DNA is now in the collection tube, ready for down-
stream processing. 
 
6.4.2: Quantification of Nucleic Acids 
 
The concentration of nucleic acids was determined using a spectrophotometer, operating at 
260 nm. It is at this wavelength that the extinction coefficient of DNA is 0.020 µg/mL-1 cm-
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1 and for RNA the extinction coefficient is 0.025 µg/ml-1 cm-1. The purity of DNA and RNA 
can be determined by the ratio of optical densities at 260:280 nm, with a ratio falling between 
1.8-2.0 for DNA being considered to be consisting of minimal contamination of a protein 
source. 
 
6.4.3: Polymerase Chain Reaction  
 
Once the amount of DNA present in the isolated sample had been quantified, it could be 
prepared for PCR. The final sample needed to be made up to 50 µL, with a DNA 
concentration of no more than 5-10 ng/ml. The sample contained 25 µl Taq polymerase from 
myTaq HS red mix (Bioline, London), 2 µL 8F1510R primer mix, the appropriate amount 
of DNA as calculated from the quantification stage and then made up to 50 µL with 
DNA/RNA grade DEPC water. 
The DNA in the correct concentration with the appropriate polymerase and primers was then 
transferred to a Techne 3Prime Thermal Cycler (Stone, Staffordshire) and the reaction was 
carried out as follows: initial denaturation at 95 °C for 2 minutes, followed by 33 cycles of: 
denaturing (95 °C for 30 seconds), annealing (55 °C for 30 seconds) and primer extension 
(72 °C for 30 seconds). This was followed by a final extension step of 72 °C for 7 minutes. 
To check whether the PCR had been successful, samples were subject to a gel 
electrophoresis. 
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6.4.4: Visualisation of PCR Samples by Gel Electrophoresis 
 
PCR products were visualised using gel electrophoresis on 1 % agarose gels prepared in tris-
acetate EDTA buffer (TAE). A 50X concentrated solution was prepared by dissolving 242 
g TRIS base, 57.1 ml glacial acetic acid and 100 ml 0.5 M Ethylenediaminetetraacetic acid 
(EDTA) per litre of ultra-pure water (pH 8.0) and diluted when required. The 1 % agarose 
solution was then completely melted by microwaving (2-3 minutes per 100 ml) before being 
allowed to cool to ~45 °C, prior to the addition of 1 µL of SYBR safe stain (Life 
Technologies, Paisley, UK). The gel was then cast and allowed to set. 5 µl of each PCR 
product was loaded into each gel utilising the dye present in the original PCR master mix, 
alongside 5 µL of ladder (Hyperladder 1 kb) and electrophoresed for 60 minutes at 100 V. 
Gels were then visualised under UV light and an image taken using BioDoc-It® 210 imaging 
system (UVP LLC, Upland, CA, US). Once the presence of DNA had confirmed that the 
PCR process had been carried out correctly, the PCR samples could be purified prior to 
being sent to external sequencing. 
 
6.4.5: PCR Product Purification 
 
Following the PCR and the visualisation process, the PCR product needed to be purified 
before being sent for external sequencing. This was accomplished by using a commercially 
available PCR purification kit supplied by Qiagen (Surrey, UK), and the manufacturer’s 
instructions were followed. 5 volumes of Buffer PB are added to 1 volume of PCR sample 
in order to salt the sample, and ensure that the pH is <7.5, which was ensured by the addition 
of 10 µl of 3 M sodium acetate pH 5.0. The sample is then binded to a silica column by 
placing the sample onto a spin filter (silica column) and centrifuging for 60 seconds at 
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10,000 g. The flow through is discarded and the column is washed with 750 µl of Buffer PE 
(buffer containing ethanol) and centrifuged for 60 seconds. The flow through is discarded 
and the centrifugation step is repeated. The DNA is then eluted by placing the spin filter 
column into a clean 1.5 ml microcentrifuge tube and adding 50 µl of elution buffer (10 mM 
TRIS-Cl) to the centre of the spin column and letting the sample stand for 60 seconds before 
centrifuging the sample for 60 seconds. The purified PCR product was then ready to be sent 
for external sequencing at Eurofins Laboratories, Wolverhampton, where the Sanger 
sequencing method was used (discussed in more detail in chapter 2). 
 
6.4.6: Sequence Analysis 
 
Sequences were returned from the laboratory in Notepad file format. File formats were 
prepared for comparative analysis using MEGA 5 for Windows where duplicated sequences 
or poor data could be eliminated. They could then be uploaded into the US National Library 
of Medicine’s Basic Local Alignment Search Tool (BLAST) for 16s ribosomal RNA 
sequences, where the sequence similarity of the samples could be compared to database 
records for existing species. 
 
6.5: QToF Mass Spectrometry 
 
The QToF was used in the metabolomics experiments and some of the rest of the analytical 
experiments except those ran on the QqQ and GCMS. Data were collected using an Agilent 
Technologies 1290 Infinity II LC system coupled to an Agilent Technologies 6545 QToF 
Mass Spectrometer in negative ionisation mode using an ACE 5 C18-AR (3 µM, 50 x 4.6 
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mm) column, with the column compartment temperature set to 30 °C. The binary pump flow 
rate was 0.8 ml with an injection volume of 5 µl. The mobile phases used were A: 0.1 % 
formic acid LCMS grade water and B: 0.1 % formic acid LCMS grade ACN and the gradient 
was as follows: 3 % B for 1 minute, then a linear increase from 3 to 50 % B in 1.4 minutes, 
followed by another linear increase from 50 to 99 % B in 1.6 minutes, hold at 99 % B for 
0.5 minutes, then a return to 3 % B for 3.5 minutes, followed by an equilibration time of 10 
minutes before the next sample was injected. The carrier gas used was nitrogen and the 
source used was a jet stream electrospray ionisation (JS-ESI) with the following voltages 
and temperatures used: 
 
Table 6.3: QToF Instrument parameters. 
Instrument Parameter Value 
Gas temp (°C) 320 
Gas flow (L/min) 8 
Nebuliser pressure (psig) 35 
Sheath gas temperature (°C) 350 
Sheath gas flow (L/min) 11 
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Table 6.4: QToF source parameters. 
Scan Source Parameter Value 
Capillary voltage (V) 4000 
Nozzle voltage (V) 1000 
Fragmentor (V) 175 
Skimmer (V) 65 
Octopole RF peak (V) 750 
 
6.6: QqQ Mass Spectrometry 
 
The QqQ was used in some of the avibactam detection experiments. Data were collected 
using an Agilent Technologies 1290 Infinity II LC system coupled to an Agilent 
Technologies 6470 QqQ Mass Spectrometer in negative ionisation mode using a zero dead 
volume column, with the column compartment temperature set to 30 °C. The binary pump 
flow rate was 0.4 ml with an injection volume of 20 µl. The mobile phases used were A: 0.1 
% formic acid LCMS grade water and B: 0.1 % formic acid LCMS grade ACN and the 
method was isocratic, with a 1:1 mobile phase composition. The carrier gas used was 
nitrogen and the source used was a jet stream electrospray ionisation (JS-ESI) with the 
following voltages and temperatures used: 
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Table 6.5: QqQ Instrument parameters. 
Instrument Parameter Value 
Gas temp (°C) 300 
Gas flow (L/min) 5 
Nebuliser pressure (psig) 45 
Sheath gas temperature (°C) 250 
Sheath gas flow (L/min) 11 
 
Table 6.6: QqQ source parameters. 
Scan Source Parameter Value 
Capillary voltage (V) 3500 
Fragmentor (V) 135 
Collision cell (V) 5 
 
6.7: Gas Chromatography Mass Spectrometry 
 
The GCMS was used for the liberation of alcohol experiments. Data were collected using 
an Agilent Technologies 5975C gas chromatography mass spectrometry (GCMS) system 
with auto sampler injection, in positive ionisation mode using a HP5 column. The source 
temperature was set at 230 °C with an injection volume of 1 °C. The oven temperature was 
set at 35 °C, held for 2 minutes after sample injection and ramped at 10 °C per minute to 80 
°C and held for 1 minute. 
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6.8: Synthesis of Carbamate Inhibitors 
 
The synthesis of the inhibitors roughly followed the same synthesis pathway. 500 mg of 
avibactam was dissolved in 300 ml of solvent (methanol, trifluoroethanol, 
hexafluoroisopropanol, hexafluoroacetone hydrate) and stirred under reflux until dissolved. 
One equivalence of triethylamine was added and was stirred under reflux until the reaction 
was complete as monitored by LCMS. At this point, the reaction was drive using a Heidolph 
Hei Vap Precision rotary evaporator operating at 20 mbar pressure with a water bath 
temperature of 40 °C with an RPM of 200. The rotary evaporator was connected to a Huber 
Mini Chiller 300 OLÉ operating at -10 °C. The instrument was kept under vacuum by an 
Edwards RV12 vacuum pump. 
6.9: Reagent Preparations 
 
6.9.1: Buffer Preparations 
All buffers used were 0.1 M concentration unless otherwise stated within the main chapters 
of the thesis. All buffers were corrected to 1 M ionic strength using KCl. All buffers used 
were obtained from Sigma Aldrich (Dorset, UK), and were of reagent grade or higher. 
Buffers were made in 1 L batches with ultra-pure water using a Millipore Milli-Q system. 
The weights of buffer used to create 1 L of 0.1 M buffer can be seen in table 6.7 below. 
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Table 6.7: Details of buffers used and preparation instructions. 
Buffer pKa Molecular Weight Weight of Buffer 
Used to Create 1 L of 
0.1 M Buffer 
Formic Acid 3.75 46.03 4.603 
MES 6.16 206.73 20.673 
HEPES 7.55 283.30 28.33 
TAPS 8.49 243.37 24.34 
 
6.9.2 Experimental Reagent Preparations 
 
All reagents (apart from those synthesised) were purchased from Sigma Aldrich (Dorset, 
UK) and were of reagent grade or higher unless otherwise stated. 
A 40 mM stock solution of cephalothin was made fresh by dissolving 16.74 mg into 1 ml of 
pH 7.0 HEPES buffer (0.1 M). 10 µl of this stock solution was added to 2 ml of test solution 
to create a final concentration of 0.2 mM in the hydrolysis/inhibition experiments. 
The inhibitor stocks were made fresh on the day of experiments and were kept in melting 
ice when not kept refrigerated. For the MA carbamate, 29.61 mg was dissolved in 1 ml pH 
7.0 HEPES buffer (0.1 M) to create a 100 mM stock. For the TA carbamate, 3.64 mg was 
dissolved into the same buffer to create a 10 mM stock for use in further downstream 
experiments. For the HFIP carbamate, 6.48 mg was dissolved in 100 ml of the same buffer 
to create a 150 µM stock. For the HFA carbamate, 6.71 mg was dissolved in 100 ml of the 
same buffer to create a 150 µM stock. Finally, for avibactam 3.96 mg was dissolved in 100 
ml of the same buffer to create a 150 µM stock. For all of these inhibition experiments, the 
experiments were conducted in 100 % aqueous buffers as described in their relevant 
chapters. 
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For ellagic acid, 3.02 mg was dissolved in 10 ml of MeOH to give a 1 mM stock solution 
and sonicated for 20 minutes to ensure all of the substance was in solution. The inhibition 
experiments for ellagic acid were conducted in the usual buffers for the respective pH but 
supplemented with 10 % MeOH to ensure the ellagic acid stayed in solution. For example, 
for inhibition experiments with ellagic acid at pH 7.0, the buffer sample would be 20 ml pH 
7.0 HEPES buffer (0.1 M) with 10 % MeOH (18 ml aqueous HEPES buffer and 2 ml MeOH) 
with ionic strength maintained to 1 M with KCl. 
Similarly, for orlistat and urolithin A, a different solvent composition was required. 4.96 mg 
of orlistat was dissolved in 1 ml ACN to create a 10 mM stock solution. For urolithin A, 
2.28 mg was dissolved in 1 ml ACN to create a 10 mM stock solution. For both of these 
inhibitors, the inhibition experiments were conducted in pH 7.0 HEPES buffer (0.1 M) with 
10 % ACN (18 ml pH 7.0 HEPES buffer and 2 ml ACN) maintained to 1 M ionic strength 
with KCl.  
 
6.10: Kinetic UV Experiments 
 
All kinetic UV experiments were performed on an Agilent Technologies Cary UV-Vis 4000 
instrument in a quartz UV cell with a 1 cm path length, operated with Cary Win UV Kinetics 
software application. All samples were blanked with all sample components minus antibiotic 
(cephalothin). The kinetics scan settings for the cephalothin experiments were as follows: 
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Table 6.8: UV kinetics parameters. 
Parameter Setting 
Wavelength (nm) 260 
Spectra bandwidth (nm) 1.000 
Average time (s) 2.000 
Thermostatted (°C) 30 
 
6.10.1: P99 Catalysed Cephalothin Hydrolysis Additional Data 
 
 
Figure 6.1: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 5.5. 
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Figure 6.2: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.0. 
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Figure 6.3: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.5. 
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Figure 6.4: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.0. 
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Figure 6.5: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.5. 
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Figure 6.6: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 8.0. 
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Figure 6.7: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 8.5. 
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Figure 6.8: P99 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 9.0. 
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Figure 6.9: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 5.5 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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Figure 6.10: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 6.0 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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Figure 6.11: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 6.5 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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Figure 6.12: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 7.0 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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Figure 6.13: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 7.5 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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Figure 6.14: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 8.0 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
200 220 240 260 280 300 320
0.20
0.25
0.30
0.35
0.40
Fit of the Hydrolysis of Cephalothin (0.2 mM) by P99 (5 nM) at pH 8.5 at 30 °C and I = 1M (KCl)
Time (Seconds)
A
b
so
rb
a
n
ce kobs = 2.07 x 10
-2
 
Figure 6.15: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 8.5 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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Figure 6.16: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by P99 (5 nM) at 
pH 9.0 obtained using GraphPad Prism (black triangles = experimental data, red line = curve 
fit from software). 
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6.10.2: CTX-M-15 Catalysed Cephalothin Hydrolysis Additional Data 
 
 
Figure 6.17: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 4.0. 
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Monitored by the Loss of Absorbance at 260 nm
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Figure 6.18: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 4.5. 
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Figure 6.19: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 5.0. 
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Figure 6.20: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 5.5. 
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Figure 6.21: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.0. 
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Figure 6.22: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.5. 
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Figure 6.23: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.0. 
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Figure 6.24: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.5. 
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Figure 6.25: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 8.0. 
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Figure 6.26: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 8.5. 
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Figure 6.27: CTX-M-15 (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 9.0. 
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Figure 6.28: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 4.0 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.29: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 4.5 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.30: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 5.0 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.31: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 5.5 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.32: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 6.0 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.33: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 6.5 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
 
Chapter Six: General Methods 
306 
 
0 50 100 150 200 250
0.0
0.2
0.4
0.6
0.8
Fit of the Hydrolysis of Cephalothin (0.2 mM) by CTX-M-15 (5 nM) at pH 7.0 at 30 °C and I = 1 M  (KCl)
Time (Seconds)
A
b
so
rb
a
n
ce kobs = 3.33 x 10
-2
 
Figure 6.34: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 7.0 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.35: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 7.5 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.36: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 8.0 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.37: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 8.5 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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Figure 6.38: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by CTX-M-15 (5 
nM) at pH 9.0 obtained using GraphPad Prism (black triangles = experimental data, red line 
= curve fit from software). 
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6.10.3: AmpC Catalysed Cephalothin Hydrolysis Additional Data 
 
Figure 6.39: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 5.5. 
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Figure 6.40: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.0. 
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Figure 6.41: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 6.5. 
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Figure 6.42: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.0. 
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Figure 6.43: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 7.5. 
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Figure 6.44: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 8.0. 
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Figure 6.45: AmpC (5 nM) catalysed hydrolysis of cephalothin (0.2 mM) at pH 8.5. 
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Figure 6.46: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 5.5 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
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Figure 6.47: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 6.0 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
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Figure 6.48: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 6.5 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
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Figure 6.49: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 7.0 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
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Figure 6.50: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 7.5 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
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Figure 6.51: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 8.0 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
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Figure 6.52: Curve fit of the hydrolysis of cephalothin (0.2 mM) catalysed by AmpC (5 nM) 
at pH 8.5 obtained using GraphPad Prism (black triangles = experimental data, red line = 
curve fit from software). 
 
6.11: Scan UV Experiments 
 
All scan UV experiments were performed on an Agilent Technologies Cary UV-Vis 4000 
instrument in a quartz UV cell with a 1 cm path length, operated with Cary Win UV Scan 
software application. All samples were baseline blanked with all sample components minus 
the analyte (for example, cephalothin or carbamate inhibitor in the case of the carbamate 
hydrolysis experiments). The scan settings for the cephalothin experiments were as follows: 
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Table 6.9: UV scan parameters. 
Parameter Setting 
Start wavelength (nm) 800 
End wavelength (nm) 200 
Average time (s) 0.100 
Data interval (nm) 1.000 
Scan rate (nm/min) 600 
Source changeover (nm) 350 
Thermostatted (°C) 30 
6.12: pH Adjustments 
 
All pH adjustments were performed using a Mettler Toledo FE20/FG2 pH meter coupled to 
a Mettler Toledo Inlab Routine Pro Electrode. The pH meter/probe were always subjected 
to a two point calibration prior to use using appropriate buffer solutions purchased from 
Fisher Scientific. Probes were washed with ultra-pure water and stored in 3 M KCl when 
not in use. 
 
6.13: Enzyme Preparation and Purifications 
 
As mentioned, the enzymes used in this thesis were a kind gift from Professor Schofield’s 
group at the University of Oxford. However, their methods of production are summarised 
here (Cahill, 2017). 
Enzyme proteins were produced in E. coli BL21 (DE3) at 37 °C using 2TY broth medium 
supplemented with 50 µg/ml-1 ampicillin. Cells were grown until an optical density at 600 
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nm (OD600) of 0.6-0.7 was reached. Then, the bacterial cultures were taken out of the 
incubator and allowed to cool. They were then supplemented with ammonium iron(II) 
sulphate hexahydrate, the final concentration of which was adjusted to 50 µM. The cells 
were incubated overnight at 37 °C in an orbital incubator and were harvested by 
centrifugation (10 minutes at 10,000 g). 
To purify the enzymes, 20 g of the pellets were resuspended in 100 ml HisTrap Buffer A, 
supplemented with DNAse I and PMSF (2 g/L-1 final concentration), and lysed by sonication 
using a Vibra-Cell VCX 500 sonicator (SONICS, 10 minutes, 60 % amplitude, 10 seconds 
pulse, 10 seconds reset). The supernatant was loaded onto a 5 nl HisTrap HP column 
followed by extensive washing with HisTrap Buffer A before elution with a gradient of 
HisTrap buffer B in HisTrap Buffer A (20-500 mM imidazole). Fractions containing purified 
enzyme were concentrated by centrifugal ulftrafiltration using an Amicon ultra 15 ml 
centricon with a 10 kDa molecular weight cut off (Millipore). The resultant solution was 
injected onto a Superdex S200 column (300 ml), pre-equilibrated with Gel Filtration Buffer, 
and eluted with an additional 300 ml of Gel Filtration Buffer. Fractions containing pure 
enzyme were incubated overnight at 4 °C with 3C protease. The 3C protease together with 
any uncleaved protein was removed from the digestion mixture with a second 5 ml HisTrap 
HP column, pre equilibrated with HisTrap Wash Buffer. Purified enzyme fractions, 
identified by SDS-PAGE analysis, were collected and concentrated by centrifugal 
ultrafiltration before buffer exchange into Exchange Buffer. 
Polyacrylamide gels were made using the Mini-PROTEAN Tetra Cell system (Bio-Rad). In 
both running and stacking and gel preparation, tetramethyleneethylenediamine (TEMED) 
was added as the last component. During production, the running buffer was covered with a 
layer of propan-2-ol to prevent it from drying out whilst setting. This was subsequently 
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removed before pouring and setting of the stacking gel layer. SDS-PAGE gels were covered 
in wet tissue and stored at 4 °C until required. 
20 µL of protein sample were mixed with 4 µL of SDS-PAGE Gel Loading Buffer. The 
samples were then heated at 100 °C on a hot block for 2 minutes before loading of up to 10 
µL of each sample per well. Electrophoresis was carried out at a constant voltage of 160 V 
for 10 minutes followed by 180 V for 50 minutes using SDS-PAGE Running Buffer. Gels 
were subsequently stained for 10 minutes in SDS-Page Staining Solution and transferred 
into water. The gels were heated by microwaving until bands were visible before destaining 
overnight in water.  
 
6.14: NMR (Nuclear Magnetic Resonance) Analysis 
 
Proton NMR was used as a tool along with the LCMS experiments to confirm it was not 
avibactam that was carrying out the inhibition. Unfortunately, there was not enough time to 
fully characterise the HFA carbamate, but as was seen in the LCMS experiments, there was 
no sign of any avibactam. This, coupled with the fact that the HFA derivative was 
significantly more effective an inhibitor than avibactam, suggests that the HFA carbamate 
was correctly synthesised, but further work is needed to fully characterise the molecule. 
NMR was carried out at 400 MHz Bruker 400 NMR instrument, and was used to the 
following parameters: 
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Table 7.0: NMR parameters. 
NMR model Bruker 400 MHz  
Frequency 400 MHz 
Probe Z116098_0048 
Pulse program zg30 
Size of FID 65536 
Solvent DMSO 
Number of Scans 16  
Dummy scans 2 
Sweep Width 8223.685 Hz  
Decay FID Res 0.250967 Hz  
Acquisition time 3.985 sec  
Receiver gain 25  
Dwell time 60.800 µsec  
Pre-scan delay 10.69 µsec  
Temperature of acquisition 294.5 K                                                 
Delay time, D1 2 s  
Nucleus 1H, 19F 
90o pulse width 8.00 µsec 
Freq of observed channel 400.130 MHz 
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Fig 6.53: Proton NMR of avibactam. 
 
Figure 6.54: Proton NMR of TA carbamate. 
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Figure 6.55: Fluorine NMR of TA carbamate. 
 
Figure 6.56: Proton NMR of HFIP carbamate. 
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Figure 6.57: Fluorine NMR of HFIP carbamate. 
 
Figure 6.58: Proton NMR of MA carbamate. 
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